

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12Q 1/04, 1/68, C12P 21/00, C07H 21/04, C12N 15/00</b>		<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 96/34112</b> <b>(43) International Publication Date:</b> 31 October 1996 (31.10.96)
<b>(21) International Application Number:</b> PCT/US96/06003 <b>(22) International Filing Date:</b> 24 April 1996 (24.04.96) <b>(30) Priority Data:</b> 427,244 24 April 1995 (24.04.95) US 427,348 24 April 1995 (24.04.95) US <b>(71) Applicant:</b> CHROMAXOME CORP. [US/US]; Suite A, 11111 Flintkote, San Diego, CA 92121 (US). <b>(72) Inventors:</b> THOMPSON, Katie, A.; 12991 Caminito Bodega, Del Mar, CA 92014-3818 (US). FOSTER, Lyndon, M.; 968 Beach Crest Court, Carlsbad, CA 92009 (US). PETERSON, Todd, C.; 652 Diamond Drive, Chula Vista, CA 91911 (US). <b>(74) Agents:</b> CORUZZI, Laura, A. et al.; Pennie & Edmonds, 1155 Avenue of the Americas, New York, NY 10036 (US).			<b>(81) Designated States:</b> AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> METHODS FOR GENERATING AND SCREENING NOVEL METABOLIC PATHWAYS			
<b>(57) Abstract</b> <p>The present invention relates to a novel drug discovery system for generating and screening molecular diversity. The system provides methods for mixing and cloning genetic materials from a plurality of species of organisms in combinatorial gene expression libraries to generate novel metabolic pathways and classes of compounds. The system also involves methods for pre-screening or identifying for host organisms containing a library that are capable of generating such novel pathways and compounds. The host organisms may be useful in drug screening for particular diseases, and in commercial production of compounds of interest. The methods of the invention are also useful in preserving the genomes of organisms that are known or prospective sources of drugs.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

<b>AM</b>	Armenia	<b>GB</b>	United Kingdom	<b>MW</b>	Malawi
<b>AT</b>	Austria	<b>GE</b>	Georgia	<b>MX</b>	Mexico
<b>AU</b>	Australia	<b>GN</b>	Guinea	<b>NE</b>	Niger
<b>BB</b>	Barbados	<b>GR</b>	Greece	<b>NL</b>	Netherlands
<b>BE</b>	Belgium	<b>HU</b>	Hungary	<b>NO</b>	Norway
<b>BF</b>	Burkina Faso	<b>IE</b>	Ireland	<b>NZ</b>	New Zealand
<b>BG</b>	Bulgaria	<b>IT</b>	Italy	<b>PL</b>	Poland
<b>BJ</b>	Benin	<b>JP</b>	Japan	<b>PT</b>	Portugal
<b>BR</b>	Brazil	<b>KE</b>	Kenya	<b>RO</b>	Romania
<b>BY</b>	Belarus	<b>KG</b>	Kyrgyzstan	<b>RU</b>	Russian Federation
<b>CA</b>	Canada	<b>KP</b>	Democratic People's Republic of Korea	<b>SD</b>	Sudan
<b>CF</b>	Central African Republic	<b>KR</b>	Republic of Korea	<b>SE</b>	Sweden
<b>CG</b>	Congo	<b>KZ</b>	Kazakhstan	<b>SG</b>	Singapore
<b>CH</b>	Switzerland	<b>LI</b>	Liechtenstein	<b>SI</b>	Slovenia
<b>CI</b>	Côte d'Ivoire	<b>LK</b>	Sri Lanka	<b>SK</b>	Slovakia
<b>CM</b>	Cameroon	<b>LR</b>	Liberia	<b>SN</b>	Senegal
<b>CN</b>	China	<b>LU</b>	Luxembourg	<b>SZ</b>	Swaziland
<b>CS</b>	Czechoslovakia	<b>LT</b>	Lithuania	<b>TD</b>	Chad
<b>CZ</b>	Czech Republic	<b>LV</b>	Latvia	<b>TG</b>	Togo
<b>DE</b>	Germany	<b>MC</b>	Monaco	<b>TJ</b>	Tajikistan
<b>DK</b>	Denmark	<b>MD</b>	Republic of Moldova	<b>TT</b>	Trinidad and Tobago
<b>EE</b>	Estonia	<b>MG</b>	Madagascar	<b>UA</b>	Ukraine
<b>ES</b>	Spain	<b>ML</b>	Mali	<b>UG</b>	Uganda
<b>FI</b>	Finland	<b>MN</b>	Mongolia	<b>US</b>	United States of America
<b>FR</b>	France	<b>MR</b>	Mauritania	<b>UZ</b>	Uzbekistan
<b>GA</b>	Gabon			<b>VN</b>	Viet Nam

Methods for Generating and Screening Novel Metabolic Pathways1. FIELD OF THE INVENTION

The present invention relates to a novel approach to drug discovery. More particularly, the invention relates to a system for preserving the genomes of organisms that are good or promising sources of drugs; for randomly combining genetic materials from one or more species of organisms to generate novel metabolic pathways; and for pre-screening or screening such genetically engineered cells for the generation of novel biochemical pathways and the production of novel classes of compounds. The novel or reconstituted metabolic pathways can have utility in commercial production of the compounds.

2. BACKGROUND OF THE INVENTION2.1. SOURCES OF DRUG LEADS

The basic challenges in drug discovery are to identify a lead compound with the desirable activity, and to optimize the lead compound to meet the criteria required to proceed with further drug development. One common approach to drug discovery involves presenting macromolecules implicated in causing a disease (disease targets) in bioassays in which potential drug candidates are tested for therapeutic activity. Such molecules could be receptors, enzymes or transcription factors.

Another approach involves presenting whole cells or organisms that are representative of the causative agent of the disease. Such agents include bacteria and tumor cell lines.

Traditionally, there are two sources of potential drug candidates, collections of natural products and synthetic chemicals. Identification of lead compounds has been achieved by random screening of such collections which encompass as broad a range of structural types as possible. The recent development of synthetic combinatorial chemical libraries will further increase the number and variety of

compounds available for screening. However, the diversity in any synthetic chemical library is limited to human imagination and skills of synthesis.

Random screening of natural products from sources such as terrestrial bacteria, fungi, invertebrates and plants has resulted in the discovery of many important drugs (Franco et al. 1991, Critical Rev Biotechnol 11:193-276; Goodfellow et al. 1989, in "Microbial Products: New Approaches", Cambridge University Press, pp. 343-383; Berdy 1974, Adv Appl Microbiol 18:309-406; Suffness et al. 1988, in Biomedical Importance of Marine Organisms, D.G. Fautin, California Academy of Sciences, pages 151-157). More than 10,000 of these natural products are biologically active and at least 100 of these are currently in use as antibiotics, agrochemicals and anti-cancer agents. The success of this approach of drug discovery depends heavily on how many compounds enter a screening program. Typically, pharmaceutical companies screen compound collections containing hundreds of thousands of natural and synthetic compounds. However, the ratio of novel to previously-discovered compounds has diminished with time. In screens for anti-cancer agents, for example, most of the microbial species which are biologically active may yield compounds that are already characterized. Partly, this is due to the difficulties of consistently and adequately finding, reproducing and supplying novel natural product samples. Since biological diversity is largely due to underlying molecular diversity, there is insufficient biological diversity in the organisms currently selected for random screening, which reduces the probability that novel compounds will be isolated.

Novel bioactivity has consistently been found in various natural sources. See for example, Cragg et al., 1994. (in "Ethnobotany and the search for new drugs" Wiley, Chichester. p178-196). Few of these sources have been explored systematically and thoroughly for novel drug leads. For example, it has been estimated that only 5000 plant species have been studied exhaustively for possible medical

use. This is a minor fraction of the estimated total of 250,000-3,000,000 species, most of which grow in the tropics (Abelson 1990, Science 247:513). Moreover, out of the estimated millions of species of marine microorganisms, only  
5 a small number have been characterized. Indeed, there is tremendous biodiversity that remains untapped as sources of lead compounds.

Terrestrial microorganisms, fungi, invertebrates and plants have historically been used as sources of natural  
10 products. However, apart from several well-studied groups of organisms, such as the *actinomycetes*, which have been developed for drug screening and commercial production, reproducibility and production problems still exist. For example, the antitumor agent, taxol, is a constituent of the  
15 bark of mature Pacific yew trees, and its supply as a clinical agent has caused concern about damage to the local ecological system. Taxol contains 11 chiral centers with 2048 possible diastereoisomeric forms so that its de novo synthesis on a commercial scale seems unlikely (Phillipson,  
20 1994, Trans Royal Soc Trop Med Hyg 88 Supp 1:17-19).

Marine invertebrates are a promising source of novel compounds but there exist major weaknesses in the technology for conducting drug screens and large-scale resupply. For instance, marine invertebrates can be difficult to recollect,  
25 and many have seasonal variability in natural product content.

Marine microorganisms are a promising source of novel compounds but there also exist major weaknesses in the technology for conducting drug screens and industrial  
30 fermentation with marine microorganisms. For instance, marine microorganisms are difficult to collect, establish and maintain in culture, and many have specialized nutrient requirements. A reliable source of unpolluted seawater is generally essential for fermentation. It is estimated that  
35 at least 99% of marine bacteria species do not survive on laboratory media. Furthermore, available commercial

fermentation equipment is not optimal for use in saline conditions, or under high pressure.

Furthermore, certain compounds appear in nature only when specific organisms interact with each other and the environment. Pathogens may alter plant gene expression and trigger synthesis of compounds, such as phytoalexins, that enable the plant to resist attack. For example, the wild tobacco plant *Nicotiana sylvestris* increases its synthesis of alkaloids when under attack from larvae of *Manduca sexta*. Likewise fungi can respond to phytoalexins by detoxification or preventing their accumulation. Such metabolites will be missed by traditional high-throughput screens, which do not evaluate a fungus together with its plant host. A dramatic example of the influence of the natural environment on an organism is seen with the poison dart frog. While a lethal dose of the sodium channel agonist alkaloid, batrachotoxin, can be harvested by rubbing the tip of a blow dart across the glandular back of a field specimen, batrachotoxin could not be detected in second generation terrarium-reared frogs (Daly, 1995, Proc. Natl. Acad. Sci. 92:9-13). If only traditional drug screening technologies are applied, potentially valuable molecules such as these may never be discovered.

Moreover, a lead compound discovered through random screening rarely becomes a drug, since its potency, selectivity, bioavailability or stability may not be adequate. Typically, a certain quantity of the lead compound is required so that it can be modified structurally to improve its initial activity. However, current methods for synthesis and development of lead compounds from natural sources, especially plants, are relatively inefficient. There are significant obstacles associated with various stages of drug development, such as recollection, growth of the drug-producing organism, dereplication, strain improvement, media improvement, and scale-up production. These problems delay clinical testing of new compounds and

affect the economics of using these new sources of drug leads.

At present, the above-mentioned marine, botanical and animal sources of natural products are underused. The currently available methods for producing and screening lead compounds cannot be applied efficiently to these under-explored sources. Unlike some terrestrial bacteria and fungi, these drug-producing organisms are not readily amenable to industrial fermentation technologies. Simultaneously, the pressure for finding novel sources for drugs is intensified by new high-efficiency and high-throughput screening technologies. Therefore, there is a general need for methods of harnessing the genetic resources and chemical diversity of these as yet untapped sources of compounds for the purpose of drug discovery.

## 2.2. EXPRESSION LIBRARIES

Most recently drug discovery programs have shifted to mechanism-based discovery screens. Once a molecular target is identified (e.g., a hormone receptor involved in regulating the disease), assays are designed to identify and/or synthesize therapeutic agents that interact at a molecular level with the target.

Gene expression libraries are used to identify, investigate and produce the target molecules. Expression cloning has become a conventional method for obtaining the target gene encoding a single protein without knowing the protein's physical properties.

Many proteins identified by screening gene expression libraries prepared from human and mammalian tissues are potential disease targets, e.g., receptors (Simonsen et al. 1994, Trends Pharmacol Sci 15:437-441; Nakayama et al. 1992, Curr Opin Biotechnol 3:497-505; Aruffo, 1991, Curr Opin Biotechnol, 2:735-741), and signal-transducing proteins (Margolis et al., US 5,434,064). See Seed et al., 1987, Proc Natl Acad Sci 84:3365-3369; Yamasaki et al., 1988, Science 241:825-828; and Lin et al., 1992, Cell 68:775-785, (type III

TGF- $\beta$  receptor) for examples of proteins identified by functional expression cloning in mammalian cells.

Once a disease target is identified, the protein target or engineered host cells that express the protein target have  
5 been used in biological assays to screen for lead compounds (Luyten et al. 1993, Trends Biotechnol 11:247-54). Thus, within the scheme of drug discovery, the use of gene expression libraries has been largely limited to the identification and production of potential protein disease  
10 targets. Only in those instances where the drug is a protein or small peptide, e.g., antibodies, have expression libraries been prepared in order to generate and screen for molecules having the desirable biological activity (Huse et al. 1991, Ciba Foundation Symp 159:91-102).

15 However, there are other applications of gene expression libraries that are relevant to drug discovery. Gene libraries of microorganisms have been prepared for the purpose of identifying genes involved in biosynthetic pathways that produce medicinally-active metabolites and  
20 specialty chemicals. These pathways require multiple proteins (specifically, enzymes), entailing greater complexity than the single proteins used as drug targets. For example, genes encoding pathways of bacterial polyketide synthases (PKSs) were identified by screening gene libraries  
25 of the organism (Malpartida et al. 1984, Nature 309:462; Donadio et al. 1991, Science 252:675-679). PKSs catalyze multiple steps of the biosynthesis of polyketides, an important class of therapeutic compounds, and control the structural diversity of the polyketides produced. A host-  
30 vector system in *Streptomyces* has been developed that allows directed mutation and expression of cloned PKS genes (McDaniel et al. 1993, Science 262:1546-1550; Kao et al. 1994, Science 265:509-512). This specific host-vector system has been used to develop more efficient ways of producing  
35 polyketides, and to rationally develop novel polyketides (Khosla et al., WO 95/08548).



Another example is the production of the textile dye, indigo, by fermentation in an *E. coli* host. Two operons containing the genes that encode the multienzyme biosynthetic pathway have been genetically manipulated to improve  
5 production of indigo by the foreign *E. coli* host. (Ensley et al. 1983, Science 222:167-169; Murdock et al. 1993, Bio/Technology 11:381-386). Overall, conventional studies of heterologous expression of genes encoding a metabolic pathway involve directed cloning, sequence analysis, designed  
10 mutations, and rearrangement of specific genes that encode proteins known to be involved in previously characterized metabolic pathways.

In view of numerous advances in the understanding of disease mechanisms and identification of drug targets, there  
15 is an increasing need for innovative strategies and methods for rapidly identifying lead compounds and channeling them toward clinical testing.

### 3. SUMMARY OF THE INVENTION

20 The present invention provides a drug discovery system for generating and screening molecular diversity for the purpose of drug discovery. The method of the invention captures and preserves in combinatorial gene expression libraries the genetic material of organisms that are known/or  
25 prospective sources of drug leads.

In one embodiment, the invention involves the construction of combinatorial natural pathway gene expression libraries from one or more species of donor organisms including microbes, plants and animals, especially those that  
30 cannot be recovered in substantial amounts in nature, or be cultured in the laboratory. The donor organisms in the pool may be selected on the basis of their known biological properties, or they may be a mixture of known and/or unidentified species of organisms collected from nature.  
35 Random fragments of the genomes of donor organisms, some of which contain entire biochemical pathways or portions thereof, are cloned and expressed in the host organisms.

According to the invention, a subset of the gene products of the transferred DNA are capable of functioning in the host organism. The naturally-occurring pathways of the donor organisms may thus be reconstituted in the host  
5 organism. The expression of donor genes in the dissimilar physiological and regulatory environment of a heterologous host can unmask otherwise silent metabolic pathways. The metabolic pathways of the donor organism may also interact with metabolic pathways resident in the host organism to  
10 generate novel compounds or compounds not normally produced by the host organism.

Moreover, because only a defined subset of donor organism genes is expressed in the host organism at any one time, the system can render metabolic pathways and compounds  
15 easier to detect against an already characterized biochemical/cellular background of the host organism. Essentially, the genetic resources of these donor organisms are captured and preserved in the gene expression libraries which can be replicated and used repeatedly in different drug  
20 discovery programs.

In another embodiment, the invention involves the construction of combinatorial chimeric pathway expression libraries in which genetic material derived from one or more species of donor organism is randomly combined, cloned, and  
25 expressed in the host organism. Such libraries generate random combinations of genes from multiple pathways and organisms, which gives rise to metabolic pathways and discrete gene sets previously non-existent in nature. The term "discrete gene set" refers to any assemblage of two or  
30 more genes obtained from the ligation of genes from one or more pathway or organism in a combinatorial gene expression library. The plurality of gene products are capable of functioning in the host organism, where they interact to form novel chimeric metabolic pathways that produce novel classes  
35 of compounds. Thus, the diversity of molecular structures available for drug screening is increased by mixing the

genetic material of the extant pathways and organisms in the combinatorial chimeric gene expression library.

While standard methods of screening gene expression libraries can be used, the libraries can be further modified  
5 to incorporate a reporter regimen tailored to identify clones that are expressing the desirable pathways and metabolic products. In a specific embodiment, the host organisms are engineered to include a gene encoding a reporter protein  
operatively associated with a chemoresponsive promoter that  
10 responds to the desirable class of metabolites to be detected in the expression library.

In an alternative embodiment, the host organism may be exposed to a physiological probe which is a precursor of a reporter molecule that is converted directly or indirectly to  
15 the reporter molecule by a compound produced in the pathway sought. Activation of expression of the reporter or conversion of a reporter precursor produces a signal that allows for identification and isolation of the desirable clones.

20 In yet another embodiment of the invention, the host organisms in the library may be embedded in a semi-solid matrix with a reporter regimen or another indicator cell type that contains an assay or is itself a target for the desirable compound, e.g., pathogens for anti-infectives, or  
25 cancer cells for antitumor agents. High-throughput screening processes can be used, e.g., macrodroplet sorting, fluorescence activated cell sorting or magnetic activated cell sorting, to identify and isolate the desired organisms in a combinatorial gene expression library.

30 The positive clones may be further analyzed for the production of novel compounds. The genetics and biochemistry of the metabolic pathway that lead to production of the novel compounds may be delineated by characterizing the genetic material that was introduced into the isolated clones.

35 The present invention also relates to recombinant DNA vectors useful for constructing combinatorial gene expression libraries, specific combinatorial gene expression libraries,

host organisms containing a particular type of reporter system, host organisms modified for facilitating production of otherwise toxic compounds, and compositions comprising host organisms, indicator cells and/or a reporter regimen.

5

### 3.1. DEFINITIONS

As used herein, the following terms will have the meanings indicated.

A "combinatorial natural pathway expression library" is  
10 a library of expression constructs prepared from genetic material derived from a plurality of species of donor organisms, in which genes present in the genetic material are operably associated with regulatory regions that drive expression of the genes in an appropriate host organism. The  
15 combinatorial expression library utilizes host organisms that are capable of producing functional gene products of the donor organisms. The genetic material in each of the host organism encodes naturally-occurring biochemical pathways or portions thereof from one of the donor organisms.

20 A "combinatorial chimeric pathway expression library" is a library of expression constructs prepared from randomly concatenated genetic material derived from one or more species of donor organisms, in which genes present in the genetic material are operably associated with regulatory  
25 regions that drive expression of the genes in an appropriate host organism. The host organisms used are capable of producing functional gene products of the donor organisms.

A "biased combinatorial gene expression library" is a library of expression constructs prepared from genetic  
30 material derived from one or more species of donor organisms, which has been preselected for a specific property. The preselected genetic material can be used to prepare combinatorial natural pathway or chimeric libraries.

As used herein, the term "library" refers to expression  
35 constructs or host organisms containing the expression constructs.

The terms "biochemical pathway", "natural pathway" and "metabolic pathway" encompass any series of related biochemical reactions that are carried out by an organism. Such pathways may include but are not limited to biosynthetic or biodegradative pathways, or pathways of energy generation or conversion.

A "compound" is any molecule that is the result or by-product of a biochemical pathway, and is usually the product of interactions of a plurality of gene products.

10 An "activity" is the capability of a host organism to carry out a biochemical reaction or a series of biochemical reactions leading to the production of a compound of interest.

As used in the present invention, the following  
15 abbreviations will apply: eq (equivalents); M (Molar); mM (millimolar);  $\mu$ M (micromolar); N (Normal); mol (moles); mmol (millimoles);  $\mu$ mol (micromoles); nmol (nanomoles); kg (kilograms); gm (grams); mg (milligrams);  $\mu$ g (micrograms); ng (nanograms); L (liters); mL (milliliters);  $\mu$ l (microliters);  
20 vol (volumes); s (seconds); and °C (degrees Centigrade).

In addition, the following abbreviations are used:  
Cfu: colony forming units; LB: Luria Broth; ddH<sub>2</sub>O: double-distilled, reversed osmosis purified water; sea H<sub>2</sub>O: Filtered Pacific seawater; SSW: synthetic seawater; FACS:  
25 fluorescence-activated cell sorting; GFP: *Aequorea victoria* green fluorescent protein; kbp: Kilobase pairs; g: Gravity; rpm: Rotations per minute; CIAP: Calf intestinal alkaline phosphatase; EDTA: Ethylenediamine tetraacetic acid; TE: 10mM Tris/1.5 mM EDTA pH 7.4; PEG: Polyethylene glycol; *E. coli*:  
30 *Escherichia coli*; CHO: Chinese hamster ovary; *S. cerevisiae*: *Saccharomyces cerevisiae*; *A. nidulans*: *Aspergillus nidulans*; *S. pombe*: *Schizosaccharomyces pombe*; *S. lividans*: *Streptomyces lividans*; *S. aureus*: *Staphylococcus aureus*; *S. coelicolor*: *Streptomyces coelicolor*; *B. subtilis*: *Bacillus*  
35 *subtilis*; BAC: Bacterial artificial chromosome; YAC: yeast artificial chromosome; PCR: polymerase chain reaction; CaMV: cauliflower mosaic virus; AcNPV: *autographa californica*

*nuclear polyhydrosis virus; EBV: Epstein-Barr virus; SDS: sodium dodecyl sulfate; CsCl: cesium chloride.*

#### 4. DESCRIPTION OF THE FIGURES

5        Figure 1: Expression construct for combinatorial natural pathway expression library. The expression construct contains vector DNA and a donor DNA fragment that comprises genes encoding a metabolic pathway and natively associated regulatory regions.

10       Figure 2: Expression construct for combinatorial chimeric pathway expression library. The expression construct contains vector DNA and five concatenated gene cassettes each comprising donor DNA and regulatory region.

15       Figure 3: A cloning strategy for combinatorial natural pathway expression library. Clonable DNA (B) is extracted from donor organisms (A) is partially digested with a restriction enzyme to generate fragments of genomic DNA (C) encoding naturally-occurring biochemical pathways or portions thereof. A DNA vector (D) digested with a restriction enzyme  
20       to generate a vector having compatible ends (E) is ligated to the fragments of genomic DNA to form expression constructs (F).

25       Figures 4A-4C: Assembly of a gene cassette. Figure 4A depicts an annealed, phosphorylated *lac* promoter fragment containing a cohesive *Bam*HI site and a blunt end corresponding to a portion of a *Sma*I site. Figure 4B depicts a promoter dimer containing a *Bam*HI site flanked on each side by a *lac* promoter. Figure 4C depicts concatenated promoter fragments.

30       Figures 5A-5F: Cloning strategy for combinatorial chimeric pathway expression library. Figure 5A shows the steps in preparing promoter and terminator fragments for directional cloning of cDNA and genomic DNA inserts. Figure 5B shows the steps in preparing promoter and terminator  
35       fragments for ligation to genomic DNA inserts. Figure 5C shows the steps in preparing cDNA inserts for directional cloning, assembly of gene cassettes, and attachment to solid

support. Figure 5D shows the steps in preparing genomic DNA inserts for cloning, assembly of gene cassettes and attachment to solid support. Figures 5E and 5F show the serial ligation and deprotection of gene cassettes to form a  
5 concatemer, the ligation of the concatemer to an *S. pombe*/*E. coli* shuttle vector (pDblet), release of the expression construct from the solid support and circularization of the expression construct.

Figures 6A-6B: Vectors useful for preparing  
10 combinatorial gene expression libraries. Figure 6A shows a map of Streptococ. The cosmid vector Streptococ contains a unique BamHI site flanked by T3 and T7 promoters in the multiple cloning site, the origin of replication and thiostrepton resistance gene from pIJ 699, a ColE1 origin  
15 (ori), an ampicillin gene (Amp) and two cos sites. Figure 6B shows a map of modified pDblet. The plasmid pDblet is modified in the multiple cloning site (MCS), and contains a ColE1 origin of replication, an ampicillin gene (Ap<sup>R</sup>), two copies of autonomous replicating sequence (ARS), an ura4  
20 marker, and the  $\beta$ -galactosidase gene (LacZ). A: AatII; B: BamHI N: NdeI. Figure 6C shows the oligomer containing an altered BstXI sequence and a NcoI site, which was ligated in excess to SacI/NotI cut pDblet to form modified pDblet.

Figure 7 shows a chemoresponsive construct pERD-20-GFP  
25 comprising a reporter gene encoding green fluorescent protein (GFP), a chemoresponsive promoter (Pm) and its associated regulator (XylS).

Figure 8 shows a macrodroplet comprising a permeable matrix, in which is encapsulated a clone from a combinatorial  
30 gene expression library, and an indicator cell which contains a reporter regimen.

Figures 9A and 9B provides an example of FACS sorting of a pool of *E. coli* cells, with and without the presence of expression constructs comprising marine bacterial genes. *E.*  
35 *coli*, strain XL1-MR containing the chemoresponsive construct pERD-20-GFP, referred to as XL1-GFP was infected with a cosmid library of marine bacterial genes. The XL1-GFP cells

with or without the marine bacteria genes were cultured for 12 hours at 30°C, and subjected to two cycles of FACS sorting. Figure 9A: XL1-GFP with marine bacterial genes; Figure 9B: control XL1-GFP cells.

5        Figure 10 shows an alignment of the amino acid sequence of actinorhodin dehydrase of *Streptomyces coelicolor*, and the predicted partial amino acid sequence derived from CXC-AMN20. Plain boxes indicate sequence identity, and shaded boxes indicate conservative sequence homology.

10        Figure 11: PCR detection of clone CXC-AMN20 sequences in pools of genomic DNA of marine bacteria. The figure shows a stained agarose gel containing PCR amplicons derived from marine bacteria genomic DNA. M: molecular weight markers, sizes in bp. -: negative control. +: positive controls for  
15 the amplicon and for ribosomal RNA. The lanes contain amplicons derived from T: genomic DNA from all 37 species of marine bacteria; 1, 2, 3, 4: pools of genomic DNA of marine bacteria.

Figure 12A-C. PCR detection of clone CXC-AMN20 sequences  
20 in genomic DNA of marine bacteria species. The figures show stained agarose gels containing PCR amplicons derived from genomic DNA of individual species of marine bacteria. M: molecular weight markers, sizes in bp. -: negative control. +: positive controls for the amplicon and for ribosomal RNA.  
25 The lanes contain amplicons derived from genomic DNA of marine bacteria: species #1-10, #12-20 and #21-35 in pool 1, 2 and 3 respectively.

## 5. DETAILED DESCRIPTION OF THE INVENTION

30        The present invention relates to a drug discovery system that provides methods and compositions for capturing and preserving the diversity of genetic resources in nature, and for translating and expanding the captured genetic resources into diversity of chemical structures. The invention also  
35 facilitates screening for desirable activities and compounds.

More particularly, the invention provides methods for constructing and screening combinatorial gene expression



libraries. These libraries comprise random assortments of gene products of multiple species which are in some cases allowed to interact with each other in the expression host, and result in some cases in the formation of novel

5 biochemical pathways and/or the production of novel classes of compounds. Moreover, the libraries of the invention provide efficient access to otherwise inaccessible sources of molecular diversity.

The novel biochemical pathways may carry out processes  
10 including but not limited to structural modification of a substance, addition of chemical groups to the substance, or decomposition of the substance.

The novel classes of compound may include but are not limited to metabolites, secondary metabolites, enzymes, or  
15 structural components of an organism. A compound of interest may have one or more potential therapeutic properties, including but not limited to antibiotic, antiviral, antitumor, pharmacological or immunomodulating properties or be other commercially-valuable chemicals such as pigments. A  
20 compound may serve as an agonist or an antagonist to a class of receptor or a particular receptor.

As used in the present invention, the term "combinatorial gene expression library" encompasses combinatorial natural pathway expression library,  
25 combinatorial chimeric pathway expression library as well as host organisms containing the libraries of expression constructs.

A "combinatorial natural pathway expression library" is a library of expression constructs prepared from genetic  
30 material derived from one or more species of donor organisms, in which genes present in the genetic material are operably associated with regulatory regions that drives expression of the genes in an appropriate host organism. The combinatorial expression library utilizes host organisms that are capable  
35 of producing functional gene products of the donor organisms. The genetic material in each of the host organism encodes

naturally-occurring biochemical pathways or portions thereof from one of the donor organisms.

A "combinatorial chimeric pathway expression library" is a library of expression constructs prepared from randomly  
5 concatenated genetic material derived from a plurality of species of donor organisms, in which genes present in the genetic material are operably associated with regulatory regions that drives expression of the genes in an appropriate host organism. The host organisms used are capable of  
10 producing functional gene products of the donor organisms. Upon expression in the host organism, gene products of the donor organism(s) may interact to form novel chimeric biochemical pathways.

Generally, the methods of the invention comprise  
15 providing genetic material derived from one or more donor organism(s), manipulating said genetic material, and introducing said genetic material into a host organism via a cloning or expression vector so that one or more genes of the donor organism(s) are transferred to and expressed in the  
20 host organism. Such host organisms containing donor genetic material are pooled to form a library.

The transferred genetic material, typically comprises a random assortment of genes, the expression of which is driven and controlled by one or more functional regulatory regions.  
25 The expression construct or vector may provide some of these regulatory regions. The genes of the donor organism(s) are transcribed, translated and processed in the host organism to produce functional proteins that in turn generate the metabolites of interest.

30 According to the present invention, gene expression libraries comprising complete naturally occurring biochemical pathways or substantial portions thereof can greatly facilitate searches for donor multi-enzyme systems responsible for making compounds or providing activities of  
35 interest. Genes that are involved in a particular biochemical pathway can be conveniently isolated and characterized in a single expression construct or clone. A

typical arrangement of such an expression construct is shown in Figure 1.

Once a desirable activity or compound is identified, this convenient feature can greatly facilitate downstream  
5 drug development efforts, such as strain improvement and process development. The positive clone can be cultured under standard conditions to produce the desired compound in substantial amounts for further studies or uses. The genes of the biochemical pathway are immediately available for  
10 sequencing, mutation, expression, and further rounds of screening. The cloned biochemical pathway is readily amenable to traditional and/or genetic manipulations for overproduction of the desired compound.

Furthermore, biochemical pathways that are otherwise  
15 silent or undetectable in the donor organism may be discovered more easily by virtue of their functional reconstitution in the host organism. Since the biochemical characteristics of the host organism are well known, many deviations as a result of expression of donor genetic  
20 material can readily be recognized. Novel compounds may be detected by comparing extracts of a host organism containing donor genetic material against a profile of compounds known to be produced by the control host organism under a given set of environmental conditions. Even very low levels of a  
25 desirable activity or compound may be detected when the host biochemical and cellular background of the host organism is well characterized. As described in later sections, the present invention provides methods for detecting and isolating clones that produce the desirable activity or class  
30 of compounds.

In a preferred embodiment, the methods may be applied to donor organism(s) that cannot be recovered in substantial amounts in nature, or cultured in the laboratory. By transferring genetic material from such organisms into a host  
35 organism, the organisms' metabolic pathways can be reproduced, and their products tested efficiently for any

desirable properties. Thus, the genetic diversity of these organisms is captured and preserved.

In another embodiment of the invention, a combinatorial chimeric pathway gene expression library can be constructed  
5 in which the genetic materials from one or multiple donor organisms are randomly concatenated prior to introduction into the host organism. Thus, each host organism in the library may individually contain a unique, random combination of genes derived from the various donor pathways or  
10 organisms. Figure 2 shows the arrangement of genes and regulatory regions in an expression construct of a combinatorial chimeric pathway gene expression library. For the most part, such combinations of genes in the library do not occur in nature. Upon expression, the functional gene  
15 products of the various donor pathways or organisms interact with each other in individual host organisms to generate combinations of biochemical reactions which result in novel chimeric metabolic pathways and/or production of novel compounds. Collectively, the genetic resources of the donor  
20 organisms in the library are translated into a diversity of chemical compounds that may not be found in individual donor organisms.

In another aspect of the invention, the species of donor organisms may be selected on the basis of their biological  
25 characteristics, or ability to carry out desirable but uncharacterized biochemical reactions that are complementary to the host organism. Such desirable characteristics may include, but are not limited to the capability to utilize certain nutrients, to survive under extreme conditions, to  
30 derivatize a chemical structure, and the ability to break down or catalyze formation of certain types of chemical linkages. When genes of the donor organism are expressed in the host organism, the donor gene products can modify and/or substitute the functions of host gene products that  
35 constitute host metabolic pathways, thereby generating novel hybrid pathways. Novel activities and/or compounds may be produced by hybrid pathways comprising donor and host-derived

components. The target metabolic pathway modified by donor gene products may be native to the host organism. Alternatively, the target metabolic pathway may be provided by products of heterologous genes which are endogenous or  
5 have been genetically engineered into every host organism prior to or contemporaneous to construction of the gene expression library. Thus, the present invention also embodies constructing and screening gene expression libraries, wherein DNA fragments encoding metabolic pathway  
10 of donor organisms are cloned and coexpressed in host organisms containing a target metabolic pathway.

In another embodiment of the invention, the host organism may have an enhanced complement of active drug efflux systems which secretes the compounds of interest into  
15 the culture medium, thus reducing the toxicity of the compounds to the host organism. Absorptive material, e.g., neutral resins, may be used during culturing of the host organisms, whereby metabolites produced and secreted by the host organism may be sequestered, thus facilitating recovery  
20 of the metabolites.

In order to make the process of screening combinatorial gene expression libraries more efficient, the present invention further provides methods for detecting those host organisms in the library that possess the activity or  
25 compound of interest. In one embodiment of the invention, the host organism contains a reporter system that will respond to the presence of an introduced change, such as the presence of the desirable compound or activity, by activating the *de novo* synthesis of a reporter molecule. In another  
30 embodiment, the host organism contains the precursor of a reporter molecule, or a physiological probe, which is converted to the reporter by the presence of the desirable compound or activity. The reporter molecule in the positive clone generates a signal which allows detection of the  
35 positive clone in the expression library, as well as its isolation from the other non-productive clones.

In many respects, the drug discovery system provides significant convenience and time advantage to the various steps of drug development up to clinical trials. The libraries of the invention are compatible with the  
5 established multi-well footprint format and robotics for high-throughput screening. The host organisms of the invention are organisms commonly used for genetic manipulation and/or process development. The present invention takes advantage of the fact that such host  
10 organisms or production hosts are well-characterized in terms of their biological properties and maintenance requirements. By transferring genetic materials from a donor organism to other more familiar expression systems, the need for difficult culturing conditions for the donor organism is  
15 reduced. Thus, the biological activities, the pharmacokinetic and toxic properties of any lead compound discovered in the system of the invention may be studied and optimized more efficiently.

The novel metabolic pathway generated in a positive  
20 clone can be delineated by standard techniques in molecular biology. The lead compound may be synthesized by culturing a clone of the drug-producing host organism under standard or empirically determined culture conditions, so that sufficient quantities of the lead compound may be isolated for further  
25 analysis and development. There are already high purity manufacturing protocols, such as Good Manufacturing Practice (GMP) established for some of these standard industrial host organisms. Unlike conventional methods of screening natural product sources, less effort is required to adapt the  
30 screening and production technologies to the particular requirements of each potential drug-producing organism.

The present invention also provides specific combinatorial gene expression libraries made according to the methods of the invention from genetic materials of a  
35 particular set of donor organisms and/or cell types. Not all organisms or cell types in a set, especially mixed samples,

need to be individually identified or characterized to enable preparation of the combinatorial gene expression libraries.

Any combinatorial gene expression library of the invention may be amplified, replicated, and stored.

5 Amplification refers to culturing the initial host organisms containing donor DNA so that multiple clones of the host organisms are produced. Replication refers to picking and growing of individual clones in the library. A combinatorial gene expression library of the invention may be stored and  
10 retrieved by any techniques known in the art that is appropriate for the host organism. Thus, the libraries of the invention are an effective means of capturing and preserving the genetic resources of donor organisms, which may be accessed repeatedly in a drug discovery program.

15

#### 5.1. PREPARATION OF COMBINATORIAL GENE EXPRESSION LIBRARIES

##### 5.1.1. DONOR ORGANISMS

20 Any organism can be a donor organism for the purpose of preparing a combinatorial gene expression library of the invention. The donor organisms may be obtained from private or public laboratory cultures, or culture deposits, such as the American Type Culture Collection, the International  
25 Mycological Institute, or from environmental samples either cultivable or uncultivable.

The donor organism(s) may have been a traditional source of drug leads, such as terrestrial bacteria, fungi and plants. The donor organisms may be transgenic, genetically  
30 manipulated or genetically selected strains that have been useful in generating and/or producing drugs.

The donor organism(s) may or may not be cultivable with current state-of-the-art microbiological techniques e.g., the genetic material used to prepare the libraries can be  
35 obtained directly from an environmental sample. Since only a minority ( $\leq 1\%$ ) of the microbes found in nature can be cultured in the laboratory, the major advantage of the

present invention is that the donor organism does not have to be cultivable to be utilized herein (Torsvik et al. 1990, Appl Env Micro, 56:782-787).

The invention is not limited to the use of  
5 microorganisms as donors. Plants produce an enormous range of compounds, some with dramatic activities on both animals and microorganisms, for example, phytoalexins (Abelson 1990, Science 247:513). Some of these compounds are inducible by wounding or elicitors derived from the cell walls of plant  
10 pathogens (Cramer et al. 1985, EMBO J. 4:285-289; Cramer et al. 1985, Science 227:1240-1243; Dron et al. 1988, Proc. Natl. Acad. Sci. USA 85:6738-6742). Biologically-active compounds, like taxol, camptothecin, and artemisinin are examples of plant-derived natural products which are  
15 undergoing clinical development respectively as anti-tumor and anti-malarial agents. Any plants, especially those with potential medicinal properties, may be desirable donor organisms (Phillipson, 1994, Trans R Soc Trop Med Hyg, 88 Suppl 1:S17-9; Chadwick et al. eds, 1994, in "Ethnobotany and  
20 the search for new drugs", Wiley, Chichester, Ciba Foundation Symp 185).

Another source of natural products with potentially useful antimicrobial or pharmacological properties are invertebrates and vertebrates. Some of these compounds serve  
25 as chemical defenses against competitors, pathogens and predators. Such compounds may also be used to kill prey or used as a form of communication (Caporale 1995, Proc Natl Acad Sci 92:75-82). In numerous cases, the secondary metabolites are thought to be produced by associated microbes  
30 that may be symbiotic (Faulkner et al. 1993, Gazzetta Chimica Italiana, 123:301-307; Bewley et al. 1995, in "An Overview of Symbiosis in Marine Natural Products Chemistry Symposium" in honor of Professor Antonio Gonzalez, La Laguna University, Canary Islands, September 16, 1995, p26 (abstract)).

35 Organisms known to manipulate biochemical pathways of other organisms in nature are sources of particular interest, e.g. certain plants, such as *Cycas*, can produce an ecdysone-



mimic which disrupts the development of certain insects. Such organisms may live in the same ecological niche where they exist as competitors, symbionts, predator and prey, or host and parasite. Thus, it may be advantageous to use  
5 genetic materials derived from organisms that interact chemically with others in nature.

Yet another rich source of natural products is marine organisms. For instance, marine microbes produce novel molecular structures, many of which are bioactive, e.g.  
10 octalactin A which is a potential anti-cancer agent with a molecular structure not previously seen in terrestrial bacteria (Tapiolas et al. 1991, J Amer Chem Soc, 113:4682-83); and salinamides (Trischman et al. 1994, J Amer Chem Soc 116:757-758) which have potent anti-inflammatory properties.  
15 Certain compounds derived from marine microorganisms contain bromine from seawater which renders the compounds highly active because of the chemical reactivity of the incorporated halogen, e.g., marinone (Pathirana et al. 1992, Tetrahedron Lett 33:7663-7666), a product of mixed polyketide and  
20 mevalonic acid biosynthetic pathways, which has selective antibiotic activity against gram positive bacteria. There is a vast diversity of marine species which live in a range of habitats, from polar to tropical regions, with different salinities, temperatures and pressures. The unique nature of  
25 these habitats is reflected in the distinct genetics and biochemistry of these organisms, and may provide many useful drug leads. See, for example, Fenical et al. 1992, in "Marine Microorganisms; a new biological resource", Adv in Marine Biotechol, Vol. I, Plenum Press, New York.  
30 Environmental samples may be obtained from natural or man-made environments, and may contain a mixture of prokaryotic and eukaryotic organisms, and viruses, some of which may be unidentified. Samples can either be randomly collected or collected from areas that are ecologically  
35 stressed, for example, near an industrial effluent. Soil, freshwater or seawater filtrates, deposits around hot springs or thermal vents, and marine or estuarine sediments may be

used as sources of donor organisms. Samples may be collected from benthic, pelagic, and intertidal marine sources. Samples may be collected from tropical, subtropical, temperate and other regions. The donor organisms may be  
5 thermophilic, halophilic, acidophilic, barophilic, or methanogenic.

It is also preferable to use organisms that are facing the possibility of extinction, such as those plants and microorganisms found in the tropical rain forest. Insofar as  
10 such habitats are being destroyed, species are being lost that might yield useful medicines.

Organisms with potential medicinal properties, including algae, lichens, fungi, plants, and animals, may also be collected on the basis of their uses in traditional or ethnic  
15 medical practices.

In many aspects, it is desirable that the library is constructed with genetic material derived from donor organisms that are not generally amenable to traditional drug discovery or development technologies. Such donor organisms  
20 may have one or more of the following characteristics:

(i) the organism cannot be propagated or cultured in the laboratory; (ii) the organism cannot be recovered from nature in amounts sufficient for further experiments; and/or (iii) the organism requires special conditions for production  
25 of the desirable compound that are unknown or are not commercially reasonable. The latter characteristics also describe organisms in extant culture collections, where no drug leads may have been detected in conventional screening processes due to inappropriate culture conditions.

30 For the purpose of constructing an expression library, the donor organisms need not be taxonomically defined or biochemically characterized. Identification or genetic footprinting of a cultivable species or a representative group of species from an environmental sample may be  
35 performed depending on the complexity of the sample and the needs of the drug discovery program, such as, for example, a requirement for donor species dereplication.

The donor organisms may be concentrated or cultured in the laboratory or field prior to extraction of their nucleic acids. For preparing cDNAs, specific growth conditions or the presence of certain chemicals in the culture may be  
5 required to induce or enhance the transcription of gene products encoding the activities of interest in the donor organisms. Standard growth conditions may be used to culture the organisms if only genomic DNA is required.

Since it is unlikely that all donor organisms in an  
10 environmental sample may be propagated at the same rate, if at all under laboratory conditions, some of the donor organisms may overgrow and lead to the loss or dilution of slow-growing organisms. Thus, it may be preferable to prepare nucleic acids directly from donor organisms in an  
15 environmental sample without prior culturing in the laboratory. This may be especially useful when attempting to access the secondary metabolites of invertebrates such as marine sponges, where the metabolites are often believed to be produced by the associated symbiotic and uncultivable  
20 microbes. Methods for preparing high quality nucleic acids from donor organisms in environmental samples are provided below in Sections 5.1.2.

Donor organisms contemplated by the invention may include, but are not limited to viruses; bacteria;  
25 unicellular eukaryotes, such as yeasts and protozoans; algae; fungi; plants; tunicates; bryozoans; worms; echinoderms; insects; mollusks; fishes; amphibians; reptiles; birds; and mammals. Non-limiting examples of donor organisms are listed in Tables I and II.

30

35

Table I:

List of exemplary bacterial and fungal donor organisms (Berdy 1974, Adv Appl Microbiol, 18: 309-406; Goodfellow et al. 1989, in "Microbial Products: New Approaches", Cambridge University Press 343-383)

Group	Genera
Bacteria	
10	<i>Actinomycetales</i> <i>Streptomyces, Micromonospora, Norcadia, Actinomadura, Actinoplanes, Streptosporangium, Microbispora, Kitasatosporia</i> <i>Eubacteriales</i> <i>Azobacterium, Rhizobium, Achromobacterium, Enterobacterium, Brucella, Micrococcus, Lactobacillus, Bacillus, Clostridium, Brevibacterium</i>
15	<i>Pseudomonadales</i> <i>Pseudomonas, Aerobacter, Vibrio, Halobacterium</i> <i>Mycoplasmatales</i> <i>Myxobacteriales</i> <i>Mycoplasma</i> <i>Cytophaga, Myxococcus</i>
Fungi	
20	<i>Myxothallophytes</i> <i>Physarum, Fuligo</i> <i>Phycomycetes</i> <i>Mucor, Phytophthora, Rhizopus</i> <i>Ascomycetes</i> <i>Aspergillus, Penicillium</i> <i>Basidiomycetes</i> <i>Coprinus, Phanerochaete</i> <i>Fungi Imperfecti</i> <i>Acremonium (Cephalosporium), Trochoderma, Helminthosporium, Fusarium, Alternaria, Myrothecium</i>
25	<i>Yeasts</i> <i>Saccharomyces</i>

30

35

Table II:

## Higher forms of exemplary donor organisms

5	Group	Exemplary Genera, Compounds & Properties
	Plants	
	Algae	<i>Digenea simplex</i> (kainic acid, antihelminthic)
		<i>Laminaria angustata</i> (laminine, hypotensive)
	Lichens	<i>Usnea fasciata</i> (vulpinic acid, antimicrobial; usnic acid, antitumor)
10	Higher Plants	<i>Catharanthus</i> (Vinca alkaloids), <i>Digitalis</i> (cardiac glycosides), <i>Podophyllum</i> (podophyllotoxin), <i>Taxus</i> (taxol), <i>Cephalotaxus</i> (homoharringtonine), <i>Camptotheca</i> (Camptothecin), <i>Artemisia</i> (artemisinin), <i>Coleus</i> (forskolin), <i>Desmodium</i> (K channel agonist)
15	Protozoa	
	Dinoflagellates	<i>Ptychodiscus brevis</i> (brevitoxin, cardiovascular)
	Insects	<i>Dolomedes</i> ("fishing spider" venoms), <i>Epilachna</i> (mexican bean beetle alkaloids)
20	Bryozoans	<i>Bugula neritina</i> (bryostatins, anti cancer)
	Molluscs	<i>Conus</i> toxins
	Sponges	<i>Microciona prolifera</i> (ectyonin, antimicrobial) <i>Cryptotethya</i> <i>crypta</i> (D-arabino furanosides)
25	Corals	<i>Pseudoterogonia species</i> (Pseudoteracins, anti-inflammatory) <i>Erythropodium</i> (erythrolides, anti-inflammatory)
	Worms	
	Annelida	<i>Lumbriconereis heteropa</i> (nereistoxin, insecticidal)
30	Spinunculida	<i>Bonellia viridis</i> (bonellin, neuroactive)
	Tunicates	<i>Trididemnum solidum</i> (didemnin, anti-tumor and anti-viral) <i>Ecteinascidia turbinata</i> (ecteinascidins, anti-tumor)
35	Fish	<i>Eptatretus stoutii</i> (eptatretin, cardioactive), <i>Trachinus draco</i> (proteinaceous toxins, reduce blood pressure, respiration and reduce heart rate)

Amphibians	<i>Dendrobatid frogs</i> (batrachotoxins, pumiliotoxins, histrionicotoxins, and other polyamines)
Reptiles	Snake venom toxins
Birds	histrionicotoxins, modified carotenoids, retinoids and steroids (Goodwin 1984 in "The Biochemistry of the Carotenoids" Vol. II, Chapman and Hall, New York, pp. 160- 168)
5	
Mammals	<i>Ornithorhynchus anatinus</i> (duck- billed platypus venom), modified carotenoids, retinoids and steroids (Goodwin 1984, supra, pp. 173-185; Devlin 1982 in "Textbook of Biochemistry", Wiley, New York, p. 750)
10	
15	
20	
25	
30	
35	

#### 5.1.2. PREPARATION OF HIGH QUALITY NUCLEIC ACIDS FROM DONOR ORGANISMS

Nucleic acids may be isolated from donor organisms by a variety of methods depending on the type of organisms and the source of the sample. It is important to obtain high quality nucleic acids that are free of nicks, single stranded gaps, and partial denaturation, and are of high molecular weight (especially for genomic DNA cloning), in order to construct gene expression libraries that are fully representative of the genetic information of donor organisms. To prepare high quality nucleic acid, the methods of the invention provide gentle, rapid and complete lysis of donor organisms in the sample, and rapid and complete inactivation of nucleases and other degradative proteins from the organisms. Initial extraction may be carried out in the field to stabilize the nucleic acids in the sample until further isolation steps can be performed in the laboratory

Any nucleic acid isolation procedure requires efficient breakage of the donor organism. A number of standard techniques may be used, including freezing in liquid nitrogen, grinding in the presence of glass or other disruptive agents, as well as simple mechanical shearing or enzymatic digestion.

For mixed materials such as soil, or for samples that contain high amounts of tough materials, such as cellulose or chitin (as in filamentous fungi and plants, for instance), freeze-drying may be employed to render the samples fragile, thus making them more amenable to disruption. Such lyophilized materials preserve both enzymatic as well as high molecular weight materials (such as nucleic acids) for long periods (Gurney 1984, in Methods in Molecular Biology, Vol. 2, p35-42, John M. Walker ed.). Samples may be flash frozen in liquid nitrogen. Samples that are loose, such as soil, can be frozen in fine gauze or nylon mesh. Lyophilization can be carried out on frozen samples under vacuum for a period of 24-72 hours. Freeze-dried samples can be stored desiccated under vacuum at -70°C. Additional steps may be

required for preparation of environmental samples, such as concentration of microbial populations (Jacobson et al. 1982, Appl Env Microbiol, 58:2458-2462; Zhou et al. 1996, Appl Env Microbiol, 62:316-322; Somerville et al. 1989, Appl Env Microbiol, 55:548-554).

One principal method of the present invention, though certainly not the only one to be used, is modified from Chirgwin et al. (1979, Biochem 24:5294), Sadler et al. (1992, Curr Genet, 21:409-416) and Foster (1991, Ph.D. thesis, University of California, Santa Barbara). The method uses the strong chaotropic agent, guanidinium isothiocyanate, with 2-mercaptoethanol to denature proteins and inactivate nucleases, followed by purification of the nucleic acid material by cesium chloride gradient centrifugation. The method provided herein differs from Chirgwin's method in that both DNA and RNA are extracted. Also included in the method of the invention is a high speed centrifugation step, and the optional addition of bisbenzimidazole dye. Depending on the donor organism used, additional steps may include, but are not limited to, treatment with hexadecylpyridinium chloride or cetyltrimethyl ammonium bromide (CTAB) to selectively remove polysaccharides, treatment with polyvinylpyrrolidone for removal of phenolics, and cellulose chromatography for removal of starch and other carbohydrates (Murray & Thompson, 1980, Nuc Acid Res 8: 4321-25).

RNA isolated from donor organisms can be converted into complementary DNA (cDNA) using reverse transcriptase.

Damaged nucleic acid may be difficult to clone resulting in loss of donor organism DNA and low numbers of clones in a library. The problem can be worsened if the host organism is permissive for recombination and lacks effective endogenous DNA repair mechanisms. The present invention also provides that damaged DNA can be repaired *in vitro* prior to cloning, using enzymatic reactions commonly employed during second strand synthesis of complementary DNA (Sambrook et al. 1989, in "Molecular Cloning" 2nd Edition, section 8). For example, DNA gaps and nicks may be repaired by the Klenow fragment of



DNA polymerase, and *E. coli* DNA ligase. Such enzymatic reactions are well known to those skilled in the arts.

When preparing a combinatorial expression library from DNA extracted from environmental samples, the quantity of available DNA is often limited, and is a consideration in the selection of ligation strategy. If the quantity is low after extraction or concatenation (<100  $\mu$ g), the DNA may be ligated into a high-efficiency cloning system e.g., SuperCos, as described in Section 5.1.3. The inserts in the clones are amplified and are released from the vector by restriction enzyme digestion. Due to the nature of environmental DNA samples, which may contain both prokaryotic and eukaryotic donor organisms, it may be desirable to use multiple host organisms. If sufficient amount of original environmental DNA sample is available, or if the DNA has been amplified, the DNA may be ligated to each of a panel of vectors appropriate for the desired panel of expression host cells. Preferably, the vectors have the capacity to shuttle between two or more expression hosts.

20

#### 5.1.3. HOST ORGANISMS AND VECTORS

The term "host organism" as used herein broadly encompasses unicellular organisms, such as bacteria, and multicellular organisms, such as plants and animals. Any cell type may be used, including those that have been cultured *in vitro* or genetically engineered. Any host-vector systems known in the art may be used in the present invention. The use of shuttle vectors that can be replicated and maintained in more than one host organism is advantageous.

30

Host organisms or host cells may be obtained from private laboratory deposits, public culture collections such as the American Type Culture Collection, or from commercial suppliers. Such host organisms or cells may be further modified by techniques known in the art for specific uses.

35

According to the invention, it is preferable that the host organism or host cell has been used for expression of

heterologous genes, and are reasonably well characterized biochemically, physiologically, and/or genetically. Such host organisms may have been used with traditional genetic strain improvement methods, breeding methods, fermentation  
5 processes, and/or recombinant DNA techniques. It is desirable to use host organisms which have been developed for large-scale production processes, and that conditions for growth and for production of secondary metabolites are known.

The host organisms may be cultured under standard  
10 conditions of temperature, incubation time, optical density, and media composition corresponding to the nutritional and physiological requirements of the expression host. However, conditions for maintenance and production of a library may be different from those for expression and screening of the  
15 library. Modified culture conditions and media may also be used to emulate some nutritional and physiological features of the donor organisms, and to facilitate production of interesting metabolites. For example, chemical precursors of interesting compounds may be provided in the nutritional  
20 media to facilitate modifications of those precursors. Any techniques known in the art may be applied to establish the optimal conditions.

The host organism should preferably be deficient in the abilities to undergo homologous recombination and to restrict  
25 foreign DNA. The host organism should preferably have a codon usage similar to that of the donor organism. If eukaryotic donor organisms are used, it is preferable that the host organism has the ability to process the donor messenger RNA properly, e.g., splice out introns.

30 Preferred prokaryotic host organisms may include but are not limited to *Escherichia coli*, *Bacillus subtilis*, *Streptomyces lividans*, *Streptomyces coelicolor*. Yeast species such as *Saccharomyces cerevisiae* (baker's yeast), *Schizosaccharomyces pombe* (fission yeast), *Pichia pastoris*,  
35 and *Hansenula polymorpha* (methylophilic yeasts) may also be used. Filamentous ascomycetes, such as *Neurospora crassa* and *Aspergillus nidulans* may also be used. Plant cells such as

those derived from *Nicotiana* and *Arabidopsis* are preferred. Preferred mammalian host cells include but are not limited to those derived from humans, monkeys and rodents, such as chinese hamster ovary (CHO) cells, NIH/3T3, COS, 293, VERO, 5 etc (see Kriegler M. in "Gene Transfer and Expression: A Laboratory Manual", New York, Freeman & Co. 1990).

A host organism may be chosen which modifies and processes the expressed gene products in a specific fashion as desirable. Such modifications (e.g., glycosylation) and 10 processing (e.g., cleavage) of protein products may be important for the function of the protein in a biochemical pathway. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins. Appropriate cells lines or host 15 systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper and accurate processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be 20 preferred if the donor organism(s) are eukaryotic.

For example, it has been shown that eukaryotic fungi share much of the same core molecular biology, and that gene exchange is possible between many of the most common fungal species (Gurr et al. 1987, in Gene Structure in Eukaryotic 25 Microbes, Kinghorn ed., p.93; Bennet & Lasure 1992, Gene Manipulations in Fungi, Academic Press, NY). A preferred example of a eukaryotic host organism is the fission yeast, *Schizosaccharomyces pombe*. First, the molecular biology of *S. pombe* is highly developed and many major culture and 30 purification processes and manipulations are routinely performed. Second, it is unicellular, and thus can easily be cultured, stored, and manipulated in a laboratory setting. Third, and of particular importance for use in expressing mixed eukaryotic DNAs, it is capable of properly splicing and 35 expressing genes of other species of fungi, plants, and mammals. Studies of the splicing and processing of heteronuclear RNA (RNA which contains introns) have indicated

that *S. pombe* shares with other fungi and higher metazoans a remarkable similarity of pattern and structure of small nuclear RNA (snRNA) components needed for splicing. Finally, many non-*S. pombe* promoters, some of which derive from  
5 mammalian and plant viruses, are capable of driving moderate to high levels of gene expression (Forsburg, 1993, Nuc Acids Res, 21:2955) This feature can allow the shuttling of a fungal DNA/cDNA library to mammalian cell expression hosts such as NIH3T3 (fibroblasts), GT1-7 (neuronal), or other cell  
10 types.

A cloning vector or expression vector may be used to introduce donor DNA into a host organism for expression. An expression construct is an expression vector containing donor DNA sequences operably associated with one or more regulatory  
15 regions. The regulatory regions may be supplied by the donor DNA or the vector. A variety of vectors may be used which include, but are not limited to, plasmids; cosmids; phagemids; artificial chromosomes, such as yeast artificial chromosomes (YACs), and bacterial artificial chromosomes  
20 (BACs, Shizuya et al. 1992, Pro Natl Acad Sci 89: 8794-8797) or modified viruses, but the vector must be compatible with the host organism. Non-limiting examples of useful vectors are  $\lambda$ gt11, pWE15, SuperCos1 (Stratagene), pDblet (Brun et al. 1995, Gene, 164:173-177), pBluescript (Stratagene), CDM8,  
25 pJB8, pYAC3, pYAC4 (see Appendix 5 of Current Protocols in Molecular Biology, 1988, Ed. Ausubel et al., Greene Publish. Assoc. & Wiley Interscience, which is incorporated herein by reference).

When the regulatory regions and transcription factors of  
30 the host and donor organisms are compatible, donor transcriptional regions will be able to bind host factors, such as RNA polymerase, to effect transcription in the host organism. If the donor and host organisms are not compatible, regulatory regions compatible to the host  
35 organism may be attached to the donor DNA fragment in order to ensure expression of the transferred genes.

In cases where the entire operon, including its own translation initiation codon, ribosome binding regions, and adjacent sequences, is inserted into the appropriate cloning or expression vector, no additional control signals may be  
5 needed. However, in cases where only a portion of the coding sequence of a gene is inserted, exogenous control signals, including the translation initiation codon (frequently ATG) and adjacent sequences, must be provided. These exogenous regulatory regions and initiation codons can be of a variety  
10 of origins, both natural and synthetic. Both constitutive and inducible regulatory regions may be used for expression of the donor DNA. It is desirable to use inducible promoters when the products of the expression library may be toxic. The efficiency of the expression may be enhanced by the inclusion  
15 of appropriate transcription enhancer elements, (see Bittner et al. 1987, Methods in Enzymol. 153:516-544).

"Operably-associated" refers to an association in which the regulatory regions and the DNA sequence to be expressed are joined and positioned in such a way as to permit  
20 transcription, and ultimately, translation. The precise nature of the regulatory regions needed for gene expression may vary from organism to organism. Generally, a promoter is required which is capable of binding RNA polymerase and promoting the transcription of an operably-associated nucleic  
25 acid sequence. Such regulatory regions may include those 5'-non-coding sequences involved with initiation of transcription and translation, such as the TATA box, capping sequence, CAAT sequence, and the like. The non-coding region  
3' to the coding sequence may also be retained or replicated  
30 for its transcriptional termination regulatory sequences, such as terminators and polyadenylation sites. Two sequences of a nucleic acid molecule are said to be "operably-associated" when they are associated with each other in a manner which either permits both sequences to be transcribed  
35 onto the same RNA transcript, or permits an RNA transcript, begun in one sequence to be extended into the second sequence. A polycistronic transcript may thus be produced.

Two or more sequences, such as a promoter and any other nucleic acid sequences are operably-associated if transcription commencing in the promoter will produce an RNA transcript of the operably-associated sequences. In order to  
5 be "operably-associated" it is not necessary that two sequences be immediately adjacent to one another.

In addition, the expression vector may contain selectable or screenable marker genes for initially isolating, identifying or tracking host organisms that  
10 contain donor DNA. The expression vector may also provide unique or conveniently located restriction sites to allow severing and/or rearranging portions of the DNA inserts in an expression construct.

The expression vector may contain sequences that permit  
15 maintenance and/or replication of the vector in one or more host organism, or integration of the vector into the host chromosome. Such sequences may include but are not limited to replication origins, autonomously replicating sequences (ARS), centromere DNA, and telomere DNA. As a result, one or  
20 more copies of an expression construct may be generated and maintained in a host organism. The expression construct may be integrated in the host genome or remain episomal in the host organism.

Generally, it may be advantageous to use shuttle vectors  
25 which can be replicated and maintained in at least two host organisms, such as, for example, bacteria and mammalian cells, bacteria and yeasts, bacteria and plant cells, or gram positive and gram negative bacteria. A shuttle vector may contain a broad host range replication origin, such as those  
30 derived from IncP, IncQ plasmids, or at least two or more replication origins. A shuttle vector may also contain sequences derived from naturally-occurring plasmids which may be used to mobilize the library to various compatible host organisms via conjugative transfer (Hayman et al. 1993,  
35 Plasmid 30: 251-257). By using a shuttle vector for constructing a library, the DNA sequences of the donor

organisms may readily be replicated and transferred from one host organism to another.

For instance, a preferred and exemplary expression vector-host organism combination is the cosmid, SuperCos 1 5 and the *Escherichia coli* strain, XL1-Blue MR, both of which are commercially available from Stratagene (La Jolla, CA). The vector accepts through a *Bam*HI cloning site DNA inserts ranging from 30-42 kbp in size, and carries a neomycin resistance marker (neoR) and an SV40 promoter that is used 10 for expression in mammalian cell. The vector also contains an ampicillin resistance gene for selection in prokaryotic cells. The *E. coli* host organism is deficient in certain restriction systems (hsdR, mcrA, mcrCB and mrr), is endonuclease-deficient (endA1), and recombination deficient 15 (recA). The host organism cannot cleave inserted DNA carrying cytosine and/or adenine methylation, which is often present in eukaryotic DNA and cDNA synthesized using methyl-dNTP analogs.

Advantages of this system include the utilization of 20 highly efficient lambda *in vitro* packaging systems for initially generating a library in restriction minus, recA minus, *E. coli* hosts. Since the quality of source genomic DNA may be lower than that is required for naked DNA transformations, packaged genomic DNA inserts may be 25 protected against degradation. Once inside an *E. coli* host cell, damaged inserts may be repaired by the host's cellular DNA repair mechanisms. The system requires only small amounts of starting genomic DNA (5-10  $\mu$ g), and size selection may not be required since the packaging system only accepts 30 inserts in a certain size range. The initial library in *E. coli* may be amplified to produce supercoiled cosmid DNA which may be used in high efficiency transformation methods for introduction into other expression host organisms.

The SuperCos 1 vector may be further modified for 35 cloning in a *Streptomyces* host by replacing the SV40 origin of replication and the neoR gene with the *Streptomyces* origin of replication (e.g., from the plasmid pIJ101 or pIJ922), and

the thiostrepton resistance gene. This shuttle vector, termed *Streptocos* (see Figure 6A), is constructed by isolation of the 4.0 kb fragment from pIJ699 (Hopwood et al. 1985, Genetic Manipulation of *Streptomyces*, A Laboratory Manual, The John Innes Foundation) containing the pIJ101 origin and the thiostrepton resistance gene by digestion with KpnI and HindIII. This fragment is blunted at the KpnI site and cloned into SuperCos at the *Sma*I-HindIII restriction sites (See Bierman 1992, Denis 1992 for related examples).

10 In addition, sequence elements may be introduced for shuttle cosmid mobilization via conjugative transfer (Bierman et al. 1992, Gene 416:43-49). Different *Streptocos* versions containing *Streptomyces*-specific promoters may be introduced into the vector adjacent to the *Bam*HI cloning site. By using

15 PCR, *Streptomyces* promoter fragments may be generated that can be directionally cloned into the NotI/EcoRI sites of SuperCos 1. A variety of known *Streptomyces* promoters may be used including *ermE*, *Pptr* (1995, Mol Microbiol, 17:989) and *hrdB* (Buttner, M.J. 1989, Mol Microbiol, Vol. 3, pp. 1653-

20 1659). This approach can generally be useful for a wide range of host-vector systems. Accordingly, SuperCos 1 may be modified by introduction of host replication origins, selectable marker genes, and homologous promoters if necessary.

25 For combinatorial gene expression libraries using plant cells as hosts, the expression of the donor coding sequence may be driven by any of a number of promoters. For example, preferred strains are described in Principles of Gene Manipulation 1985, R.W. OLD and S.B. Primrose 3rd ed.

30 Blackwell Scientific Pub.; Vectors: A survey of molecular cloning vectors and their uses 1988, R.L. Rodriguez, D.T. Denhardt, Butterworths Pub.; A Practical guide to molecular Cloning 1988, B. Perbal, John Wiley and Sons, viral promoters such as the 35S RNA and 19S RNA promoters of CaMV (Brisson et

35 al. 1984, Nature 310:511-514), or the coat protein promoter of TMV (Takamatsu et al. 1987, EMBO J. 6:307-311) may be used; alternatively, plant promoters such as the small



subunit of RuBISCO (Coruzzi et al. 1984, EMBO J. 3:1671-1680; Broglie et al. 1984, Science 224:838-843); or heat shock promoters, e.g., soybean hsp17.5-E or hsp17.3-B (Gurley et al. 1986, Mol. Cell. Biol. 6:559-565) may be used.

5 Both plant cells and protoplasts may be used as host cells. Plant hosts may include, but are not limited to, those of maize, wheat, rice, soybean, tomato, tobacco, carrots, peanut, potato, sugar beets, sunflower, yam, *Arabidopsis*, rape seed, and petunia. Plant protoplasts are  
10 preferred because of the absence of a cell wall, and their potential to proliferate as cell cultures, and to regenerate into a plant.

In addition, the recombinant constructs may comprise plant-expressible selectable or screenable marker genes which  
15 include, but are not limited to, genes that confer antibiotic resistances, (e.g., resistance to kanamycin or hygromycin) or herbicide resistance (e.g., resistance to sulfonylurea, phosphinothricin, or glyphosate). Screenable markers include, but are not be limited to, genes encoding  $\beta$ -  
20 glucuronidase (Jefferson, 1987, Plant Molec Biol. Rep 5:387-405), luciferase (Ow et al. 1986, Science 234:856-859), and B protein that regulates anthocyanin pigment production (Goff et al. 1990, EMBO J 9:2517-2522).

To introduce donor organism DNA into plant cells, the  
25 *Agrobacterium tumefaciens* system for transforming plants may be used. The proper design and construction of such T-DNA based transformation vectors are well known to those skilled in the art. Such transformations preferably use binary *Agrobacterium* T-DNA vectors (Bevan, 1984, Nuc. Acid Res.  
30 12:8711-8721), and the co-cultivation procedure (Horsch et al. 1985, Science 227:1229-1231). Generally, the *Agrobacterium* transformation system is used to engineer dicotyledonous plants (Bevan et al. 1982, Ann. Rev. Genet  
16:357-384; Rogers et al. 1986, Methods Enzymol. 118:627-  
35 641), but it may also be used to transform as well as transfer DNA to monocotyledonous plants and plant cells.  
(see Hernalsteen et al. 1984, EMBO J 3:3039-3041 ; Hooykass-

Van Slogteren et al. 1984, Nature 311:763-764; Grimsley et al. 1987, Nature 325:1677-1679; Boulton et al. 1989, Plant Mol. Biol. 12:31-40.; Gould et al. 1991, Plant Physiol. 95:426-434).

5 In other embodiments, various alternative methods for introducing recombinant nucleic acid constructs into plant cells may also be utilized. These other methods are particularly useful where the target is a monocotyledonous plant cell. Alternative gene transfer and transformation  
10 methods include, but are not limited to, protoplast transformation through calcium-, polyethylene glycol (PEG)- or electroporation-mediated uptake of naked DNA (see Paszkowski et al., 1984, EMBO J 3:2717-2722, Potrykus et al. 1985, Molec. Gen. Genet. 199:169-177; Fromm et al., 1985,  
15 Proc. Nat. Acad. Sci. USA 82:5824-5828; Shimamoto, 1989, Nature 338:274-276) and electroporation of plant tissues (D'Halluin et al., 1992, Plant Cell 4:1495-1505). Additional methods for plant cell transformation include microinjection, silicon carbide mediated DNA uptake (Kaeppeler et al., 1990,  
20 Plant Cell Reporter 9:415-418), and microprojectile bombardment (see Klein et al., 1988, Proc. Nat. Acad. Sci. USA 85:4305-4309; Gordon-Kamm et al., 1990, Plant Cell 2:603-618).

For general reviews of plant molecular biology  
25 techniques see, for example, Weissbach & Weissbach, 1988, Methods for Plant Molecular Biology, Academic Press, NY, Section VIII, pp. 421-463; and Grierson & Corey, 1988, Plant Molecular Biology, 2d Ed., Blackie, London, Ch. 7-9.

In an insect system, *Autographa californica* nuclear  
30 polyhydrosis virus (AcNPV) a baculovirus, is used as a vector to express donor genes in *Spodoptera frugiperda* cells. The donor DNA sequence may be cloned into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the  
35 polyhedrin promoter). These recombinant viruses are then used to infect host cells in which the inserted gene is

expressed. (e.g., see Smith et al. 1983, J Virol 46:584; Smith, U.S. Patent No. 4,215,051).

In yeast, a number of vectors containing constitutive or inducible promoters may be used with *Saccharomyces cerevisiae* (baker's yeast), *Schizosaccharomyces pombe* (fission yeast), *Pichia pastoris*, and *Hansenula polymorpha* (methylotropic yeasts). For a review see, Current Protocols in Molecular Biology, Vol. 2, 1988, Ed. Ausubel et al., Greene Publish. Assoc. & Wiley Interscience, Ch. 13; Grant et al. 1987, Expression and Secretion Vectors for Yeast, in Methods in Enzymology, Eds. Wu & Grossman, 1987, Acad. Press, N.Y., Vol. 153, pp. 516-544; Glover, 1986, DNA Cloning, Vol. II, IRL Press, Wash., D.C., Ch. 3; and Bitter, 1987, Heterologous Gene Expression in Yeast, Methods in Enzymology, Eds. Berger & Kimmel, Acad. Press, N.Y., Vol. 152, pp. 673-684; and The Molecular Biology of the Yeast *Saccharomyces*, 1982, Eds. Strathern et al., Cold Spring Harbor Press, Vols. I and II.

In mammalian host cells, a variety of mammalian expression vectors are commercially available. In addition, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the donor DNA sequence may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by *in vitro* or *in vivo* recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing heterologous products in infected hosts. (e.g., See Logan & Shenk, 1984, Proc. Natl. Acad. Sci. (USA) 81:3655-3659). The Epstein-Barr virus (EBV) origin (OriP) and EBNA-1 as a trans-acting replication factor has been used to create shuttle episomal cloning vectors, e.g., EBO-pCD (Spickofsky et al. 1990, DNA Prot Eng Tech 2:14-18). Viral vectors based on retroviruses may also be used (Morgenstern et al. 1989, Ann Rev Neurosci, 12:47-65). Alternatively, the vaccinia 7.5K promoter may be used. (See, e.g., Mackett et al. 1982, Proc.

Natl. Acad. Sci. (USA) 79:7415-7419; Mackett et al. 1984, J. Virol. 49:857-864; Panicali et al. 1982, Proc. Natl. Acad. Sci. 79:4927-4931).

A number of selection systems may be used for mammalian  
5 cells, including but not limited to the Herpes simplex virus  
thymidine kinase (Wigler, et al. 1977, Cell 11:223),  
hypoxanthine-guanine phosphoribosyltransferase (Szybalska &  
Szybalski, 1962, Proc. Natl. Acad. Sci. USA 48:2026), and  
adenine phosphoribosyltransferase (Lowy, et al. 1980, Cell  
10 22:817) genes can be employed in tk<sup>-</sup>, hgp<sup>r</sup>t<sup>-</sup> or ap<sup>r</sup>t<sup>-</sup> cells,  
respectively. Also, antimetabolite resistance can be used as  
the basis of selection for dihydrofolate reductase (dhfr),  
which confers resistance to methotrexate (Wigler, et al.  
1980, Natl. Acad. Sci. USA 77:3567; O'Hare, et al. 1981,  
15 Proc. Natl. Acad. Sci. USA 78:1527); gpt, which confers  
resistance to mycophenolic acid (Mulligan & Berg, 1981),  
Proc. Natl. Acad. Sci. USA 78:2072); neomycin  
phosphotransferase (neo), which confers resistance to the  
aminoglycoside G-418 (Colberre-Garapin, et al. 1981, J. Mol.  
20 Biol. 150:1); and hygromycin phosphotransferase (hyg), which  
confers resistance to hygromycin (Santerre, et al. 1984, Gene  
30:147).

The present invention also provides specific  
modifications of host organisms that improve the performance  
25 of the combinatorial gene expression libraries. When the  
libraries are used for the purpose of generating secondary  
metabolites, the toxicity of the compounds can lead to under-  
representation of these productive host organisms in the  
library. In one embodiment of the invention, the host  
30 organism may be modified so that the growth and survival of  
the host organism is less adversely affected by the  
production of compounds of interest. The increased tolerance  
can reduce the loss of host organisms that are producing  
potent drugs at the screening stage as well as the production  
35 stage.

One preferred modification of the host organism is the  
introduction into and/or over-production of active drug

efflux systems in the host organism. Membrane-associated energy driven efflux plays a major role in drug resistance in most organisms, including bacteria, yeasts, and mammalian cells (Nikaido 1994, Science 264:382-388; Balzi et al. 1994, 5 Biochim Biophys Acta 1187:152-162; Gottesman et al. 1993, Ann Rev Biochem 62:385). A modified host organism having an enhanced complement of efflux systems can actively secrete a broader range of potentially toxic compounds, thus reducing their accumulation inside the host organism. Negative 10 feedback mechanisms, such as end-product inhibition of the metabolic pathway producing the compounds, may be avoided. Moreover, the isolation of the compounds may be made more efficient since the compounds of interest do not accumulate inside the host organisms.

15 In bacteria, a large number of efflux systems have been studied which can pump out a wide variety of structurally unrelated molecules ranging from, for example, polyketide antibiotics (acrAE genes of *E. coli*, Ma et al. 1993, J Bacteriol 175:6299-6313), fluroquinolones and ethidium 20 bromide (bmr of *Bacillus subtilis* and nor A of *Staphylococcus aureus*, Neyfakh et al. 1993, Antimicrob Agents Chemother 37:128-129), doxorubicin (drr of *Streptomyces peucetius*, to quaternary amines (qacE of *Klebsiella aerogenes* and mvrC of *E. coli*). See Table III for a list of non-limiting examples 25 of efflux systems. Any such efflux systems may be used in a prokaryotic host organism.

In yeast, many genes conferring pleiotropic drug resistance encode efflux systems, and may be useful in the present invention. For example, the bfr1+ gene confers 30 brefeldin A resistance to *Schizosaccharomyces pombe*, and the CDR1 gene of *Candida albicans* confers resistance to cyclohexamide and chloramphenicol (Prasad et al. 1995, Curr Genet 27:320-329).

For mammalian cells, the multidrug resistance proteins 35 which belong to the class of ATP-binding pump protein may be used (Juranka et al. 1989, FASEB J, 3:2583-2592; Paulusma et al. 1996, Science 271:1126-1128; Zaman et al. 1994, Proc.

Natl Acad Sci, 91:8822-8826; Breuninger et al. 1995, Cancer Res 55:5342-5347, Koepsell EP 0699753). The human mdrl multiple drug resistance gene has been functionally expressed in *Saccharomyces cerevisiae* (Kuchler et al. 1992, Proc Natl Acad Sci 89:2302-2306). Any other efflux systems may also be used for eukaryotic cells.

10

15

20

25

30

35

Table III:

List of compounds that are secreted by  
active drug efflux systems

5			
	<u>chemical class</u>	<u>specific name</u>	<u>efflux systems</u>
	cationic dyes	rhodamine-6G ethidium bromide	bmr
		acriflavine	acrAE
10	basic antibiotics	puromycin doxorubicin	bmr drr, mdr
	hydrophilic antibiotics	novobiocin macrolide	acrAE
	hydrophobic antibiotics	beta-lactams	
15	organic cation	tetraphenyl phosphonium	bmr
	uncharged	taxol chloramphenicol	mdr bmr
20	weak acid	nalidixic acid mithramycin	emr mdr
	zwitterions	fluoroquinolones	bmr
	detergent	SDS	acrAE

25

30

35

One or more efflux systems may be introduced, induced or overproduced into a host organism. The genes encoding components of an efflux system may be introduced into a host organism and expressed using the expression vectors and techniques described above. In some instances, it may be advantageous to use an inducible promoter for expression of the efflux system genes.

#### 5.1.4. COMBINATORIAL NATURAL PATHWAY EXPRESSION LIBRARIES

10

The present invention relates to the construction and uses of combinatorial gene expression libraries, wherein the host organisms contain genetic material encoding natural biochemical pathways or portions thereof that is derived from a plurality of species of donor organisms, and are capable of producing functional gene products of the donor organisms. Biochemical pathways or portions thereof of the donor organisms are thus functionally reconstituted in individual host organisms of a library. Novel activities and compounds of such biochemical pathways may be more accessible to screening by traditional drug discovery techniques or by methods provided herein.

20

Either DNA or RNA may be used as starting genetic material for preparing such libraries which may include cDNA libraries, genomic DNA libraries, as well as mixed cDNA/genomic DNA libraries. DNA fragments derived from a plurality of donor organisms, e.g., organisms described in Section 5.1.1, are introduced into a pool of host organisms, such that each host organism in the pool contains a DNA fragment derived from one of the donor organisms.

30

It may be advantageous if the host organism and the donor organisms share certain genetic features, such as similar GC content of DNA and common RNA splicing mechanisms, or physiological features, such as optimal growth temperature. It may thus be desirable to use a host organism that is phylogenetically closely related to the donor organisms. For instance, a prokaryotic host organism may be

35



more desirable for cloning and expression of operons of other prokaryotes.

Donor organisms that are not amenable to traditional drug discovery or drug development technologies may be preferred. For example, most marine bacteria are poorly characterized and not amenable to conventional terrestrial microbiology protocols. The present invention can simplify the development of production and purification processes.

The fragment of donor DNA that is transferred may comprise coding regions encoding functional proteins of a complete biochemical pathway or portions thereof, as well as natively associated regulatory regions such as promoters and terminators. Optimal results may be obtained by using large prokaryotic genomic DNA fragments which have a greater probability of encoding an entire biochemical pathway. If the native function and organization of the transferred DNA fragment is maintained in the host organism, the genes of the donor organism may be coordinately expressed. Also provided are exogenous regulatory regions that may be attached to the DNA fragments so as to ensure transcription of the transferred genes in the host organism, thereby replacing or supplementing transcription initiated from the native promoters.

Interestingly, many of the genes derived from marine bacteria have been found to utilize the native promoters to express functional proteins in *E. coli*. Thus, genes of marine microorganisms may be expressed even without the need to use exogenous regulatory regions. An exemplary list of marine bacterial genes that uses its native promoter in *E. coli* is provided in Table IV.

Table IV:

List of marine bacterial genes that use its native promoter in *E.coli*

5	<u>Gene(s)</u>	<u>Genus &amp; Species</u>	<u>Reference</u>
	kappa-carrageenase (cgkA)	<i>Alteromonas</i> <i>carrageenovora</i> , gram(-) aerobe	Barbeyron et al., 1994, Gene 139:105-109
10	Na <sup>+</sup> /H <sup>+</sup> antiporter (NhaA)	<i>Vibrio</i> <i>alginolyticus</i>	Nakamura et al., 1994, Biochim Biophys Acta 1190:465-468
	phosphodiesterase (cpdP)	<i>Vibrio fischeri</i> , symbiont	Dunlap et al., 1993, J. Bact. 175(15):4615-4624
15	chitinase	<i>Alteromonas</i> sp., Strain 0-7	Tsujibo et al., 1993, J. Bact. 175(1):176-181
	tributyl tin chloride resistance	<i>Alteromonas</i> sp. M-1, gram(-) rod	Fukagawa et al., 1993, Biochem. Biophys. Res. Comm. 194(2):733-740
20	dagA-complementing	<i>Alteromonas</i> <i>haloplanktis</i> , gram(-)	MacLeod et al., 1992, Mol. Micro. 6(18): 2673-2681
	vibriolysin (nprV)	<i>Vibrio</i> <i>proteolyticus</i> , gram(-)	David et al., 1992, Gene 112:107-112
25	tetracycline resistance	<i>Vibrio salmonicida</i> , aerobe	Sorum et al., 1992, Chemo. 36(3):611-615
	melanin synthesis (melA)	<i>Shewanella</i> <i>colwelliana</i> , gram(-) periphyte	Fuqua et al., 1991, Gene 109:131-136
30	DNA modification cluster	<i>Hyphomonas</i> <i>jannaschiana</i> , thermophile	Danaher et al., 1990, Gene 89:129-133

In a preferred embodiment, the method of the invention takes advantage of the way that genes of prokaryotes, such as bacteria, are organized into discrete functionally-related gene clusters in the genome, termed operons. In these  
5 clusters, genes encoding components of a biochemical pathway are linked together to common regulatory sequences. Functionally related genes in filamentous fungi (*Actinomycetes*) are also known to be clustered. Gene clusters for many bacterial and *actinomycete*, and few  
10 eukaryotic fungal, biosynthetic pathways have been isolated and characterized. For example, twelve proteins used to produce the carotenoids zeaxanthin and beta-cryptoxanthin de novo in *Erwinia herbicola*, can be activated and produced synchronously in the bacterium *E. coli* (Perry et al. 1986, J.  
15 Bacteriol, 168:607-612; Hundle et al. 1991, Photochem and Photobiol 54:1:89-93). In addition, prokaryotic amino acid biosynthetic pathways such as leucine and isoleucine biosynthesis, as well as glucose transfer systems are also contained in discrete clusters. Thus, when prokaryotes are  
20 used as donor organisms, it is likely that genes that are functionally related in a biosynthetic pathway would be isolated in one clone.

Donor organisms having compact genomes that contain relatively few non-coding regions are preferred. In many  
25 aspects, the donor organisms are bacteria which have a relatively small genome, for example, 4400 kbp in length for *E. coli*, and 2500-3500 kbp for archaeobacteria. The number of independent clones required in a library to achieve a 99% probability of containing all of the sequences of the donor  
30 genomes is calculated from the following formula (Clarke et al. 1976, Cell 9:91-99):

$$N = \frac{\ln (1-P)}{\ln (1-f)}$$

35

Where

N = number of recombinant clones necessary in the library

P = the probability a sequence is represented

f = the fractional proportion of the genome in a

5 single recombinant clone

For example, *E. coli* has approximately 4400 kbp of DNA; a cosmid vector can package approximately 40 kbp of DNA. Following these calculations, the entire genome of *E. coli* can be expected to be thoroughly represented in as few as 504  
10 clones in a cosmid library. Since a typical DNA library can contain 500,000 independent recombinant clones, one such library can effectively represent the genomes of up to 1,000 different bacterial species having a genome size similar to *E. coli*. Thus, considerable chemical diversity can be  
15 generated and assessed efficiently by screening a gene expression library comprising the diverse genetic material of 1,000 or more species of bacteria.

The procedures described in standard treatises, e.g., Maniatis et al. 1989, *Molecular Cloning*, 2nd Edition, Cold  
20 Spring Harbor Press, New York; and Ausubel et al., *Current Protocols in Molecular Biology*, Greene Publishing Associates and Wiley Interscience, New York, may be followed to carry out routine molecular biology reactions used in constructing the combinatorial gene expression libraries.

25 A cloning strategy for combinatorial natural pathway gene expression library is shown in Figure 3. Any cell from a donor organism can potentially serve as the source of nucleic acid for construction of a gene expression library. Genomic DNA, which includes chromosomal DNA as well as DNA of  
30 extrachromosomal genetic elements, such as naturally occurring plasmids, may be used. Alternatively, RNA of a donor organism may be used. RNA, preferably messenger RNA (mRNA), may be extracted, purified and converted to complementary DNA (cDNA) by any technique known in the art.  
35 An oligo-(dT) primer or random sequence primers may be used for priming first strand synthesis of cDNA. DNA inserts may optionally be amplified by polymerase chain reaction (PCR).

Genomic DNA and RNA may be extracted and purified by the procedure provided in Section 5.1.2 or by those that are known in the art. For filamentous fungi and bacteria, such procedures may comprise any of several techniques including

5 a) rapid SDS/high salt lysis of protoplasts prepared from young *mycelia* grown in liquid culture and immediate extraction with equilibrated phenol; b) rapid lysis of protoplasts in guanidinium isothiocyanate followed by ultracentrifugation in a CsCl gradient; or c) isolation of

10 high molecular weight DNA from protoplasts prepared in agarose plugs and pulsed field gel electrophoresis. For bacteria, an alternative procedure of lysis by lysozyme/detergent, incubation with a non-specific protease, followed by a series of phenol/chloroform/isoamyl alcohol

15 extractions may be useful.

For optimal results, large random prokaryotic genomic DNA fragments are preferred for the higher probability of containing a complete operon or substantial portions thereof. The genomic DNA may be cleaved at specific sites using

20 various restriction enzymes. Random large DNA fragments (greater than 20 kbp) may be generated by subjecting genomic DNA to partial digestion with a frequent-cutting restriction enzyme. The amount of genomic DNA required varies depending on the complexity of the genome being used. Alternatively,

25 the DNA may be physically sheared, as for example, by passage through a fine-bore needle, or sonication.

Prior to insertion into a vacant expression vector, such DNA inserts may be separated according to size by standard techniques, including but not limited to, agarose gel

30 electrophoresis, dynamic density gradient centrifugation, and column chromatography. A linear 10-40% sucrose gradient is preferred. The insertion can be accomplished by ligating the DNA fragment into an expression vector which has complementary cohesive termini. The amounts of vector DNA

35 and DNA inserts used in a ligation reaction is dependent on their relative sizes, and may be determined empirically by techniques known in the art. However, if the complementary

restriction sites used to fragment the DNA are not present in the expression vector, the ends of the DNA molecules may be enzymatically modified, as for example, to create blunt ends. Alternatively, any site desired may be produced by ligating 5 nucleotide sequences *i.e.*, linkers or adaptors, onto the DNA termini; these ligated linkers or adaptors may comprise specific chemically-synthesized oligonucleotides encoding restriction endonuclease recognition sequences. In an alternative method, the cleaved expression vector and DNA 10 inserts may be modified by homopolymeric tailing.

After ligation of vector DNA to DNA inserts, the expression constructs are introduced into the host organisms. A variety of methods may be used, which include but are not limited to, transformation, transfection, infection, 15 conjugation, protoplast fusion, liposome-mediated transfer, electroporation, microinjection and microprojectile bombardment. In specific embodiments, the introduction of bacteriophage or cosmid DNA into an *E. coli* host is carried out by *in vitro* packaging the DNA into bacteriophage 20 particles then allowing these particles to infect *E. coli* cells. Other naturally-occurring mechanisms of DNA transfer between microorganisms may also be used, *e.g.*, bacterial conjugation.

After the host cells containing expression constructs 25 are pooled to form a library, they can be amplified and/or replicated by techniques known in the art. The purpose of amplification is to provide a library that can be used many times. Amplification may be achieved by plating out the library, allowing the bacteria to grow, and harvesting the 30 phage or bacteria for storage.

Alternatively, the library may be stored in an ordered array. The bulk of the library can be plated out at low density to allow formation of single, discrete plaques or colonies, followed by transfer of individual plaques or 35 colonies into the wells of coded multi-well master plates, *e.g.*, 96-well plates or 384-well plates. The individual clones are allowed to grow in the wells under the appropriate

conditions. The coded master plates can be used as an archival source to replicate each clone separately into one or more working plates. Thus, each clone in the library may be handled and assayed individually. The coded archival  
5 plates may be sealed and stored for future use. Replication and transfer of the clones may be done with a multi-pin replicator, or multi-channel devices for fluid handling. Preferably, all or most of the transfers and manipulations are performed by laboratory robots (Bentley et al. 1992,  
10 Genomics 12:534-541).

The libraries of the invention may be preserved by lyophilization, or cryopreservation in a freezer (at -20°C to -100°C) or under liquid nitrogen (-176°C to -196°C).

Host organisms containing donor DNA in a library may be  
15 identified and selected by a variety of methods depending on the host-vector system used. In one approach, such host organisms are identified and selected upon the presence or absence of marker gene functions, e.g., thymidine kinase activity, resistance to antibiotics, such as kanamycin,  
20 ampicillin, bleomycin, or thiostrepton, production of pigment, such as melanin, and resistance to methotrexate. Alternatively, a change in phenotype or metabolism of the host organism, indicated by metabolic testing, foci formation in tissue culture, or occlusion body formation in baculovirus  
25 may be used. Once selected for the presence of donor DNA, a series of enzymatic assays or metabolic tests may be carried out on the clones for further characterization.

To characterize the donor DNA inserts in a library of clones containing donor DNA or a portion thereof, mini  
30 preparations of DNA and restriction analysis may be performed with a representative set of clones. The results will provide a fingerprint of donor DNA size and restriction patterns that can be compared to the range and extent of insert DNA which is expected of the library.

35

#### 5.1.5. COMBINATORIAL CHIMERIC PATHWAY EXPRESSION LIBRARIES

The present invention also relates to the construction and uses of combinatorial chimeric pathway expression libraries, wherein the host organisms contain randomly concatenated genetic materials that are derived from one or more species of donor organisms, and are capable of producing functional gene products of the donor organisms. A substantial number of host organisms in the library may contain a random and unique combination of genes derived from one or more species of donor organism(s). Coexpression of the transferred genes may be effected by their respective native regulatory regions or by exogenously supplied regulatory regions. The plurality of gene products derived from the different donor organisms interact in the host organism to generate novel chimeric metabolic pathways and novel compounds. Novel activities and compounds of such chimeric pathways may become more accessible to screening by traditional drug discovery techniques or by methods provided herein.

While not limited to any theory of how novel pathways or compounds are generated in a combinatorial chimeric pathway gene expression library, the coexpression of functional heterologous genes derived from one or a plurality of species of donor organisms enables the gene products to interact *in vivo* with each other, and with elements of the host organism. Through such interactions, new sets of biochemical reactions will arise, some of which can act in concert to form a chimeric biochemical pathway. The heterologous gene products may encounter substrates, cofactors and signalling molecules that are not present in their respective donor organism. Such substrates, cofactors and signalling molecules may be supplied by the host organism, by other heterologous gene products that are coexpressing in the same host organism, or from the medium.

Moreover, some of the heterologous gene products may be modified structurally, and compartmentalized or localized differently during biosynthesis in the host organism. Some



of the heterologous gene products may be exposed to a host cellular environment that is different from that of their respective donors.

It is envisioned that some heterologous gene products  
5 may also act on the host organism and modify the host cellular environment. Elements of the host cellular environment that may affect, or be affected by, the function of heterologous gene products may include but are not limited to concentrations of salts, trace elements, nutrients,  
10 oxygen, metabolites, energy sources, redox states, and pH. Some heterologous gene products may also interact with host gene products which can result in the modification of the host's metabolic pathways.

Depending on the combination of heterologous genes,  
15 novel chimeric biochemical pathways and novel classes of compounds that do not exist in nature may be formed in the host organisms of the library. In combinatorial chimeric pathway expression libraries, the genetic resources of the donor organisms are multiplied and expanded to provide a  
20 diversity of chemical structure that may not be found in individual organisms. The libraries so prepared may be screened using traditional methods or methods provided by the present invention. Thus, the novel pathways and compounds are made more accessible to drug screening.

25 Any of the donor organisms described in Section 5.1.1 may be used in preparing a combinatorial chimeric pathway expression library. Donor organisms may be selected on the basis of their known biological properties, or they may be a mixture of known and/or unidentified organisms.

30 The combinatorial chimeric pathway expression libraries of the invention may be assembled according to the principles described in section 5.1.3. In order to allow the random concatenation of DNA fragments from multiple species of donor organisms, the procedure for library assembly may be modified  
35 by including the following steps: generation of smaller genomic DNA fragments, ligation with regulatory sequences

such as promoters and terminators to form gene cassettes, and concatenation of the gene cassettes.

Insert DNAs may be complementary DNA (cDNA) derived from mRNA, and/or fragments of genomic DNA. The DNA or RNA of  
5 different species of donor organisms may be copurified, or they may be isolated separately and then combined in specific proportions. The random mixing of insert DNAs can be done at any stage prior to insertion into the cloning or expression vector.

10 Methylated nucleotides, e.g., 5-methyl-dCTP, may be used in cDNA synthesis to provide protection against enzymatic cleavage, and allow directional cloning of the cDNA inserts in the sense orientation relative to the promoter and terminator fragments.

15 Random fragments of genomic DNA in the range of 2-7 kbp may be generated by partial digestion with a restriction enzyme having a relatively high frequency of cutting sites, e.g., *Sau3AI*. Partial digestion is monitored and confirmed by subjecting aliquots of the samples to agarose gel  
20 electrophoresis.

Exogenous regulatory regions, such as constitutive or inducible promoters and terminators may be provided to drive expression of the transferred genes. When the host and donor expression systems are not compatible, it is essential to  
25 provide such regulatory sequences. PCR may be used to generate various promoter and terminator fragments that are specific to a particular expression host, and have defined restriction sites on their termini. Any method for attachment of a regulatory region to the DNA inserts may be  
30 used. Treatment with the Klenow fragment and a partial set of nucleotides, i.e., a partial fill-in reaction, may be used to create insert DNA fragments which will only ligate specifically to promoter and terminator fragments with compatible ends.

35 The present invention provides a method involving the use of gene cassettes which contains two copies of a promoter, oppositely positioned on either side of a unique

restriction site. Any DNA inserted into this restriction site will be transcribed on both strands by the two promoters respectively from both sides.

The present invention also provides an alternative method involving the use of gene cassettes which contain a promoter and a terminator positioned on either side of a DNA insert. If the procedure for directional cloning of cDNA is followed, the 5' ends and 3' ends of the cDNA inserts would have unique matching restriction sites with the 3' ends of the promoter fragments and the 5' ends of the terminator fragments respectively.

Genomic DNA fragments or cDNAs bearing compatible restriction sites at both ends are ligated to the promoters and in some cases, terminator fragments, to form gene cassettes having a mean size of approximately 1-10 kbp.

Concatemers comprising multiple transcription units are assembled by an approach similar to that used in peptide synthesis. A subset of the pool of gene cassettes is bound at one end to a solid phase, e.g., a magnetic bead. The other free end is subjected to several successive cycles of "de-protection" and serial ligation of the remaining pool of transcription units. The solid phase allows separation of the concatemers from the unligated DNA fragments after each addition cycle. When concatenation is completed, the concatemers are released by incubation with a restriction enzyme, such as an intron nuclease, that cleaves a unique and very rare site adjacent to the solid phase to reduce the probability of cleaving the concatenated DNA. Concatenated DNA may then be inserted into a cloning vector to form expression constructs which are introduced into the appropriate host organisms. Alternatively, the constructs may be transformed into an *E. coli* recA minus strain for amplification prior to introduction into the host organisms.

Details of the synthesis of the promoter and terminator fragments, the preparation of gene cassettes, the assembly of the DNA inserts, and the ligation of insert and vector, are provided in Sections 5.4 and 5.5.

Once the combinatorial chimeric pathway expression library is assembled, it can be stored, amplified, replicated, pre-screened and screened essentially in the same manner as described in section 5.1.3.

5

#### 5.1.6. BIASED COMBINATORIAL EXPRESSION LIBRARIES

In another embodiment of the invention, a biased combinatorial natural or chimeric pathway expression library may be prepared from preselected fragments of DNA that are

10 pooled together from one or more species of donor organisms. Instead of using only the total pooled genomic DNA or cDNA of the donor organism(s), this approach will reduce the number of clones that need to be screened and increase the percentage of clones that will produce compounds of interest.

15 The preselected fragments of DNA contain genes encoding partial or complete biosynthetic pathways, and may be preselected by hybridizing to an initial DNA library a plurality of probes prepared from known genes that may be related to or are involved in producing compounds of

20 interest. The initial DNA library, preferably a cosmid library and not necessarily an expression library, may contain DNA from one or more species of donor organisms. For further pre-screening, if the initial library is an expression library, DNA in the positive clones may be

25 transferred into and expressed in a host for production, such as *E. coli* or *Streptomyces lividans*. More than one initial library may be pre-screened, and DNA from all the positive clones can be pooled and used for making the biased combinatorial gene expression library.

30 The initial library may be amplified so that DNA of the donor organisms can be pre-screened in a variety of host organisms. For example, once a gene expression library in *Streptomyces lividans* is generated, it can be introduced into specialized host organisms for expression and screening, such

35 as *S. rimosis* that produces oxytetracycline, or *S. parvus* that produces actinomycin D. If the expression vector contains the appropriate sequences for genetic transfer in

naturally occurring plasmids, such sequences may be used to mobilize the library to various compatible host via conjugative transfer.

The probes used for pre-screening may be derived from  
5 any cloned biosynthetic pathway, such as the polyketide biosynthetic loci, as these are the best characterized biosynthetic loci and there is considerable sequence conservation between the known clusters, e.g., *actI* (actinorhodin biosynthesis - Malpartida et al. 1987 Nature  
10 325:818-820), *whiE* (spore pigment biosynthesis - Blanco et al. 1993 Gene 130:107-16) and *eryA1* (Donadio et al. 1991 Science 252, 675-679). Similar principles may be applied to other antibiotic or secondary metabolite biosynthetic loci. For example the cloned peptide synthetase genes in low-GC  
15 gram positive bacteria, such as *Bacillus* (Stachelhaus et al. 1995 Science 269: 69-72) and in high-GC gram positive bacteria, such as *actinomycetes* species that produce thiostrepton, virginiamycin, valinomycin and actinomycin, may have enough sequence similarities to be used as probes to  
20 identify new biosynthetic loci in both groups of bacteria. Other cloned biosynthetic pathway, such as peptide synthases and aminoglycoside synthases, can also provide probes for pre-screening the initial libraries.

Alternatively, the initial DNA library may be screened  
25 by probes derived from DNA that encode proteins involved in secondary metabolism. Such probes may be prepared by subtracting non-coding DNA and DNA encoding proteins that relate to primary metabolism biosynthetic pathways from total DNA. The remaining DNA is thus biased toward coding regions  
30 that encode proteins involved in secondary metabolism. Details of the subtraction procedure are provided in Section 5.3.5.

## 5.2. SCREENING COMBINATORIAL EXPRESSION LIBRARIES

35 The drug discovery system of the present invention further encompasses novel methods for screening combinatorial expression libraries. While standard methods of screening

expression libraries, such as antibody binding and ligand binding, can also be used with expression libraries of the present invention, the libraries can be adapted to a reporter regimen tailored to identify host organisms that are  
5 expressing the desirable pathways and metabolic products.

The methods claimed herein enables the management of large sample numbers with minimal handling to permit efficient and high-throughput detection and isolation of productive clones in the library. The libraries may be pre-  
10 screened for a broad range of activities, for the production of a class of compounds or for the presence of relevant DNA sequences. The libraries may also be used directly with a target in both *in vivo* and *in vitro* assays. The identified or isolated population of cells may readily be cultured,  
15 expanded in numbers, and subjected to further analysis for the production of novel compounds. The genes encoding the metabolic pathway that lead to production of the novel activity or compound may be delineated by characterizing the genetic material that was introduced into the isolated  
20 clones. Information on the genes and the pathway, and the clones, will greatly facilitate drug optimization and production.

As used herein, the terms "library clones" or "library cells" refer to host cells or organisms in a combinatorial  
25 gene expression library that contain at least one fragment of donor DNA that may encode a donor metabolic pathway or a component thereof. The term "positive clones" or "positive cells" refers to library clones or cells that produce a signal by virtue of the reporter regimen. The term  
30 "productive cells" or "productive clones" refers to host cells or organisms in the library that produce an activity or compound of interest, in distinction from the remainder "non-productive cells" in the library.

The term "pre-screen" refers to a general biological or  
35 biochemical assay which indicates the presence of an activity, a compound or a gene of interest. The term "screen" refers to a specific therapy-oriented biological or

biochemical assay which is directed to a specific disease or clinical condition, and employs a target. The term "target" refers generally to whole cells as well as macromolecules, such as enzymes, to which compounds under test are exposed in a screen. The use of both pre-screens and screens generally embodies visual detection or automated image analysis of a colorigenic indicator, fluorescence detection by fluorescence-activated cells sorting (FACS) or the use of a magnetic cell sorting system (MACS) performed on a population of library cells in the presence of a reporter regimen.

The methods of the invention provide alternative but not mutually exclusive approaches to generation of detectable signal associated with productive cells for the purpose of detecting and isolating these cells of interest. A reporter can be a molecule that enables directly or indirectly the generation of a detectable signal. For example, a reporter may be a light emitting molecule, or a cell surface molecule that may be recognized specifically by other components of the regimen. A reporter regimen comprises a reporter and compositions that enable and support signal generation by the reporter. The reporter regimen may include live indicator cells, or portions thereof. Components of a reporter regimen may be incorporated into the host organisms of the library, or they may be co-encapsulated with individual or pools of library cells in a permeable semi-solid medium to form a discrete unit for screening.

To facilitate detection of compounds of interest as described in the following text, absorptive materials such as neutral resins, e.g., Diaion HP20 or Amberlite XAD-8 resin, may be added to cultures of library cells (Lam et al. 1995, J Industrial Microbiol 15:453-456). Since many secondary metabolites are hydrophobic molecules, the release or secretion of such metabolites may lead to precipitation on the cell exterior. Inclusion of such resins in the culture causes the sequestration to occur on the resin which may be removed from the culture for elution and screening.

In one embodiment of the invention, the host organisms are engineered to contain a chemoresponsive construct, comprising a gene encoding a reporter molecule operably-associated with a chemoresponsive promoter that responds to  
5 the desired class of compounds or metabolites to be screened in the expression library. In the presence of the desirable activity or compound, the chemoresponsive promoter in a positive clone is induced to initiate transcription of the operably-associated reporter gene. The positive cell is  
10 identified by detectable signals generated by the expression of the reporter gene.

In an alternative embodiment, a physiological probe can be used which generates a signal in response to a physiological change in individual cells as a result of the  
15 presence of a desirable activity or compound. Such a probe may be a precursor of a reporter molecule that is converted directly or indirectly to the reporter molecule by an activity or compound in the biochemical pathway sought. Upon contact with a productive cell, the physiological probe or  
20 reporter precursor generates a detectable signal which enables identification and/or isolation of the productive cell. Contact may be effected by direct addition of the probe or precursor to the library cells. Alternatively, contact may be effected by encapsulation and diffusion of the  
25 probe or precursor to the library cells during screening.

In yet another embodiment of the invention, indicator cells may be used to signal the production of a desirable activity or compound, thereby enabling identification and/or isolation of productive cells in the library. Whole live or  
30 fixed indicator cells, or cellular fractions thereof may be mixed or co-encapsulated with individual or pools of library cells. Indicator cells are selected for their biological properties which is responsive to the presence of the desirable activity or compound. Indicator cells may be the  
35 target cells of the desirable compound. Alternatively, indicator cells may be used in conjunction with a reporter to generate a detectable signal.



Pre-screens and screens for each library are chosen after comprehensive characterization of the host organism and, whenever possible, of the donor organisms. Assays in which the host organisms are positive are disqualified, while  
5 assays in which the donor organisms are positive are considered acceptable library pre-screens or screens. Substrates are preferably the targets of enzymes relevant to desirable biosynthetic capabilities, may be used to alternatively irrelevant targets (e.g., amylase,  $\beta$ -  
10 galactosidase) that indicate the presence of transcriptional and translational activity for the DNA in a specific clone.

In yet another embodiment of the invention, antibiotic resistance may be used as an indicator of production or potential production of interesting secondary metabolites.  
15 When library clones are exposed to a panel of antibiotics, resistance to the antibiotics may indicate the presence of a self-defense mechanism, such as efflux pumps which are frequently found adjacent to secondary metabolite biosynthetic pathways as protection against auto-toxicity.  
20 Such clones may not exhibit secondary metabolite production at the time of detection, but have increased probability of containing adjacent biosynthetic pathways that can be further manipulated or examined as desired.

The present invention also provides encapsulation as an  
25 efficient high-throughput method for growing cells in a confined space, replacing the classic method of growing bacteria in petri dishes. Growing cells in a plate format is both labor- and materials- intensive, while encapsulated cells can be grown easily in a liquid culture with the  
30 advantage that dividing cells are kept together, and thus facilitating detection of interesting secondary metabolites. Another advantage of encapsulation is the ability to co-encapsulate components of the reporter regimen and/or other indicator cells with library cells so that pre-screening or  
35 screening may be performed in a discrete unit. Encapsulation of cells can be performed easily by means of thermal or ionic

gelation using materials such as agarose, alginate or carrageenan.

FACS is a well-known method for separating particles (1-130 $\mu$ m in size) based on the fluorescent properties of the particles (Kamarch, 1987, Methods Enzymol, 151:150-165). FACS works on the basis of laser excitation of fluorescent moieties in the individual particles. Positive fluorescence results in addition of a small electrical charge to the particle. The charge allows electromagnetic separation of positive and negative particles from a mixture. Separated particles may be directly deposited into individual wells of 96-well or 384-well plates.

MACS is a well-known method for separating particles based on their ability to bind magnetic microspheres (0.5-100 $\mu$ m diameter) (Dyna, 1995). A variety of useful modifications can be performed on the magnetic microspheres, including covalent addition of antibody which specifically recognizes a cell-surface antigen or hapten. Alternatively, for magnetization of encapsulated cells, a reporter regimen can be incorporated into host cells that generate magnetogenic reporter proteins, such as ferritin. In this case, encapsulated cells that generate a positive signal act as magnetic microspheres. The selected microspheres can be physically manipulated by exposure to a magnetic field. For example, the selected microspheres may be sequestered by application of a magnet to the outside of the reaction vessel.

#### 5.2.1. REPORTER CONSTRUCTS

According to the present invention, the host organisms in the library may be engineered to contain a chemoresponsive reporter construct comprising a chemoresponsive promoter operably-associated with a reporter gene. The host organism and/or the construct may contain other genes encoding accessory proteins that are involved in the regulation of transcription from the chemoresponsive promoter or the production of signals.

A chemoresponsive promoter is any double-stranded DNA sequence that is capable of binding an RNA polymerase and initiating or modulating transcription of an operably-associated reporter gene only in the presence of a certain  
5 kind of activity or a certain class of compounds.

Preferably, the chemoresponsive promoter has no or only a negligible level of constitutive background transcriptional activity in the host organism in the absence of the inducing activity or compound. A chemoresponsive promoter that  
10 respond negatively to the presence of an activity or compound by decreasing or ceasing transcriptional activity may also be used.

Promoters useful in the present invention may include, but are not limited to, promoters for metabolic pathways,  
15 biodegradative pathways, cytochromes and stress response (Orser et al. 1995, In vitro Toxicol 8:71-85), such as heat shock proteins. For example, the Pm promoter of the *Pseudomonas* TOL plasmid meta-cleavage pathway and its positive regulator XylS protein which is inducible and  
20 modulated by a range of benzoates and halo- or alkylaromatic compounds may be used (Ramos et al. 1988, FEBS Letters 226:241-246; de Lorenzo et al. 1993, Gene 130:41-46; Ramos et al. 1986, Proc Natl Acad Sci 83:8467-8471; Mermod et al. 1986, J. Bacteriol 167:447-454). Other non-limiting examples  
25 of chemoresponsive promoters are promoters relating to phosphonate utilization (Metcalf et al. 1993, J Bacteriol 175:3430-3442), promoters sensitive to cis-cis-muconate (Rothmel, 1990); promoters sensitive to antibiotics and salicylates (Cohen et al. 1993, J Bacteriol, 175:7856-7862;  
30 Cohen et al. 1993, J. Bacteriol, 175:1484-1492), promoters from the arsenic and cadmium operons from *Staphylococcus aureus* (Corbisier et al, 1993, FEMS Letters 110:231-238); *sfiA* (Quillardet et al. 1982, Proc Natl Acad Sci 79:5971-5975), *zwf* (Orser et al., 1995, supra).

35 A reporter gene encodes a reporter molecule which is capable of directly or indirectly generating a detectable signal. This includes colorigenic or magnetogenic reporters

as well as any light-emitting reporter such as bioluminescent, chemiluminescent or fluorescent proteins may be used, which includes but are not limited to the green fluorescent protein (GFP) of *Victoria aequoria* (Chalfie et al. 1994, Science 263:802-805), a modified GFP with enhanced fluorescence (Heim et al. 1995, Nature 373:663-4), the luciferase (luxAB gene product) of *Vibrio harveyi* (Karp, 1989, Biochim Biophys Acta 1007:84-90; Stewart et al. 1992, J Gen Microbiol, 138:1289-1300), and the luciferase from firefly, *Photinus pyralis* (De Wet et al. 1987, Mol Cell Biol 7:725-737). Any fluorogenic or colorigenic enzymes may be used which includes but are not limited to beta-galactosidase (LacZ, Nolan et al. 1988, Proc Natl Acad Sci USA 85:2603-2607), and alkaline phosphatase. Any cell surface antigen may be used, for example, *E. coli* thioredoxin-flagellin fusion protein, i.e., *E. coli* thioredoxin (the *trxA* gene) expressed as a fusion protein with flagellin (the *fliC* gene) on the surface of *E. coli* flagellae (Lu et al. 1995, Bio/Technology 13:366-372).

20 An exemplary chemoresponsive reporter construct provided herein is pERD-20-GFP which contains the Pm promoter and the XylS gene of *Pseudomonas* (Ramos et al. 1988, FEBS Letter 226:241-2476) that are responsive to certain classes of benzoates, resulting in transcription and translation (expression) of the reporter, GFP (see Figure 6).

Different promoter sequences may be generated by PCR and attached to the coding regions of GFP or flagellin-thioredoxin reporter. Genomic and plasmid DNA containing the promoter of interest may be purified from the relevant species using standard DNA purification methods, and resuspended in TE. Primers may be synthesized corresponding to the 5' and 3' boundaries of the promoter regions with additional sequences of restriction sites to facilitate subcloning. The amplification reactions are carried out in a thermocycler under conditions determined to be acceptable for the selected template and primers. The reaction products are separated by agarose gel electrophoresis, and subcloned using

the TA Cloning Kit (Invitrogen, La Jolla). The amplified promoter sequences may be recloned into a general purpose cloning vector in a context 5' to the GFP or flagellin-thioredoxin cDNA.

5

#### 5.2.2. PHYSIOLOGICAL PROBES AND REPORTER PRECURSORS

A physiological probe as used herein is a fluorescent or colorigenic agent which upon contact or entry, generates a signal in response to changes in physiological and/or  
10 metabolic parameters of a library cell or indicator cell.

The probe can be an enzyme substrate linked to a fluorogenic agent. For example, a fluorogenic alkyl ether can be incubated with the cells. If the cell is producing polyaromatic hydrocarbons, the hydrocarbons can induce  
15 microsomal dealkylases, which in turn cleave the fluorogenic alkyl ether, yielding a fluorescent product.

Fluorescent probes may be selected for detection of changes in the following physiological and metabolic parameters such as, but not limited to, those described in  
20 Shechter, et al. (1982, FEBS Letters 139:121-124), and Bronstein et al. (Anal Biochem 219:169-81).

	<u>Metabolic activity</u>	<u>Cause (specific example)</u>	<u>Stain/ Substrate (class of chemical)</u>
25	Decrease in membrane potential	Stress, injury (isopropanol)	BacLight stain (Semi-permeant nucleic acid stain)
	Intracellular pH	Physiological changes	BCECF-AM (lipophilic acetoxymethyl ester of phenolic fluor)
30	Increase in cytochrome-mediated oxidation	Induction of microsomal dealkylases by polyaromatic hydrocarbons (naphthalene)	7-ethoxy-heptadecyl-coumarin (fluorogenic alkyl ether)

35

### 5.2.3. PRE-SCREENING AND SCREENING OF THE LIBRARY

The combinatorial gene expression libraries of the invention may be pre-screened or screened by a variety of methods, including but not limited to, visual inspection, automated image analysis, hybridization to molecular beacon DNA probes (Tyagi et al. 1996, Nature Biotechnol, 14:303-308) fluorescence activated cell sorting (FACS) and magnetic cell sorting (MACS). Screening may be performed on bulk cultures of unamplified or amplified libraries.

10 In specific embodiments of the invention, individual or pools of library cells are encapsulated in an inert, stable and porous semi-solid matrix in the form of droplets during pre-screening or screening. The semi-solid matrix is permeable to gas, liquid, as well as macromolecules, and  
15 permits the growth and division of encapsulated cells. Examples of suitable matrices may include but are not limited to agarose, alginate, and carrageenan. The encapsulated library cells may be cultured and tested in the droplets, and remain viable so that the cells may be recovered from the  
20 droplets for further manipulations. The matrix may optionally be exposed to substances, such as an antibiotic, which can select for library cells that contain a selectable marker. The droplets may also be exposed to nutrients to support the growth of library cells. The following examples  
25 are offered by way of illustration and are not intended to limit the invention in any manner.

Encapsulation may be performed in one of many ways, producing either macrodroplets (droplets from 0.5 to 2.5 mm) or microdroplets (droplets from 10 to 250  $\mu$ m) depending upon  
30 the method of detection employed during subsequent pre-screening or screening. The size and the composition of the droplets may be controlled during formation of the droplets. Preferably, each macrodroplet or microdroplet will contain one to five library cells.

35 For example, macrodroplets may be prepared using sodium alginate as follows: sodium alginate is dissolved in 100 mL of sterile water at a concentration of 1% using an overhead

mixer at 2000 rpm. A volume of library cells of *E. coli* or yeast, such as *Schizosaccharomyces pombe* and *saccharomyces* species; or spores for *Streptomyces* species; *Bacillus subtilis*; and filamentous fungus such as *Aspergillus* and  
5 *Neurospora* species; is added to the sodium alginate solution so that 1-5 cells are encapsulated per droplet. The mixture is allowed to sit for at least 30 minutes to degas, and is then extruded through any device that causes the formation of discrete droplets. One such device is a syringe with a 25  
10 gauge needle. The droplets are formed by adding the sodium alginate solution drop-wise into a beaker of gently stirring 135 mM calcium chloride solution. Droplets are allowed to solidify for 10 minutes, and are then transferred to a sterile flask where the calcium chloride solution is removed  
15 and replaced with a suitable growth media. Encapsulated library cells can be grown under standard conditions.

Microdroplets may be generated by any method or device that produces small droplets, such as but not limited to, two-fluid annular atomizer, an electrostatic droplet  
20 generator, a vibrating orifice system, and emulsification. Other methods for preparing semi-solid droplets are well known in the art; see for example, Weaver, U.S. patent 4,399,219.

The following example is a protocol for producing  
25 microdroplets using the emulsification technique (Monshipouri et al. 1995, J. Microencapsulation, 12:255-262). Using an overhead mixer at 2000 rpm, 0.6g sodium polyphosphate and 2% sodium alginate are dissolved in 100 ml sterile water, and the alginate solution is allowed to degas for 60 minutes. An  
30 oil phase is prepared by mixing 300ml oil, such as canola or olive oil, with 1.0g purified soy bean lecithin for at least 30 minutes. A slurry containing 1.9g calcium sulphate in 10 ml 50% glycerol is prepared by sonication for at least 15 minutes. This slurry and a volume of library cells which  
35 will yield 1-5 cells per droplet are blended into the alginate solution immediately before introduction to the oil phase. The emulsification process is initiated by slowly

transferring the alginate mixture into the oil phase and mixing for 10 minutes at 580 rpm. 500 ml sterile water is then added and the mixing allowed to continue for 5 minutes. Microdroplets can then be removed from the oil by

5 centrifugation. The microdroplets are washed and resuspended in a suitable growth media, ready for culture under standard conditions if required. The size of the droplets can be examined by phase microscopy. For the purpose of sorting by FACS or MACS, if the droplets are outside of the desired size

10 range necessary for sorting, the droplets can be size selected using a filter membrane of the required size limit.

According to the invention, components of the reporter regimen or the target of a drug screen may also be co-encapsulated in a drop with library cell(s). Whole indicator

15 cells or cellular fractions containing a bioassay, enzymes, or reporter molecules may be mixed with library cells suspended in the medium prior to formation of macro- or micro-droplets as previously described. Compounds of interest produced by the library cells may accumulate and

20 diffuse within the droplet to reach the co-encapsulated indicator cells or reporter, and generate a signal. The co-encapsulated indicator cell may be a live target of the desirable compound, e.g. pathogens for anti-infectives, or tumor cells for anticancer agents. Any change in metabolic

25 status of the indicator cells, such as death, or growth inhibition, constitutes a signal and may be detected within the droplet by a variety of methods known in the art. Such methods may include but are not limited to the use of physiological probes, such as vital stains, or measurement of

30 optical properties of the drop.

When the droplets are exposed to components of the reporter regimen, metabolites and compounds produced by the encapsulated library cells and the reporter components may diffuse through the semi-solid medium to produce a signal.

35 For example, a physiological probe may be added to a batch of droplets which are then subjected to the appropriate sorting format. If the library cell(s) are allowed to divide within



the drop, the progeny of the original positive cell(s) are kept together in a microcolony, thereby generating a stronger signal. It is preferable that the semi-solid medium is optically compatible with the signal generated by the  
5 reporter, e.g. transparent to light for a range of wavelengths, so that the signal can be efficiently detected.

Macrodroplets can be sorted using a colorigenic reporter either by screening by eye or by using any device that allows the droplets to pass through a screening point, and which has  
10 the capacity to segregate positives. Microdroplets can be sorted using either FACS or MACS. FACS services are performed by a qualified operator on any suitable machine (e.g. Becton-Dickinson FACStar Plus). Particle suspension densities (cells or droplets) are adjusted to  $1 \times 10^6$   
15 particles/ml. In all cases, positives can be sorted directly into multi-well plates at 1 clone per well. MACS is performed using an MPC-M magnetic tube rack following the manufacturer's instructions (Dyna1, 5 Delaware Drive, Lake Success, New York 11042).

20 Encapsulated cells which are found to be positive in a pre-screen or screen can be recovered by culturing the droplet by placing it either on appropriate agar or liquid growth media or by dissolving the droplet in sodium citrate. After a period of culturing, the positive cells may grow out  
25 of the droplet. For convenience in handling and storage of droplets, the subsequent culturing may be done in multi-well plates.

Pre-screened positives which have been reduced to a smaller population can then either be frozen and stored in  
30 the presence of glycerol or grown in multi-well plates. These can be used to transfer groups of clones using multi-pin replicators onto various types of assay plates (e.g. differential media, selective media, antimicrobial or engineered assay lawns). Specific assays can also be  
35 performed within these microtiter plates and read by a standard plate reader or any other format used in current high-throughput screening technologies.

For clarity of discussion, the following subsections describe in more detail the different embodiments of the invention involving prokaryotic and eukaryotic, donor and host organisms. The following embodiments are exemplary and 5 are not intended to be limiting.

### 5.3. PROTOCOLS FOR THE PREPARATION OF HIGH QUALITY NUCLEIC ACIDS FROM DONOR ORGANISMS

The availability of high quality DNA or RNA as starting 10 material is important in the construction of DNA libraries that are representative of the genetic information of the donor organisms. Methods for extracting, selecting and preparing high quality nucleic acids from cultures of donor organisms or from environmental samples are provided in this 15 section. A method for preparing subtracted DNA probes to be used in pre-screening DNA libraries for the purpose of enriching DNA related to secondary metabolism is also described.

#### 20 5.3.1. GUANIDINIUM ISOTHIOCYANATE NUCLEIC ACID ISOLATION

Lyophilized or non-lyophilized material can be disrupted by passage through a mechanical grinder, or alternatively by hand in a mortar and pestle in the presence of fine ground glass or pumice. Immediately after grinding, ground 25 lyophilized material may be mixed with 10 ml of lysis buffer per 1-2g of material. Lysis buffer is 5M guanidine isothiocyanate, 50 mM Hepes pH 7.6, 10mM EDTA, and 5%  $\beta$ -mercaptoethanol (or 250 mM DTT). After mixing and incubation at 50°C for 5 minutes, the solution is rendered to 30 4% sarcosyl, mixed, and incubated for 5 minutes more at 50°C prior to centrifugation at 8000 g. If the supernatants are visibly cloudy a 90-minute centrifugation step at 27,000g may be used to sediment unwanted carbohydrates. Alternatively, a 15,000g spin may be used to clear the lysate of unwanted 35 contaminants. Following centrifugation, the supernatant is made up to 1.42M CsCl (0.15g CsCl/ml) and layered onto a

previously-made 5.7M CsCl/TE (10 mM Tris-HCL/ 1 mM EDTA) solution in ultracentrifugation tubes. Ultra-centrifugation can be carried out at 160,000g for 18 hours, 20°C. After ultra-centrifugation, a clear, jelly-like layer at the  
5 1.42M/5.7M CsCl interface is DNA, while total cellular RNA is present as a clear pellet at the bottom of the tube.

DNA from the ultra-centrifugation step can be dialyzed against TE buffer, rendered 0.1M NaCl, precipitated with 2.5 volumes of ethanol, dried and redissolved in an appropriate  
10 volume of TE. If the DNA layer is white in color, it can be removed and recentrifuged for 8 hours in a CsCl/bisbenzidimide gradient to remove remaining carbohydrates. The dye can be removed by 2-5 washes with 85% isopropanol, and the DNA dialyzed and treated as above.

15 RNA can be redissolved in resuspension buffer (5M guanidine isothiocyanate, 50 mM Hepes, pH 7.6, 10 mM EDTA), diluted to 1.33M guanidine isothiocyanate with a solution of 50 mM Hepes pH 7.6, 10 mM EDTA. If total RNA is desired, the diluted RNA sample is precipitated by the addition of 2 vol  
20 of ethanol or 1 vol of isopropanol. The precipitated RNA is rinsed with 70% ethanol, dried, and resuspended in water or formamide, and stored at -70°C until used.

#### 5.3.2. ISOLATION OF POLY(A)-CONTAINING RNA

25 Since the vast majority of eukaryotic mRNA molecules contain tracts of poly(adenylic) acid at the 3' end, up to 250 bases in length, it can be purified by affinity chromatography using oligo-dT cellulose matrix. A wide variety of commercially available oligo-dT matrices may be  
30 used, including but not limited to, simple gravity columns, para-magnetic particles, spin and push columns. Isolated mRNA may be stored either dissolved in water, in formamide, or dried at -70°C.

### 5.3.3. ENRICHMENT OF NON-RIBOSOMAL SEQUENCES FROM TOTAL RNA

The enrichment of non-ribosomal sequences may be an essential step in obtaining useful RNA populations from difficult or uncultivable donor organisms. The  
5 fractionation of RNA on neutral sucrose gradients can be useful in purifying the predominant ribosomal RNAs away from other RNA species (R. McGookin 1984, In Methods in Molecular Biology Vol. 2 Nucleic Acids. Humana Press, pp. 109-112).  
10 Following centrifugation, the samples containing the largest amounts of ribosomal RNA can be discarded, and the remaining fractions dialyzed and precipitated.

Other methods which utilize random primers with or without random-tailed oligo-dT primers and PCR may be used to  
15 amplify low amounts of RNA in starting material.

### 5.3.4. FILL-IN REACTION USING THE KLENOW FRAGMENT

The use of the Klenow fragment of *E. coli* DNA polymerase, or other DNA polymerase which lacks 3'→5' exonuclease activity, to add nucleotides to the 5' cohesive  
20 ends is a standard technique often used to create blunt ended DNA molecules after digestion. When used without a complete nucleotide set, such an activity can be exploited in creating ligation ends that are incompatible with themselves but  
25 compatible to each other.

Such a technique has been used to produce high-titer gene libraries and constructs (Hung et al. 1984, Nuc Acids Res 12:1863-1874; Zaborovsky et al. 1986, Gene 42:119; Foster, 1991, Ph.D. thesis, University of California, Santa  
30 Barbara; Loftus et al. 1992, Biotechniques 12:172-175.)

The fill-in reaction can be carried out with Klenow buffer (50 mM Tris-HCl pH 7.5, 10 mM MgCl<sub>2</sub>, 50 mg/ml BSA, 1 mM dNTP), enzyme (10U/50μl reaction), and an incubation of 3-4 hours at 37°C. After the reaction, the DNA may be purified  
35 by a variety of methods, including but not limited to, affinity chromatography, ethanol precipitation, and spin-column centrifugation.

#### 5.3.5. PROTOCOLS FOR PREPARATION OF SUBTRACTED DNA PROBES FOR PRE-SCREENING

RNA may be isolated from young, mid log-phase cultures of organisms with complex life cycles that have not undergone differentiation. This RNA pool is complementary to genes involved in undifferentiated growth and primary metabolism. The RNA is biotinylated *in vitro* and hybridized in excess to randomly sheared, gene-sized fragments of genomic DNA from the homologous or closely related heterologous species. Phenol extraction of this mixture results in the removal of genomic sequences complementary to primary metabolism RNA at the interface. This process may be repeated once. The resulting single stranded DNA fragments are composed of the (+) strand of primary metabolism genes and the (+) and (-) strands of other genes, including secondary metabolism-related genes. This mixture of DNA is denatured, and rehybridized for 5-10 half  $C_0t_s$  under highly stringent conditions such that only related sequences can rehybridize to form double-stranded DNA. The remaining single-stranded DNA can be removed by binding to hydroxyapatite or by digestion with mung bean nuclease. The isolated double-stranded DNA representing non-primary metabolism related genes may then be labeled using random priming, and used as probe to pre-screen a library.

#### 5.3.6. PURIFICATION OF NUCLEIC ACIDS FROM SOIL OR OTHER MIXED ENVIRONMENTAL SAMPLES

Soil samples are flash frozen in liquid nitrogen and stored at  $-70^{\circ}\text{C}$  until processed. Alternatively, soil samples are stored frozen at  $-20^{\circ}\text{C}$ . Samples are either thawed on ice immediately prior to use, or freeze-dried prior to processing.

Total nucleic acids are extracted by a number of protocols with minor modifications depending on the physical state and source of the material. Dry to semi-dry samples are frozen and processed directly; very wet samples are flash frozen and freeze-dried; oily samples are diluted with

phosphate buffered saline prior to processing. Any of the following procedures may be adapted: Ogram et al. 1987, J. Microbiol. Meth. 7:57-66; Steffan et al. 1988, Appl. Environ. Microbiology, 54:137-161; Werner et al. 1992, J. of Bact. 5 174(15):5072-5078; Zhou et al. 1996, Appl. Environmental Microbiol. 62(2):316-322.

Briefly, 5 g samples are lysed directly by dropwise addition to hot guanidium isothiocyanate lysis buffer (see Section 5.3.1), and subjected to a cesium chloride 10 purification. Alternatively, the samples are mixed with 13.5 ml of DNA extraction buffer (100 mM Tris-HCl pH 8.0, 100mM EDTA, 100 mM sodium phosphate, 1.5 mM NaCl, 1% CTAB (hexadecylmethylammonium bromide) and 100 ul of 20 mg/ml proteinase K in 50 ml centrifuge tubes and shaken by 15 horizontal shaking at 225 rpm for 30 minutes at 37°C. After shaking, 1.5 ml of 20% SDS is added, and the samples incubated at 65°C for 2 hours, with end-over-end shaking every 15-20 minutes. The supernatants are collected by centrifugation at 6000 x g for 10 minutes at 20°C. The 20 pellets are re-extracted 3X by adding 4.5 ml of extraction buffer and 0.5 ml of 20% SDS, vortexing for 1 minute, followed by a 10 minute incubation at 65°C and re-centrifugation. Pooled supernatants from 3 extractions are extracted twice with chloroform-isoamyl alcohol (48:1). The 25 nucleic acids are precipitated by the addition of 0.6 volumes of isopropanol followed by a one hour incubation and centrifugation at 16,000 x g for 20 minutes at room temperature. The crude nucleic acid pellets are then resuspended in 10 mM Tris-HCl pH 8.0, 2 mM EDTA. Further 30 purification of the DNA is by DEAE chromatography if needed. Total RNA is obtained from the crude pellet by selective precipitation of RNA by 4M lithium acetate or acid phenol extraction (Ausubel et al. 1990, Greene Publishing Associates and Wiley Interscience, New York; Hoben et al. 1988, Appl., 35 Environ, Microbiology, 54:703-71).

#### 5.3.7. REPAIR OF DNA

Nicked or degraded DNA samples are repaired by first blunting any fragmented ends with T4 DNA polymerase (New England Biolabs). The DNA is treated in blunting buffer (50 mM Tris-HCl pH 7.8, 10 mM MgCl<sub>2</sub>, 40  $\mu$ M dNTPs, 5 U/10  $\mu$ g T4 DNA polymerase) for 1-2 hours at 37°C. The DNA is ethanol precipitated by the addition of 1/10 volume of 3M sodium acetate and 2.5 volumes of 100% ethanol.

After centrifugation and resuspension in water, the DNA sample is treated with *E. coli* DNA ligase in *E. coli* ligase buffer (50 mM Tris-HCl pH 7.8, 10 mM MgCl<sub>2</sub>, 10 mM DTT, 26  $\mu$ M NAD<sup>+</sup>, and 25  $\mu$ M BSA, 10U of *E. coli* for 1-2 hours at 16°C. After treatment the DNA sample is diluted 5 fold with a solution of 20 mM Tris-HCl pH 8.0, 0.3M sodium acetate and extracted once with phenol and once with chloroform. The addition of 2.5 volumes of ethanol to the aqueous phase precipitates the DNA. The samples are rinsed two times with 70% ethanol and resuspended in sterile water or 10 mM Tris-HCl, pH 8.0, 1 mM EDTA and frozen at -70°C until used.

20

#### 5.4. PROTOCOLS FOR PROKARYOTIC EXPRESSION LIBRARIES

The procedures for preparing natural pathway expression libraries and chimeric pathway expression libraries using prokaryotic host and donor organisms are provided in this section. Purified high quality DNA obtained by the techniques described in Sections 5.3.1 - 5.3.4 may be used in the following procedures.

##### 5.4.1. BACTERIAL SPECIES, STRAINS, AND CULTURE CONDITIONS

30

Particularly good expression host organisms are restriction-minus, endonuclease deficient, and recombination deficient. For *E. coli*, a preferred strain is XL1-MR (genotype: McrA<sup>-</sup>, McrCB<sup>-</sup>, McrF<sup>-</sup>, Mrr<sup>-</sup>, hsdR<sup>-</sup>, endA<sup>-</sup>, recA<sup>-</sup>). For *Streptomyces*, a preferred strain is *S. lividans* TK64. For *Bacillus subtilis*, preferred strains are *B. subtilis* PB168 trpC2; *B. subtilis* PB5002 sacA, degUhy; *B. subtilis*

35

PB168delta trpC2, pksdelta 75.8; *B. subtilis* ATCC 39320 and 39374.

The donor organisms are bacterial species. Some are selected for the ability to produce a unique compound that is detectable by current assays. Others are selected due to their presence in an environmental sample of potential interest. In some examples, marine bacteria were obtained from Harbor Branch Oceanographic Institute and Scripps Institute of Oceanography. They were generally collected from international waters more than 200 miles offshore. Metabolic tests as well as gram testing and colony morphologies were performed to the level necessary to ensure that the samples are taxonomically diverse.

*E. coli* are grown at 37°C when preparing library stocks, and at 30°C for expression. Marine, *Actinomyces* and *Streptomyces* species are grown only at 30°C.

#### 5.4.2. PREPARATION OF DONOR GENOMIC DNA

From each species of bacteria, a 10mL culture is grown. The bacteria are pelleted by centrifugation and resuspended in 10mM Tris, 5mM EDTA (TE). The DNA may be purified by the procedures described in Section 5.1.2., or the bacterial pellet may be solubilized in SDS/proteinase K, extracted by phenol:chloroform, and precipitated with isopropanol. The resulting purified DNA is resuspended overnight in TE.

Aliquots of each purified DNA are subjected to agarose gel electrophoresis to confirm integrity and to determine the DNA concentration.

To prepare random large DNA fragments for the natural pathway expression library, 20µg of DNA for each species is partially digested with a frequent-cutting enzyme, such as Sau3A, by incubating in 1X enzyme buffer and 0.01-0.5 unit enzyme per µg DNA for 1 hour at 37°C. The amount of enzyme used may be determined empirically to generate the desired size range. The digested DNAs are pooled, phenol:chloroform extracted, and ethanol-precipitated. 100µg of this mixture is used for each library that requires large native fragments of



genomic DNA. This mixture can optionally be size-fractionated through sucrose gradients. Smaller fragments of DNA for the chimeric pathway expression library can simultaneously be selected by size fractionation.

- 5 The digestion and size fractionation are confirmed by subjecting aliquots of the samples to agarose gel electrophoresis.

#### 5.4.3. GENERATION OF PROKARYOTIC PROMOTER FRAGMENTS

- 10 In one example, synthetic oligonucleotides are used to construct a fragment containing two copies of the beta-galactosidase promoter (*lac*), one on either side of a unique *Bam*H1 site, with each copy of *lac* positioned to direct transcription toward the centered *Bam*H1 site (Figure 4A).
- 15 The synthetic oligonucleotides are phosphorylated by the synthesizer. 400ng of each oligonucleotide is annealed by boiling five minutes and slow cooling over 30 minutes to 25°C before ligating 30 minutes at room temperature with T4 DNA ligase. The ligation mix is subjected to agarose gel
- 20 electrophoresis and 2-7 kbp fragments are excised and purified by Gene Clean. The joined, paired, and properly-oriented cassettes are inserted into the *Sma*I site of the pBSK plasmid vector by incubation for 16 hours at 15°C with T4 DNA ligase in 1X ligase/PEG buffer. The ligation mix is
- 25 introduced into XL1-MR cells. Individual clones are analyzed by restriction enzyme analysis and may optionally be sequenced to confirm orientation and accuracy.

- The pBSK-(*lac/lac*)<sub>n</sub> clones (where n is an integer from 2 to 10) are cultured in 0.3 liter quantities and the plasmids
- 30 purified using a plasmid preparation kit (Qiagen). 40μg of the selected and purified pBSK-(*lac-lac*)<sub>n</sub> is digested to completion with *Sma*I in 1X buffer. The digested DNA is subjected to agarose gel electrophoresis and the *lac/lac* promoter dimers are excised and purified with Gene Clean, and
- 35 digested to completion with *Bam*H1 in 1X buffer. See Figure 4B and 4C. The digested promoter monomers are phenol:chloroform extracted, ethanol precipitated, and

dephosphorylated by treatment with CIAP in 1X CIAP buffer. The dephosphorylated, digested promoters are extracted and precipitated as before, and resuspended in TE at a concentration of 20ng/ $\mu$ l before storing at -20°C or further use.

In another example, prepared promoter fragments are mixed with similarly-prepared linkers that do not contain promoter sequences, and then used in ligations with the donor genomic DNA. This allows the generation of cassettes with only one promoter, in cases where anti-sense transcription is a consideration.

#### 5.4.4. PREPARATION OF GENE CASSETTES FOR COMBINATORIAL CHIMERIC PATHWAY EXPRESSION LIBRARIES

In one example, *Bam*HI-*Bam*HI fragments of genomic DNA (mean size 3.5 kbp) are mixed with an excess of dephosphorylated promoter fragments, and then ligated. The molar ratio of promoters to genomic DNA fragments is 20:1. The resulting units (*lac* / genomic DNA fragment/ *lac*) will have a mean size of approximately 4 kbp. Other prokaryotic promoters that may be used include other *E. coli* promoters (Harley et al., 1987, Nuc Acid Res 15:2343-2361), and *Streptomyces* promoters (Strohl 1992, Nuc Acid Res V20:961-974) for use in *Streptomyces* species expression hosts. In hosts with undetermined or significant recombination ability, it is desirable to use a series of different promoters such that any clone containing several cassettes will contain several different promoters.

#### 5.4.5. PREPARATION OF SOLID SUPPORT

Ultralink Immobilized Streptavidin beads were purchased from Pierce (Cat. No. 53113). 3M Emphaze Biosupport Medium AB1 "blank beads" was purchased from Pierce (Cat. No. 53112). Similar solid supports from other vendors may be substituted for this procedure.

Oligonucleotides were purchased from Life Technologies (Gibco-BRL). Oligonucleotide "Bead-link-5" is 5' biotin-GCC GAC CAT TTA AAT CGG TTA **AT** 3'. "Bead-link-3" is 5' phosphate-TAA CCG ATT TAA ATG GTC GGC 3'. When annealed, these oligonucleotides contain a *Swa*I restriction endonuclease site (shown underlined below). Annealed bead-link oligonucleotides also leave an AT overhang at the 3' end. This overhang is shown by bolding on oligonucleotide bead-link-5.

10 biotin-GCC GAC CAT TTA AAT CGG TTA **AT**  
CGG CTG GTA AAT TTA GCC AAT

Equimolar amounts of each bead-link oligonucleotide are mixed together in an eppendorf tube. 5M NaCl is added to the tube to a final concentration of 300mM. The reaction is incubated at 60°C for 1.5 hr. Annealing was confirmed by agarose gel electrophoresis using non-annealed oligonucleotides as a control.

To prepare blank beads, 100mg dry beads was resuspended in 1ml phosphate buffered saline (PBS). Bovine Serum Albumin (BSA) was added to final concentration of 1mg/ml. Beads were rotated for 4 hrs at room temperature. Beads were pelleted by centrifugation and washed 3x with 1M Tris-HCl pH8.0 for 2 hours at room temperature to block unreacted azalactone sites. Beads were pelleted by brief centrifugation and were washed extensively with PBS. Blank beads were stored in PBS at 4°C until used.

To bind bead-link oligonucleotide to streptavidin beads 10µg previously-annealed oligonucleotides were mixed with 20µl Ultralink Immobilized Streptavidin beads in 1x binding buffer (PBS, 500mM NaCl). Beads were incubated for three hours at room temperature with inversion to keep the beads suspended. Beads are pelleted and washed 3x with 1ml binding buffer. Beads are then washed and equilibrated with 1x ligation buffer (50mM Tris-HCl pH7.8, 10mM MgCl<sub>2</sub>, 10mM dithiothreitol, 1mM ATP, 25µg/ml BSA). Beads are stored at 4°C until used.

#### 5.4.6. ASSEMBLY OF A COMBINATORIAL CHIMERIC PATHWAY EXPRESSION LIBRARY

Attachment of gene cassettes to magnetic beads: The gene cassettes are phosphorylated using T4 polynucleotide kinase in 1X kinase buffer. The phosphorylated fragments are ethanol precipitated and resuspended in TE. 1/10 of this is ligated to a mixture of two short non-phosphorylated synthetic linkers. The remaining 9/10 is used for a later procedure. Each linker will have one of two rare-cutting enzymes, either *NotI* or *SrfI*. In addition, the *NotI*-containing linker is biotinylated at the time of synthesis of the oligonucleotides. The *NotI* and *SrfI* linkers are mixed with the phosphorylated transcription units in the ratio, respectively, of 100:100:1, and ligated with T4 DNA ligase in 1X ligase/PEG buffer for 16 hours at 15°C. This mixture is allowed to bind to avidin-conjugated MPG magnetic beads, and the manufacturer's protocols are used to remove the bead-bound transcription units from the ligation mixture.

In the mixture of ligated DNA, approximately 1/2 will have a biotinylated *NotI* linker placed at one end and a *SrfI* linker at the other end. The *NotI* ends will be bound to the beads by avidin-biotin linkages. The fragments with *NotI* linkers at both ends are not involved in further addition steps. The fragments with *SrfI* linkers at both ends are not retained in the magnetic separation step.

Preparation of pool of DNA for addition to beadbound DNA: The remaining 9/10 of the phosphorylated transcription units are ligated as above, but to the *SrfI* linkers only, followed by digestion to completion with *SrfI*, dephosphorylation, purification and ethanol precipitation.

De-protection of bead-bound DNA: Transcription units bound to the beads are digested to completion with the *SrfI* enzyme in 1X *SrfI* buffer. The reaction is heat-inactivated and the beads are removed by magnetic separation.

Concatenation: The beads are then added to a ligation mix containing the dephosphorylated *SrfI*-*SrfI* digested transcription units in 1X ligation buffer. Ligations are

commenced by addition of T4 DNA ligase and proceed for 60 minutes, 25°C, before heat-inactivation of the ligase and magnetic separation of the beads. Ligations will primarily occur between phosphorylated bead-bound DNA and non-

5 phosphorylated transcription units. The transcription units on the bead are phosphorylated by T4 polynucleotide kinase, heat-inactivated, magnetically-separated, and returned to the ligation mixture with the addition of more T4 DNA ligase.

This cycle is repeated ten times before cleaving the  
10 polymer from the beads by digestion with NotI. The cleaved DNA is ethanol precipitated, resuspended in TE, and viewed on an agarose gel to gauge the quality and size range before insertion into the SuperCos 1 or other vector, according to the expression host. The concatemers are used to generate a  
15 prokaryotic library in the relevant expression host as described in Section 5.4.5.

#### 5.4.7. ASSEMBLY OF A COMBINATORIAL NATURAL PATHWAY EXPRESSION LIBRARY

20 The expression vector for an *E. coli* library is desirably the cosmid SuperCos 1, capable of maintaining inserts of 30-42kbp in size. Insertion of the DNA fragments into SuperCos 1 and packaging with Gigapack extracts are performed according to the manufacturer's directions  
25 (Stratagene).

Briefly, XL1-MR host cells are infected with SuperCos 1 phage containing the DNA library. This is performed as follows: XL1-MR cells are grown overnight in 5mL LB medium with 1% maltose, 10mM MgSO<sub>4</sub> at 300 rpm, 37°C. The overnight  
30 culture is diluted 1:10 and cultured 3 hours in LB/10mM MgSO<sub>4</sub> at 300 rpm, 37°C. The culture is pelleted by centrifugation at 800xg and resuspended in 5mL LB. 600μl of this suspension is incubated with 500cfu of library packaged in phage particles for 30 minutes at ambient temperature, followed by  
35 a 60 minute incubation with 8 vol LB at 300 rpm, 37°C.

In order to amplify the expression libraries, the infected host cells are spread on 150mm Petri dishes with

50mL LB, 50 $\mu$ g/mL ampicillin. The plates are previously dried for 48 hours at ambient temperature. After spreading, the plates are allowed to incubate overnight at 37°C. The plates are scraped and the colonies resuspended with 3mL

5 15% glycerol, 85% LB per plate. This bacterial suspension is stored at -70°C for further use.

To prepare the libraries for screening individual clones, the infected host cells are spread on 150mm Petri dishes with 50mL LB, 50mg/mL ampicillin. The plates are  
10 previously dried for 48 hours at ambient temperature. After spreading, the plates are allowed to incubate overnight at 37°C. Resulting colonies are picked with sterile toothpicks and transferred one per well to multi-well plates. Each well of a 384-well plate contains 75/ $\mu$ L LB, 50 $\mu$ g/mL ampicillin, 7%  
15 glycerol. The outer rows (80 wells total) are not inoculated but are similarly filled with medium to provide an evaporation barrier during subsequent incubation and freezing. These inoculated master plates are placed at 37°C for 16 hours without shaking. The overnight master 384-well  
20 plates are used as a source plate to replicate into one or more working 384-well plates or Omni-Trays. The master 384-well plates are then sealed individually and frozen at -80°C. Replication is done with a 384-pin replicator. Before and after each use, the 384-pin replicator is dipped sequentially  
25 into bleach for 20 seconds, water for 30 seconds, then ethanol for 5 seconds before flaming. Methods of library assembly are dependent on the selection of vector and expression host.

#### 30 5.4.8. PRE-SCREENING OF EXPRESSION LIBRARIES

There are three categories of pre-screens: intracellular differential, and selection.

Briefly, the first category, intracellular pre-screening entails introduction of the library into a host engineered to  
35 contain a chemo-responsive reporter construct. The reporter is GFP (green fluorescent protein) or  $\beta$ -galactosidase, and

selection is done by fluorescence-activated cell sorting (FACS) or macrodroplet sorting.

The second category, differential pre-screening, entails incubation of the library in the host with fluorescent or  
5 chromogenic physiological tracers, followed by FACS or macrodroplet sorting.

The third category, selection pre-screening, entails incubation of the library in the host with selective agents such as antibiotics, followed by FACS or macrodroplet sorting  
10 to identify surviving or multiplying cells.

For all methods, cell sorting is done on bulk cultures of amplified libraries prior to examination of individual cultures.

The libraries may be pre-screened by FACS or  
15 macrodroplet sorting. Pools of host cells containing the DNA libraries are cultured in one of two formats promoting either high or low density micro-environments.

In the first format, cells of the amplified library are examined as individual cells. An *E. coli* library aliquot is  
20 grown for 4 hours at 30°C in 20 vol medium at 300 rpm before pelleting, resuspension in 1 vol sterile ddH<sub>2</sub>O, incubation with fluorescent probes (as needed), and placement on ice for transfer to the FACS facilities.

In the second format, aliquots of the amplified library  
25 are encapsulated and cultured in the presence of substrates or selection agents as described in Section 5.2.3 before transfer to the FACS or macrodroplet sorting facilities.

For cultures to be examined with fluorescent tracers or substrates, the cultures resuspended in ddH<sub>2</sub>O, are stained  
30 before FACS following the manufacturers protocols, typically as follows: incubations are in the dark, at room temperature, for 15 minutes, followed by pelleting for 5 minutes in a 1.5mL microfuge tube and resuspension in 1 vol cold ddH<sub>2</sub>O.

After sorting, pools of selected 1-1000 clones or  
35 macrodroplets from the expression libraries are cultured in 0.5L nutrient media. The cultured bacteria and media are processed for chemical analysis by extraction with 0.5L ethyl

acetate. Rotary evaporation yields a crude organic extract of approximately 20mg-1g extract per liter culture. The cognate cloned DNAs are purified and re-transformed into host cells to confirm the localization of relevant sequences to the cosmid. Chemical samples generated by expression from library clones may be examined by HPLC using a series of columns (cationic, anionic, reverse phase) and subsequently by qualitative chemical analysis using NMR.

10        5.4.9.    METABOLIC TESTING OF MARINE GRAM(-)/E. COLI  
                      LIBRARY BY PLATE REPLICATION

Each wild-type marine species is tested prior to preparation of the DNA libraries to prevent redundancy and to help determine the array of metabolic tests to be done on the completed libraries.

15        To prepare the libraries for screening individual clones, the infected host cells, such as *E. coli* XL1-MR, are spread on 150mm Petri dishes with 50 ml LB, 50mg/ml ampicillin. The plates are previously dried for 48 hours at ambient temperature. After spreading, the plates are allowed to incubate overnight at 37°C. Resulting colonies are picked with sterile toothpicks and transferred one per well to 384-well plates. Each well contains 75 µl LB, 50 µg/ml ampicillin, 7% glycerol. The outer rows (80 wells total) are not inoculated but are similarly filled with medium to provide an evaporation barrier during subsequent incubation and freezing. These inoculated master plates are placed at 37°C for 16 hours without shaking. The overnight master 384-well plates are used as a source plate to replicate into one or more working multi-well plates or Omni-Trays. The master 384-well plates are then sealed individually and frozen at -80°C. Replication is done with a 384-pin replicator. Before and after each use, the 384-pin replicator is dipped sequentially into bleach for 20 seconds, water for 30 seconds, then ethanol for 5 seconds before flaming.



Working multi-well plates or Omni-Trays are used as source plates to replicate the DNA libraries onto a series of differential and/or selective media (e.g. siderophore detection media or antimicrobial lawns). The results are  
5 compiled and compared to the profiles of the wild-type marine bacteria used to construct the DNA library.

5.4.10. METABOLIC TESTING OF MARINE GRAM(-)/E. COLI  
LIBRARY BY MACRODROPLET ENCAPSULATION

10 Clones are encapsulated by taking sodium alginate and dissolving in 100 mL of sterile water at a concentration of 1% using an overhead mixer at 2000 rpm. A volume of library suspension is added so as to embed 1-5 clones per droplet. The mixture is allowed to sit for at least 30 minutes to  
15 degas. The mixture is then extruded through any device that allows it to form individual droplets. One such example is a syringe with a 25 gauge needle. These are dropped into a gently stirring beaker of 135mM calcium chloride. Droplets are allowed to harden for 10 minutes and then are transferred  
20 to a sterile flask and the calcium chloride removed and replaced with LB/Amp media and a substrate (e.g. x-glucosidamine). Flasks containing the droplets are then shaken at 30°C overnight and examined the following morning for positive clones indicated by the presence of blue  
25 colonies.

Droplets are placed in a single layer in a large clear tray and scanned by eye. Positive colonies are removed and placed in 96-well master plates containing LB/Amp and 50 mM sodium citrate pH 7.4 to dissolve the droplet, and allowed to  
30 grow at 37°C overnight. These overnight master 96-well plates are used as a source plate to replicate into one or more working multi-well plates or Omni-Trays. The master 96-well plates are then sealed individually and frozen at -80°C. Positive clones can then be either sent for specific testing  
35 of the products or sent through another round of pre-screening or screening. Further screening may be performed by replication which is done with a multi-pin

replicator. Before and after each use, the multi-pin replicator is dipped sequentially into bleach for 20 seconds, water for 30 seconds, then ethanol for 5 seconds before flaming.

5

5.4.11. METABOLIC TESTING OF MARINE GRAM(-)/*E. COLI*  
LIBRARIES BY MICRODROPLET ENCAPSULATION

Microdroplets may be generated by the following method. Using an overhead mixer at 2000 rpm, 0.6g sodium polyphosphate and 2% Sodium alginate are dissolved in 100 ml sterile water. This mixture is allowed to degas for 60 minutes. Then 1.9g calcium sulphate is sonicated in 10 ml 50% glycerol for at least 15 minutes. This slurry and a volume of the library suspension which will yield 1-5 cells per droplet are blended into the alginate solution immediately before introduction to an oil phase (olive oil) which has been premixed with the addition of 1.0g purified soy bean lecithin for at least 30 minutes. The emulsification process is initiated by slowly transferring the alginate mixture into the oil phase and mixing for 10 minutes at 580 rpm. 500 ml sterile water is then added and the mixing allowed to continue for 5 minutes. Microdroplets can then be removed from the oil by centrifugation and washed and resuspended in LB/Amp. For the purpose of sorting by FACS, if the droplets are outside of the desired size range necessary for sorting, the droplets can be size selected using a filter membrane of the required size limit. Clones can then be grown 2 hours at 30°C with shaking in LB/Amp media containing a fluorescent substrate.

Following incubation the sample is prepared for sorting with FACS by centrifuging, washing and resuspending in sterile water at a density of  $1 \times 10^6$  droplets per ml. The size of the droplets can be examined by phase microscopy. FACS services are performed by a qualified operator on a Becton-Dickinson FACStar Plus and positives are sorted directly into multi-well plates containing LB/Amp, isolating positives to 1 clone per well. These plates are allowed to

grow at 37°C until the colonies grow out of the beads (1-2 days). These overnight plates are used as a source plate to replicate into one or more working multi-well plates or Omni-Trays. The master multi-well plates are then sealed  
5 individually and frozen at -80°C. Positive clones can then be either sent for specific testing of the products or sent through another round of pre-screening or screening. Further screening may be performed by replication which is done with a 96 or 384-pin replicator. Before and after each use, the  
10 replicator is dipped sequentially into bleach for 20 seconds, water for 30 seconds, then ethanol for 5 seconds before flaming.

15 5.4.12. METABOLIC TESTING OF  
ACTINOMYCETES/STREPTOMYCES LIVIDANS LIBRARY  
BY PLATE REPLICATION

Each cultivable wild-type *actinomycete* species is tested prior to preparation of the DNA libraries to prevent taxonomic redundancy, and to help determine the array of metabolic tests to be done on the completed libraries. To  
20 prepare the libraries for screening individual clones, the transformed host cells, *Streptomyces lividans* TK66, are spread on 150mm Petri dishes with F10A. The plates are previously dried for 48 hours at ambient temperature. After spreading, the plates are allowed to incubate overnight at  
25 30°C. Selection is initiated by overlaying with thiostrepton. Resulting colonies are picked with sterile toothpicks and transferred one per well to 96-well plates. Each well contains F10A media. These inoculated master plates are placed at 30°C for 1-4 days. The overnight master  
30 96-well plates are used as a source plate to replicate into one or more working multi-well plates or Omni-Trays. The master 96-well plates are then sealed individually and frozen at -80°C. Replication is done with a multi-pin replicator. Before and after each use, the multi-pin  
35 replicator is dipped sequentially into bleach for 20 seconds,

water for 30 seconds, then ethanol for 5 seconds before flaming.

Working multi-well plates or Omni-Trays are used as source plates to replicate the DNA libraries onto a series of 5 differential and/or selective media (e.g. antibiotic plates or antimicrobial lawns). The results are compiled and compared to the profiles of the wild-type bacteria used to construct the DNA library.

10        5.4.13. METABOLIC TESTING OF  
          ACTINOMYCETES/STREPTOMYCES LIVIDANS LIBRARY  
          BY MACRODROPLET ENCAPSULATION

Clones are encapsulated by the method as described in Section 5.4.10 for *E. coli* libraries. Droplets are allowed to harden for 10 minutes and then are transferred to a 15 sterile flask and the calcium chloride removed and replaced with F10A media and a substrate (e.g. x-gal). Flasks containing the droplets are then shaken at 30°C for 1 -5 days and examined for positive clones indicated by the presence of blue colonies.

20        Droplets are placed in a single layer in a large clear tray and scanned by eye. Positive colonies are removed and placed in 96-well master plates containing F10A 50 mM sodium citrate pH 7.4 to dissolve the droplets and then grown at 30°C for 2 days. These overnight master 96-well plates are 25 used as a source plate to replicate into one or more working multi-well plates or Omni-Trays. The master 96-well plates are then sealed individually and frozen at -80°C. Positive clones can then be either sent for specific testing of the products or sent through another round of pre-screening or 30 screening. Further screening may be performed by replication as described above in Section 5.4.9.

          5.4.14. PRE-SCREENING OF CLONES BY CO-ENCAPSULATION  
          WITH INDICATOR CELLS

35        Pools of library clones are titered by plating appropriate dilutions and performing colony counts. Adequate library cells are mixed in 1% alginate to result in

approximately 1 cell per macrodroplet. In addition, adequate indicator cells are included to result in approximately 50 target cells per droplet. Macrodroplets are produced as described in Section 5.4.10, and cultured under appropriate  
5 conditions for the library and indicator cells.

In general, *S. lividans* library macrodroplets are cultured at 30°C in R5 or F10A, and *E. coli* library macrodroplets are cultured at 30-37°C in LB or B3. The media and temperature may be adjusted to accommodate the  
10 physiological needs of the indicator cells. To visualize effects of the library cell has on the indicator cells, the following reporter regimens are utilized: to detect cell death, inclusion of neutral red or congo red; to detect cell viability, inclusion of substrate relevant to indicator cell  
15 (e.g., X-glucopyranoside for *E. faecalis*); to detect *B*-galactosidase reporter activity in response to promoter activation, inclusion of 80 mg/ml X-gal in culture media. After isolation of positive macrodroplets as described in Section 5.4.10, indicator cells are eliminated by addition of  
20 antibiotics that are selective for the library cells but not the indicator cells. The library cells are then stored and/or further examined as desired.

#### 5.5. PROTOCOLS FOR EUKARYOTIC EXPRESSION LIBRARIES

25 This section describes procedures that may be generally applied to prepare combinatorial gene expression libraries of eukaryotic donor organisms. The steps involved in the preparation of a combinatorial chimeric pathway gene expression library in eukaryotes are shown in Figures 5A-5F.

30 Particularly good expression eukaryotic host organisms are stable, non-filamentous, and characterized sufficiently so as to be genetically manipulatable for the purposes of gene expression. For yeast and fungi, a preferred species is *S. pombe*, which is grown at 30°C (C. Guthrie and G.R. Funk, Guide to Yeast Genetics and Molecular Biology, Methods in  
35 Enzymology, Vol. 194, Academic Press). *A. thaliana* and *N. tabacum* cells are preferred hosts (C.P. Lichtenstein & J.

Draper, Genetic Engineering of Plants, DNA Cloning Vol. II, pp. 67-119).

5.5.1. REMOVAL OF SATELLITE GENOMIC DNA BY DENSITY GRADIENT CENTRIFUGATION

5 Eukaryotic genomes often have large amounts of repetitive DNA which consists of primarily ribosomal coding regions, or sequences of no apparent function. Thus, in preparing genomic DNA from eukaryotic donor organisms, it may be desirable to exclude such non-coding DNA sequences from a library. Standard CsCl genomic DNA purification methods in the presence of the DNA binding dye, Hoechst 33258 (Cooney & Matthews, 1984) may be used to separate out various classes of genomic DNA prior to cloning.

15 5.5.2. GENERATION OF EUKARYOTIC PROMOTERS AND TERMINATOR FRAGMENTS

Both promoter and terminator gene fragments may be produced by PCR using sequence-specific primers adapted from published sequences of known promoters and terminators. The choice of promoter and terminator sequences can be determined by the host organism used. For instance if *S. pombe* is used as an expression host, both native promoters, such as *nmt 1* or *ura 4*, and non-native promoters such as those derived from viruses, e.g., CMV, SV40 (Forsburg, 1993 Nuc Acid Res. 8:4321-4325), or from humans e.g., chorionic gonadotropin or somatostatin (R. Toyama, H. Okayama 1990, FEBS Letters 268(1) pp. 217-221). Genetically engineered promoters similar to those found in the inducible tetracycline system (Faryar et al. 1992, Curr Genet 21:345-349) may also be used.

30 PCR reactions may be performed in a commercially available PCR machine using standard PCR reaction conditions and DNA polymerases of high fidelity and throughput, such as but not limited to, *Pfu* polymerase (Stratagene) or Vent polymerase (New England Biolabs). Since not all primer sets will use the same reaction conditions, precise conditions may be determined empirically by techniques known in the art.

PCR oligonucleotide primers maybe obtained commercially or synthesized by methods well known in the art.

The promoter and terminator fragments generated by PCR may comprise restriction sites at the 5' ends. Bgl II, Xho I, and BamHI are used herein to illustrate the principle of the invention. Any restriction sites may be used as long as the site does not appear within the promoter or terminator gene sequences.

To generate cloning sites compatible to cDNA or genomic DNA inserts, cleavage of the promoter gene fragments with Bgl II and Xho I will generate promoter gene fragments which have at their 5' ends a Bgl II site and an Xho I site at their 3' ends. Terminators are cut only with Xho I and will have only an Xho I site at their 5' end. 5' and 3' orientations are based on the expected direction of transcription across the promoter or terminator gene fragment. See Figure 5B.

Partial fill-in reactions utilizing the large subunit of *E. coli* DNA polymerase I (Klenow fragment) and a subset of deoxynucleotides (in this case dCTP and dTTP) may be used to generate promoter and terminator fragments that are incapable of self-ligation by their Xho I ends. The Bgl II ends of the promoter fragments cannot be affected because of the lack of base-complementarity, and the BamHI end of the terminator fragments have no exposed 5' end for the Klenow fragment to utilize.

Treatment with a phosphatase, such as calf intestine alkaline phosphatase, will prevent BglII self-ligations, and provide similar termini for ligations in both the promoter and terminator fragments. cDNA fragments are protected from digestion with NotI by incorporation of 5'-methyl dCTP during first strand synthesis (Short, J.M. 1988, Nuc Acids Res 16:7583-7600).

In an alternative embodiment of the invention, when DNA inserts are derived from mRNA, directional cloning may be applied to improve the efficiency of cloning. The cDNA inserts can be unidirectionally ligated in the sense orientation with respect to the promoter and terminator

fragments. This can be achieved by generating different, non-ligatable ends on both promoter and terminator fragments. Bgl II, Xho I, Xma I, and BamHI are used to illustrate the invention. Any pair of enzymes that generate compatible ends  
5 and can be protected by methylation can be used.

An XmaI site is substituted for the Xho I site at the 5' ends of the terminator fragments, while the preparation of the promoter fragments is unchanged. Xma I is used because it is compatible with Not I by filling in with Klenow  
10 fragment and dCTP. This results in a terminator fragment that has a two-base dCTP-dCTP 5' overhang, which is compatible with suitably prepared Not I digested cDNA gene fragments. See Figure 5A.

#### 15 5.5.3. PREPARATION OF DNA INSERTS

Coding gene fragments for the eukaryotic libraries will be derived from two principal DNA sources, namely that of genomic DNA (gDNA) or complementary DNA derived enzymatically from messenger RNA (cDNA). Strategies for preparation of  
20 gDNA or cDNA are very similar, but not identical.

Complementary DNA is made from messenger RNA and/or total RNA using standard protocols available in the literature, or particular to a manufacturer's instructions. Isolation of total RNA may be accomplished simultaneously  
25 with genomic DNA by the guanidium-isothiocyanate method described in Section 5.3.1, and mRNA can be isolated by subsequent affinity chromatography over oligo-dT cellulose.

First strand cDNA synthesis can use an oligo-dT DNA primer that contains a cloning site, e.g., a Not I site, at  
30 the 5' end. An oligonucleotide of random sequence, which contains an internal Not I site near its 5' end, can also be used for randomly-primed first strand synthesis. The use of this alternative primer avoids 3' bias for large mRNAs. Methylated deoxynucleotide, such as 5-methyl-dCTP may be used  
35 with a polymerase such as Pfu to provide protection from restriction digestion (Short et al., supra; G.L. Costa, 1994, Strategies 7:8). Only non-methylated sites present in the



initial primers will be available for cleavage, thus ensuring a defined 3' end for the cDNAs. Methylated cDNA can also be produced by treatment with methylation, but the directionality of the cloning will be lost because all available sites will be methylated, and thus resistant to enzymatic cleavage.

Defined 5' ends of cDNA may be prepared by ligation of sequence-specific adapters, such as a modified *Bam*HI adapter which has a 5' phosphate. When annealed to its partner oligonucleotide, the adapter contains only a two-base dGTP-dATP 5' overhang and a blunt 5' phosphate end. This modified adapter can be ligated to cDNA that has been treated with Pfu or T4 DNA polymerase as in standard protocols. After ligation of modified *Bam*HI adapters and digestion of the cDNA with Not I, the adapted cDNA can be treated with Klenow fragment and dGTP generating a defined, directionally oriented cDNA gene insert ready for ligation to suitably prepared promoter and terminator fragments. The orientation of the fragments is such that the 5' end of the cDNA is located toward the 3' end of the promoter, and the 3' end of the cDNA is located toward the 5' end of the terminator fragment. See Figure 5C.

Genomic DNA fragments are obtained by partial digestion of total genomic DNA with a frequently cutting restriction enzyme, such as *Sau* 3AI. This enzyme is widely used for this purpose, and partial digestion followed by sizing through sucrose gradients is a very standard technique. Fragment pools from three different digestions that vary in the concentration of initial enzyme can be used to allow for differences in enzyme sensitivity within the genomes.

Following size fractionation and purification, the fragments can be treated with *Bam*HI methylase to protect any internal *Bam*HI sites, followed by treatment with Klenow fragment and dATP & dGTP. This results in gene fragments that are internally methylated at *Bam*HI sites, and possess only dATP-dGTP overhangs. See figure 5D. These fragments are

incapable of self-ligation, and are only capable of ligating to suitably prepared promoter and terminator gene fragments.

#### 5.5.4. LIGATION OF INSERT DNA TO PROMOTERS AND TERMINATORS

5 Suitably prepared cDNA, promoter, and terminator fragments can be ligated at 16°C over night. A ratio of 10 promoter (P): 1 cDNA: 10 terminator (T) may be used in the ligation reaction. The optimal ratio may be determined  
10 empirically by techniques known in the art. The directional cloning procedure provides only one ligation product, i.e., a correctly oriented promoter-sense insert-terminator gene cassette.

Ligation of prepared genomic DNA, promoter, and  
15 terminator gene fragments may be carried out at 16°C with varying ratios. Since none of the ligation components can self-ligate, the optimal ratios may be determined empirically. It is estimated that half of the ligation products formed are directly useable, 1/4 of the products  
20 formed cannot enter the rounds of ligations, and 1/4 of the products can be ligated only once before terminating the growing chain.

The following combinations (p=promoter, frag=5'→3' genomic DNA fragment, T=terminator garf=3'→5' genomic DNA  
25 fragment):

- |             |             |
|-------------|-------------|
| 1. P-frag-T | 5. P-garf-T |
| 2. T-frag-P | 6. T-garf-P |
| 3. P-frag-P | 7. P-garf-P |
| 4. T-frag-T | 8. T-garf-T |

30 Combinations 1,6 & 2,5 represent the desired constructs, but because the orientations of the inserts are random, it is expected that 50% of these constructs will be in the correct orientation for any given gene (1 and 6).

Terminator/terminator gene cassettes may form, but  
35 cannot be involved in any subsequent cloning step because of the lack of an exposed 5' end because of the blunted, uncut *Bam*HI end at their 3' termini.

Promoter/promoter constructs will clone in subsequent ligations only to other exposed *Bam*HI ends, because the *Bgl* II end lacks a 5' phosphate (first round). Subsequent ligations to the exposed *Bgl* II end should be rare with incoming gene cassettes because of the lack of 5' phosphates. Exposed *Bam*HI ends will only be made possible on resident forming chains and not on incoming new gene cassettes. Thus it is expected that such promoter/promoter gene cassettes will terminate a chain by circularization with a nearby *Bam*HI site on another chain, such circularizations are non-recoverable. If such promoter/promoter fragments become a significant problem to ligation efficiencies then an intermediate kinase treatment of the fixed growing chains prior to addition of new gene cassettes should allow the promoter/promoter fragments to extend the growing chains by forming *Bgl* II/*Bgl* II ligation products. The kinase treatment will promote *Bgl* II/*Bgl* II and *Bgl* II/*Bam*HI ligations on the solid phase, which will circularize the growing chains involved.

20

#### 5.5.5. SERIAL LIGATIONS OF GENE CASSETTES TO FORM CONCATEMERS

Ligation of the gene cassettes, each consisting of either genomic DNA or cDNA insert flanked by promoters/terminator combination will be performed in a method analogous to that outlined previously for prokaryotic DNAs. The major difference here is that this strategy used the endonuclease *Bam*HI to create exposed 3' restriction sites for subsequent cloning. The use of either *Bam*HI methylase or 5-methyl-dCTP insures that *Bam*HI sites within the insert DNA will be protected. See Figure 5E.

After 5-10 rounds of chain ligation, the growing chains of concatemers will be deprotected with *Bam*HI and prepared for ligation to the expression vector by treatment with the Klenow fragment and dATP and dGTP. This will render all ends of the growing chain incapable of ligating to each other,

35

thus eliminating any circularization and loss of concatemer chains.

Vector DNA can be ligated to concatemer chains in a 5:1 molar ratio. Other ratios may also be used. The can be done  
5 at 16°C for 8-12 hours, or at 22°C for four hours. Following ligation the beads can be washed and resuspended in intron nuclease restriction buffer. Digestion will be carried out as described by the manufacturer's instructions. Any intron nuclease may be used. The enzyme CeuI is preferred for it  
10 produces non-palindromic 3' overhangs, which are useful in preventing self-ligations. See Figure 5F.

#### 5.5.6. CIRCULARIZATION AND TRANSFORMATION OF VECTOR CONTAINING Concatemer CONSTRUCTS

Concatemer-vector molecules released from the solid  
15 phase can be encouraged to undergo intra-molecular ligation by dilution of the CeuI digestion mix 100-fold with 1X ligase buffer. T4 ligase can be added, and the reactions may be carried out at 22°C for 4-6 hours, or 16°C overnight. See  
20 Figure 5F. The resulting constructs may be concentrated by microfiltration or freeze-drying, and introduced into either *S. pombe* strains, or alternatively into *E. coli* or *S. lividans* strains by standard methods. Any method may be used, including but not limited to electroporation, and  
25 modified calcium-phosphate transformation methods.

#### 5.5.7. PREPARATION AND LIGATION OF PREPARED VECTOR FOR EXPRESSION IN YEAST

This section describes procedures that may be generally applied to prepare combinatorial gene expression libraries  
30 using yeast as the host organism.

For preparing a library in *S. pombe*, one possible vector, but certainly not the only vector, is the *E. coli*/*S. pombe* shuttle vector pDblet (Brun et al. 1995, Gene, 164:173-177). This vector has the advantage of having multiple  
35 cloning sites and fl phage origins, being expressed at

moderately high copy number and being very stable in both *E. coli* and *S. pombe*.

For the present invention, the multiple cloning site (MCS) of pDblet may be modified to accommodate a *Bst*XI site of known sequence. See Figure 6B. This is because the intron nuclease enzyme that is used to release the concatemer chain from the solid phase generates 3' nucleotide overhangs of a defined sequence (3'GATT...). An engineered *Bst*XI site having the sequence CCACCTAACTGG generates the appropriate CTAA-3' overhang after cleavage.

To modify pDblet, it can be first cut with *Sac*I & *Not*I to remove the existing *Bst*XI site which does not have the correct sequence. The pDblet plasmid, once purified by spin-chromatography or other means, can be mixed with a presynthesized oligonucleotide which contains in addition to a correct sequence for the *Bst*XI site, a new *Nco*I site and *Sac*I- and *Not*I- compatible overhangs. See Figure 6C. After ligation and transformation, mini-preps of clones are checked for correctness by digestion with *Nco*I. Correct clones will be identified by the presence of both a *Bst*XI and *Nco*I site. Treatment of this modified pDblet, with *Bst*XI followed by *Xho*I sites generates a vector that contains a 5' *Xho*I site and a 3' CTAA *Bst*XI overhang. See Figure 5E. This cleaved vector can be treated with Klenow fragment and dCTP and dTTP to render it incapable of ligating to itself. Such a vector may be used to accept the concatemer chains.

#### 5.5.8. PLANT EXPRESSION LIBRARIES

This section describes procedures that may be generally applied to prepare combinatorial gene expression libraries using plant cells as donor and/or host organisms.

For preparation of donor DNA from plants, the following

general procedure is applied: (1) a pretreatment of the plant tissue in cold ether to enhance cell disruption; (2) mechanical homogenization of the tissue by grinding with sand, glass beads or aluminum oxide; (3) filtration through a 5 mesh to remove cell debris; and (4) extraction of the DNA by the procedures described in 5.1.2. The resulting purified DNA is modified as described in Sections 5.5.3. The CaMV 35S or nopaline synthase promoter, and nopaline synthase terminator fragments are prepared by PCR as described in 10 Section 5.5.3. The promoter and terminator fragments are attached to the DNA fragments, and ligated to a plant DNA vector as described in 5.5.5 and 5.5.6.

A preferred plant DNA vector is Bin19 or its variants which uses T-DNA borders and trans acting functions of the 15 vir region of a co-resident Ti plasmid in *Agrobacterium tumefaciens* to transfer the donor genetic material into the nuclear genome of plant host cells (Bevan 1984, supra). Modified Bin19 vectors containing a multiple cloning site, such as pBI121 or pBI221 which are commercially available 20 (Clontech, Palo Alto), can be used. Kanamycin resistance and/or  $\beta$ -glucuronidase activity are used as markers for monitoring transformation, and for pre-screening.

Plant protoplasts are prepared from leaves of *Nicotiana tabacum* plants as described in Potrykus et al. 1988 in 25 "Methods for Plant Molecular Biology" Weissbach and Weissbach ed. Academic Press, page 376-378. The expression constructs are introduced into protoplast cells by transformation using polyethylene glycol as described in Power et al. 1988 in "Methods for Plant Molecular Biology" Weissbach and Weissbach 30 ed. Academic Press, page 388-391. The transformed protoplasts are selected by antibiotic resistance, e.g., kanamycin, and can be encapsulated for pre-screening as described in Section 5.4.10.

6. EXAMPLE: CONSTRUCTION AND SCREENING OF  
COMBINATORIAL GENE EXPRESSION  
LIBRARY

The following subsections describe the preparation and pre-screening of combinatorial gene expression libraries using mixtures of terrestrial microorganisms or marine microorganisms as donor organisms. The libraries utilize *Streptomyces lividans*, *E. coli* and *S. pombe* as host organisms. The results show that some of the library cells display metabolic activity of the donor organisms indicating that potentially interesting donor metabolic pathways are functional in the host organisms. In addition, it is shown that one library clone contains DNA encoding a marine bacterial protein that shares sequence homology to a known enzyme in a metabolic pathway.

6.1. MATERIALS AND METHODS

Reagents useful in the present method are generally commercially available. For example:

Gene Clean, Genome kit (Bio101, Vista, CA); Restriction enzymes, PCR reagents, and buffers (Promega, Madison, WI; New England Biolabs; Stratagene, La Jolla, CA); TA cloning kit (Invitrogen, La Jolla, CA); Bacterial media (Difco, Inc.); Mira Tip (Hawaiian Marine Imports, Inc.); pBSK plasmid, XL1-MR cells, SuperCos 1 cosmid, Gigapack packaging extracts (Stratagene, La Jolla, CA); Qiagen QIAprep plasmid purification kit (Qiagen, Inc., Chatworth, CA); avidin-conjugated magnetic porous glass (MPG) beads (CPG, Inc., New Jersey); petri dishes, 96- and 384-well plates, Omni-Trays (Nunc), 96- and 384-pin replicator and forms (V & P Scientific, San Diego, CA); ampicillin (IBI, Inc., CA); green fluorescent protein and GFP cDNA (Clontech, Inc.); oligonucleotides (Genset, La Jolla, CA); bacterial species and DNA sequences not elsewhere designated (American Type Culture Collection, Rockville, MD); 7-ethoxy-heptadecyl-coumarin, BCECF-AM (Molecular Probes, Oregon); 3-methyl benzoate, 3-chlorotoluene, m-toluate, tetracycline,

chloramphenicol, acetaminophen, arsenic, antimony, cis-cis-muconate, and other chemicals unless noted (Sigma); and Dynabeads, MPC-M (Dynal, Inc., Lake Success, NY).

## 5 6.1.1. MEDIA PREPARATION

Purified water (ddH<sub>2</sub>O) for general use in media and solutions is purified by softening, reverse osmosis, and deionization. Pacific seawater (sea H<sub>2</sub>O) is obtained from Scripps Institute of Oceanography (La Jolla, CA) and filtered  
10 before use. Synthetic seawater (SSW) is prepared from ddH<sub>2</sub>O by the addition of salts (45.2mm NaF, 48.8mm SrCl<sub>2</sub>, 0.324mM H<sub>3</sub>BO<sub>3</sub>, 0.563mM KBr, 6.25mM KCl, 4.99mM CaCl<sub>2</sub>, .7mM Na<sub>2</sub>SO<sub>4</sub>, 16.4mM MgCl<sub>2</sub>, 268mM NaCl, 45.8mM Na<sub>2</sub>SiO<sub>3</sub>, 1.10mM EDTA, 1.58mM NaHCO<sub>3</sub>) and marine trace elements (0.01 % Mira Tip).

15 LB medium is prepared from ddH<sub>2</sub>O with 1% tryptone, 0.5% yeast extract, 1% NaCl. W2-B1 is prepared from 75% sea H<sub>2</sub>O or SSW with 0.25% peptone, 0.15% yeast extract, 0.6% (vol/vol) glycerol.

F10A is prepared from ddH<sub>2</sub>O containing 2.5% soluble  
20 potato starch, 0.2% glucose, 0.5% yeast extract, 0.5%  
peptone, 0.5% Distiller's solubles (Nutrition Products Co.,  
Louisville, KY), 0.3% calcium carbonate with pH adjusted  
to 7.

25      6.2.      PRE-SCREENING OF *ACTINOMYCETES*/*STREPTOMYCES*  
                 *LIVIDANS* COMBINATORIAL NATURAL PATHWAY  
                 EXPRESSION LIBRARY BY PLATE REPLICATION AND  
                 MACRODROPLET ENCAPSULATION

Thirty four *actinomycetes* species, identified as species # 501-534 were used as donor organisms. The organisms were  
30 cultured in F10A medium separately, and genomic DNA was extracted and purified as described in Section 5.3.1.

Approximately 100  $\mu$ g genomic DNA per species was obtained and mixed together for partial restriction digestion by *Sau*3A as described in Section 5.4.2. Fragments of genomic DNA were subjected to size fractionation by sucrose gradient centrifugation, and fractions containing 20-40 kb fragments were pooled and partially filled-in with the Klenow fragment



so as to be compatible with similarly-prepared vectors below (Korch 1987, Nuc Acids Res 15:3199-3220; Loftus et al. 1992 Biotechniques 12:172-175). 0.5-3.0  $\mu$ g of the pooled fragments were ligated in multiple batches to 0.5-3.0  $\mu$ g of 5 pIJ922 and pIJ903 (Hopwood 1985, supra) vector prepared with BamHI or XhoI. The ligated expression constructs were transformed into the host organism, *Streptomyces lividans*, strain TK64 which had been made competent by removal of cell walls with lysozyme (Hopwood 1985, supra). Approximately 10 11,000 unique clones were generated, amplified and stored as mycelia in 20% glycerol and as spore suspensions in 50% glycerol at -70°C.

To prepare the libraries for screening individual clones, the transformed TK64 host cells were spread on 150mm 15 Petri dishes filled with F10A agar. After spreading, the plates were allowed to incubate for 21 hours at 30°C. A selection was performed by overlaying plates with thiostrepton at 5  $\mu$ g/ml, 1 ml/plate. After 48-72 hours, colonies were picked with sterile toothpicks and transferred 20 one per well to 96-well plates. Each well contained F10A media. These inoculated master plates were placed at 30°C for 1-4 days. The overnight master 96-well plates were used as source plates to replicate into one or more working 96-well plates or Omni-Trays. The master 96-well plates were 25 then sealed individually and frozen at -80°C. Replication was done with a 96-pin replicator which was sterilized by flaming before each use.

Working 96-well plates were used as source plates to replicate the library onto a series of differential and/or 30 selective media and indicator plates. Selective antibiotics included erythromycin, novobiocin and neomycin. Differential media included F10A and R5 medium containing substrates X-glucopyranoside and X-gluconic acid. Indicator plates included library clones grown on F10A then overlaid with a 35 indicator lawn of *Enterococcus faecalis* (*E. faecalis*), *Bacillus subtilis* (*B. subtilis*) or SOS Chromotest (with X-

gal). The results are compiled and compared to the profiles of *Streptomyces* host TK64.

The clones of the library are also pre-screened by macrodroplet encapsulation. For each pre-screen, 50,000  
5 amplified clones of the library are encapsulated by the method as described in Section 5.4.13.

6.3. PRE-SCREENING OF *ACTINOMYCETES/E. COLI*  
COMBINATORIAL CHIMERIC PATHWAY EXPRESSION  
LIBRARY BY MACRODROPLET ENCAPSULATION

10 Genomic DNA obtained from the thirty four *actinomycetes* species (identified as species # 501-534) as described in Section 6.2, were used in the preparation of a combinatorial chimeric pathway gene expression library in a *S. lividans* host. Fractions containing fragments of Sau3A-digested  
15 genomic DNA of 2-7 kb were pooled.

Aliquots of the genomic DNA fragments are ligated to the different promoters separately to form gene cassettes as described in Section 5.5.3. The concatemers are formed by 8  
cycles of ligation and deprotection using a different pool of  
20 gene cassettes for each cycle, such that the resultant concatemers each have 8 gene cassettes comprising 8 different promoters attached to fragments of genomic DNA.

Ten micrograms of the concatemers were circularized and ligated to 0.5  $\mu$ g of SuperCos 1 vectors at the *Bam*H1 site to  
25 form expression constructs, which were packaged *in vitro* for infection of the *E. coli* host cells XL1-MR according to the manufacturer's directions (Stratagene). Approximately 1,000,000 of unique clones are obtained, amplified and pooled to form an amplified library. The library was stored at -  
30 70°C. Amplified cells are encapsulated as in Section 5.4.10, and pre-screened as in 5.4.14.

35

6.4. PRE-SCREENING OF FUNGAL/*SCHIZOSACCHAROMYCES*  
*POMBE* COMBINATORIAL CHIMERIC PATHWAY  
EXPRESSION LIBRARIES BY MACRODROPLET  
ENCAPSULATION

---

Two combinatorial chimeric pathway expression libraries  
5 were prepared using the following fungal donor organisms  
obtained from ATCC: *Trichoderma reesei*, *Fusarium oxysporum*,  
*Penicillium roquefortii*, *Rhizopus oligosporus*, *Neurospora*  
*crassa*, *Phycomyces blakesleeanus*, *Aspergillus fumigatus*,  
*Aspergillus flavus*, *Emericella heterothallica*, *Chaetomium*  
10 *gracile*, *Penicillium notatum*, *Penicillium chrysogenum*.

Each species was cultured separately in 500 ml potato  
dextrose agar (PDA; Difco) or malt extract agar (MEA; Difco)  
at medium rpm for 48-72 hours. Spore inoculations of  $1 \times 10^4$  -  
 $1 \times 10^6$  spores per ml were placed into 500 ml of potato extract  
15 or malt extract broths in 1 liter culture flasks and grown at  
22 C, 225 rpm, 48-72 hours.

Cultures were harvested by filtration through Miracloth  
(Calbiochem) under vacuum. The collected mycelial masses were  
washed with 2 litres of ddH<sub>2</sub>O, and air-dried for 10 minutes  
20 before freeze drying. Fungal genomic DNA and mRNA were  
extracted and purified from the mycelia as described in  
Sections 5.3.1 and 5.3.2. A portion of the harvested mycelia  
were freeze-dried and stored at -70°C.

Fungal genomic DNA fragments were prepared as described  
25 in Sections 5.4.2. Fungal mRNA was converted into cDNA  
according to standard methods. (Sambrook et al. 1989, Watson  
CJ & Jackson JF (1985) DNA cloning: A practical approach 79-  
88, IRL Press). Weight equivalents of DNA fragments from  
each species were pooled to yield a genomic DNA pool and a  
30 cDNA pool.

Each of these pools containing approximately 5-10 µg of  
DNA is used independently to assemble a combinatorial  
chimeric pathway expression library. The following *S.*  
*pombe*-compatible promoters and terminators were generated as  
35 described in Section 5.5.2: CMV immediate/early, SV40  
early, RSV, HSV thymidine kinase, CaMV, nmtI, adh1 and uva4  
promoters. The promoter and terminator fragments are

combined with the cDNA and genomic DNA pools as described in Sections 5.5.4. Each gene cassette averaging 5 kb in length is concatenated as described in Section 5.5.5. The final concatemers containing 8 gene cassettes each are circularized and inserted into the vector modified pDblet (Brun et al. 1995, Gene, Vol. 164 pp. 173-177) as described in Section 5.5.7. The expression constructs were transformed into *S. pombe* cells via lithium acetate method of Gietz and Woody (FD Gietz & RA Woody, Molecular genetics of yeast: A practical approach, chapter 8, pp 121-134). Upon selection for presence of the *ura4* marker, 110,000 *S. pombe* clones are obtained and amplified. The clones are pooled to form an amplified library ready for pre-screening. The following pre-screens are performed: enzyme substrate test, anti-microbial activity, antibiotic resistance.

#### 6.5. PRE-SCREENING OF MARINE GRAM(-)/E. COLI LIBRARY BY PLATE REPLICATION

Marine bacteria obtained from seawater collected near the Bahamas Islands were provided by the Harbor Branch Oceanographic Institute. Each of the wild-type gram-negative pigmented marine bacterial species was tested prior to preparation of the DNA libraries to determine redundancy, and to help determine the array of pre-screens to be done on the completed libraries.

The following assays were performed on the parental species of marine gram-negative/*E. coli* library, with the indicated results:

<u>Assay</u>	<u>Positive species out of 37 species</u>
Chromazurol S (CAS)	27
<i>Streptococcus pyogenes</i>	0
<i>Enterococcus faecalis</i>	3
<i>Proteus mirabilis</i>	1
<i>Sarcina aurantiaca</i>	10
<i>Staphylococcus aureus</i>	6
Starch digestion	17

Of these assays, the following were selected to be performed on the cells of the combinatorial gene expression

library in *E. coli* : CAS; *S. aureus*; *S. aurantiaca*; starch digestion.

Briefly, each of the 40 parental species was inoculated into 5 ml of B3 medium and cultured overnight at 30°C, 300 rpm in Falcon 2059 tubes. the overnight cultures were pelleted and the total genomic DNA extracted by standard procedures. Genomic DNA was quantified by visualization on an agarose gel and 5 µg DNA from each of the 40 species was contributed to a pool totaling 200 µg. The combinatorial natural pathway expression libraries were assembled in *E. coli* as described in Section 5.1.4. This DNA was partially digested, ligated to SuperCos1 and packaged in λ phage for introduction into *E. coli* according to the SuperCos1 manufacturer's directions (Stratagene). This resulted in 5 x 10<sup>6</sup> unique clones, which was amplified to 7 x 10<sup>8</sup>/ml cfu by standard protocols. The amplified stock was stored in 15% glycerol at -70°C for subsequent use.

To prepare the libraries for screening individual clones, the amplified library cells were spread on 150mm Petri dishes with 50ml LB, 100mg/ml ampicillin and 50mg/ml kanamycin. The plates were previously dried for 24 hours at ambient temperature in the dark. The 7 X 10<sup>8</sup>/ml cfu stock was diluted in LB to 500 cfu/ml. One ml was spread on each 150mm plate. After spreading, the plates were allowed to incubate overnight at 37°C. Resulting colonies were picked with sterile toothpicks and transferred one per well to 384-well plates. 6400 colonies were picked and archived. Each well contained 75 µl LB, 50 µg/ml ampicillin, 7% glycerol. The outer rows (80 wells total) were not inoculated but were similarly filled with medium to provide an evaporation barrier during subsequent incubation and freezing. These inoculated master plates were placed at 37°C for 16 hours without shaking. The overnight master 384-well plates are used as a source plate to replicate into one or more working multi-well plates or Omni-Trays. The master 384-well plates were then sealed individually and frozen at -80°C. Replication was done with a multi-pin replicator. Before and

after each use, the 384-pin replicator was dipped sequentially into bleach for 20 seconds, water for 30 seconds, then ethanol for 5 seconds before flaming.

Working multi-well plates or Omni-Trays were used as source plates to replicate the DNA libraries onto a series of differential and/or selective media (e.g. siderophore detection media (CAS) or antimicrobial lawns). The results were compiled and compared to the profiles of the wild-type marine bacteria used to construct the DNA library.

10 Six clones were isolated that were positive for starch digestion ability. These clones were tested for the ability to inhibit growth of *S. aureus* or *S. aurantiaca*, and one clone was found to inhibit the growth of *S. aurantiaca*. This clone was subjected to further analysis, including DNA  
15 sequence analysis, and was found to contain DNA sequences encoding proteins homologous to those in a polyketide synthesis pathway. Figure 10 shows the alignment of the predicted amino acid sequence of a DNA sequence derived from clone CXC-AMN20 with the actinorhodin dehydrase gene of  
20 *Streptomyces coelicolor*.

The active component from this clone is further analyzed by extraction with organic solvents and purification guided by anti-microbial assays.

The DNA sequence contained in this clone was further  
25 examined by multiplex PCR to determine the cognate parental species. PCR primers were selected and synthesized based on sequence of the clone. Highly conserved ribosomal RNA primer sequences were used in the PCR as positive control. The positive control generates a fragment of approximately 2 kb.  
30 The amplicon generated from the clone or its cognate parental species was less than 600 bp. Initially, multiplex PCR reactions were performed by standard method using a set of four pools of genomic DNA of the parental species. Genomic DNA from Pool 1-3 produced the amplicon upon amplification.  
35 See Figure 11. The multiplex PCR reactions were repeated with genomic DNA of individual parental species. Figure 12 shows that genomic DNA derived from species #6 from Pool 1,

species #18 from Pool 2 and species #31 from Pool 3 were positive in the PCR reaction. This suggested that the identified DNA sequence was likely derived from any of these 3 species of marine bacteria.

5 Thus, the results show that the combinatorial gene expression library contains clones carrying genetic material derived from marine bacteria that encodes metabolic pathway of interest. Furthermore, it is shown that such clones in the library can be identified, and isolated by pre-screening.

10

#### 6.6. PRE-SCREENING OF MARINE GRAM(-)/E. COLI LIBRARY BY MACRODROPLET ENCAPSULATION

30,000 clones were encapsulated by taking sodium  
15 alginate (Protanol LF 20/60, Pronova Biopolymer, Drammer, Norway) and dissolving it in 100 mL of sterile water at a concentration of 1% using an overhead mixer at 2000 rpm. One ml of library suspension containing 30,000 cells was added so as to embed 1-5 clones per droplet. The mixture was  
20 allowed to sit for 30 minutes to degas. The mixture was then extruded through a 25 gauge needle. These fluids were dropped into an 0.5L gently stirring beaker of 135mM calcium chloride. Droplets were allowed to harden for 10 minutes and then were transferred to a sterile flask and the calcium  
25 chloride removed and replaced with LB/Amp media and a substrate, X-glucosaminide, at 80 µg/ml. Other substrates were X-acetate, X-glucopyranoside, X-gal and specific custom substrates relevant to polyketide pathways. Flasks containing the droplets were then shaken at 30°C overnight and examined the following morning for positive clones  
30 indicated by the presence of blue colonies. Clones are also co-encapsulated with indicator cells as described in 5.4.14. Indicator cells include *S. aureus*, *S. aurantiaca*.

Droplets were placed in a single layer in a large clear  
35 tray and scanned by eye. One X-glucosaminide positive was recovered, resuspended in 15% glycerol and stored at -70°C. Other positive colonies are removed and placed in 96-well

master plates containing LB/Amp and 50 mM sodium citrate pH 7.4 to dissolve the matrix, and allowed to grow at 37°C overnight. These overnight master 96-well plates are used as a source plate to replicate into one or more working  
5 multi-well plates or Omni-Trays. The master 96-well plates are then sealed individually and frozen at -80°C. Positive clones are either sent for specific testing of the products or sent through another round of pre-screening or screening. Further screening is performed by replication which is done  
10 with a multi-pin replicator.

Having thus disclosed exemplary embodiments of the present invention, it should be noted by those skilled in the art that the disclosures are exemplary only and that various  
15 other alternatives, adaptations, and modifications may be made within the scope of the present invention. Accordingly, the present invention is not limited to the specific embodiments as illustrated herein, but is only limited by the following claims.

20

25

30

35



WHAT IS CLAIMED IS:

1. A combinatorial gene expression library,  
5 comprising a pool of expression constructs, each expression  
construct containing a cDNA or genomic DNA fragment derived  
from a plurality of species of donor organisms, in which the  
cDNA or genomic DNA fragment is operably-associated with one  
10 or more regulatory regions that drives expression of genes  
encoded by the cDNA or genomic DNA fragment in an appropriate  
host organism.

15 2. A combinatorial chimeric pathway gene expression  
library, comprising a pool of expression constructs, each  
expression construct containing randomly concatenated cDNA or  
genomic DNA fragments derived from one or more species of  
20 donor organisms, in which the concatenated cDNA or genomic  
DNA fragments are operably-associated with one or more  
regulatory regions that drive expression of genes encoded by  
the concatenated cDNA or genomic DNA fragments in an  
25 appropriate host organism.

3. A biased combinatorial gene expression library,  
30 comprising a pool of expression constructs, each expression  
construct containing cDNA or genomic DNA fragments some of  
which are preselected from a plurality of species of donor  
organisms for a specific property, in which the cDNA or  
35 genomic DNA fragments are operably-associated with one or  
more regulatory regions that drive expression of genes

encoded by the cDNA or genomic DNA fragments in an appropriate host organism.

5           4.           The gene expression library of Claim 1, 2 or 3  
in which the expression construct comprises a plasmid vector,  
a phage, a viral vector, a cosmid vector, or an artificial  
chromosome.

10

5.           The gene expression library of Claim 4 in which  
the vector is a shuttle vector capable of replicating in  
different host cell species or strains.

15

6.           The gene expression library of Claim 1, 2 or 3  
in which the cDNA or genomic DNA fragments are derived from  
20 bacteria, fungi, algae, lichens, plants, protozoans,  
metazoans, coelenterates, insects, mollusca, sponges, worms,  
amphibians, reptiles, tunicates, birds or mammals.

25           7.           The gene expression library of Claim 1, 2 or 3  
in which the donor organisms comprise a mixture of  
terrestrial microorganisms or marine microorganisms, or a  
mixture of terrestrial microorganisms and marine  
30 microorganisms.

8.           The gene expression library of Claim 1, 2 or 3  
in which the cDNA or genomic DNA fragments are derived from  
35 an environmental sample.

9. The gene expression library of Claim 7 in which the cDNA or genomic DNA fragments comprise one or more operons, or portions thereof, of the donor microorganism.

5

10. The gene expression library of Claim 9 in which the operon or portions thereof encodes a complete or partial metabolic pathway.

10

11. The gene expression library of Claim 1, 2 or 3 in which each expression construct is contained in a host cell.

15

12. The gene expression library of Claim 11 in which the host cells have been modified by the introduction, induction or overproduction of active efflux systems.

20

13. The gene expression library of Claim 11 in which the host cells have been modified by the introduction, induction or overproduction of a known metabolic pathway of interest or portion thereof.

25

14. The gene expression library of Claim 11 in which the host cell is a bacterium, fungus, plant cell, insect cell, or animal cell.

30

15. The gene expression library of Claim 14 in which the host cell is *Escherichia coli*, *Bacillus subtilis*, *Streptomyces lividans*, *Streptomyces coelicolor*, *Saccharomyces*

35

cerevisiae, Schizosaccharomyces pombe, Spodoptera frugiperda, Aspergillus nidulans, Arabidopsis thaliana, Nicotiana tabacum, COS cells, 293 cells, VERO cells, NIH/3T3 cells or 5 CHO cells.

16. The gene expression library of Claim 11 in which the host cells further contain a reporter regimen tailored to 10 identify clones in the library that are expressing desirable metabolic pathways or compounds.

17. The gene expression library of Claim 16 in which 15 the reporter regimen comprises DNA encoding a reporter gene operably-associated with a regulatory region that is inducible or modulated by the desirable metabolic pathways or 20 compounds expressed by the host cell.

18. The gene expression library of Claim 11 in which the host cells are in a matrix containing a reporter regimen 25 tailored to identify clones in the library that are expressing desirable metabolic pathways or compounds.

19. A method for making a combinatorial gene 30 expression library, comprising ligating a DNA vector to cDNA or genomic DNA fragments obtained from a plurality of species of donor organisms to generate a library of expression constructs in which genes contained in the cDNA or genomic 35 DNA fragments are operably-associated with their native or

exogenous regulatory regions which drive expression of the genes in an appropriate host cell.

5           20.           A method for making a chimeric pathway gene expression library, comprising randomly concatenating cDNA or genomic DNA fragments obtained from one or more species of donor organisms, and ligating the concatenated DNA fragments  
10 to a DNA vector to generate a library of expression constructs in which genes contained in the cDNA or genomic DNA fragments are operably-associated with their native or exogenous regulatory regions which drive expression of the  
15 genes in an appropriate host cell.

          21.           A method for making a biased combinatorial gene expression library, comprising ligating a DNA vector to cDNA  
20 or genomic DNA fragments obtained from one or more species of donor organisms, some of which are selected for a specific property, to generate a library of expression constructs in  
25 which genes contained in the cDNA or genomic DNA fragments are operably-associated with their native or exogenous regulatory regions which drive expression of the genes in an appropriate host cell.

30

          22.           The method of Claim 19, 20 or 21 in which the DNA vector is a plasmid vector, a phage, a viral vector, a cosmid vector, or an artificial chromosome.

35

23. The method of Claim 22 in which the vector is a shuttle vector capable of replicating in different host cell species or strains.

5

24. The method of Claim 19, 20 or 21 in which the cDNA or genomic DNA fragments are derived from bacteria, fungi, algae, lichens, plants, protozoans, metazoans,  
10 coelenterates, insects, mollusca, sponges, worms, amphibians, reptiles, tunicates, birds or mammals.

25. The method of Claim 19, 20 or 21 in which the  
15 donor organisms comprise a mixture of terrestrial microorganisms or marine microorganisms, or a mixture of terrestrial microorganisms and marine microorganisms.

20

26. The method of Claim 19, 20 or 21 in which the cDNA or genomic DNA fragments are derived from an environmental sample.

25

27. The method of Claim 25 in which the cDNA or genomic DNA fragments comprise at least an operon, or portions thereof, of the donor microorganisms.

30

28. The method of Claim 27 in which the operon encodes a complete or partial metabolic pathway.

35

29. The method of Claim 19, 20 or 21 further comprising introducing the library of expression constructs into a host cell.

5

30. The method of Claim 29 in which the host cell is a bacterium, fungus, plant cell, insect cell, or animal cell.

10

31. The method of Claim 30 in which the host cell is Escherichia coli, Bacillus subtilis, Streptomyces lividans, Streptomyces coelicolor, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Spodoptera frugiperda, Aspergillus  
15 nidulans, Arabidopsis thaliana, Nicotiana tabacum, COS cells, 293 cells, VERO cells, NIH/3T3 cells or CHO cells.

20

32. The method of Claim 29 in which the host cells further contain a reporter regimen tailored to identify clones in the library that are expressing desirable metabolic pathways or compounds.

25

33. The method of Claim 32 in which the reporter regimen comprises DNA encoding a reporter gene operably-associated with a regulatory region that is inducible or  
30 modulated by the desirable metabolic pathways or compounds expressed by the host cell.

35

34. The method of Claim 29 in which the host cells in which the host cells have been modified by the

introduction, induction or overproduction of active efflux systems.

5        35.        The method of Claim 29 in which the host cells have been modified by the introduction, induction or overproduction of a known metabolic pathway of interest or portion thereof.

10

36.        A method for identifying a compound of interest in a gene expression library, comprising:

15        (a)        culturing the gene expression library of claim 11; and

(b)        screening the gene expression library for a clone which produces the compound.

20

37.        A method for screening a gene expression library for a compound of interest, comprising:

25        (a)        culturing the gene expression library of claim 16; and

(b)        detecting a signal generated by the reporter regimen;

thereby identifying a clone which produces the compound.

30

38.        A method for screening a gene expression library for a compound of interest, comprising:

35        (a)        culturing the gene expression library of claim 18; and



(b) detecting a signal generated by the reporter regimen;  
thereby identifying a clone which produces the compound.

5

39. A method for producing a compound of interest, comprising:

- (a) culturing the clone identified in claim 36; and  
10 (b) recovering the compound from the culture of the identified clone.

40. A method for producing a compound of interest, comprising:

- (a) culturing the clone identified in claim 37; and  
15 (b) recovering the compound from the culture of the identified clone.

20

41. A method for producing a compound of interest, comprising:

- 25 (a) culturing the clone identified in claim 38; and  
(b) recovering the compound from the culture of the identified clone.

30

35

1/20




FIG.1

2/20




FIG.2

3/20








FIG.3

4/20



5/20

PROMOTERS FOR  
cDNA & gDNA INSERTS



SUBSTITUTE SHEET (RULE 26)

TERMINATORS  
FOR cDNA INSERTS







FIG.5A

6/20










**FIG. 5D**

9/20






FIG. 5F

11/20





FIG.6A

12/20



MCS = SacI-NcoI-BstXI-NotI-Xba...

FIG.6B

```

5' CCTAGCCATGGCCACCTAACTGGGATCGC 3'
3' TCGAGGATCGGTACCGGTGGATTGACCCTAGCGCCGG 5'
   SacI   NcoI   BstXI   NotI END

```

FIG.6C

13/20




FIG.7

14/20




FIG.8

15/20




FIG.9A




FIG.9B



16/20

POSITION		
CXC-AMN20	(1)	-----NSHFIIITIQGVLVFDSGSSSEHIGNA (23)
ACTINORHODIN DEHYDRASE	1	MTVEVREVAEGVYAYEQAPGCVCVSNAGIVVCGDGCALVVDITLSTIPRARR 50
CXC-AMN20	(24)	IIAAVKRVTEQPIRWVNVSSHSHADHWLGNAAALAKLGAELIISTLSAETMK (73)
ACTINORHODIN DEHYDRASE	51	LAEWVDKLAAGPCRTVVNTTHFHGCDHAFGNQVFAP-GTTRIIAHEDMRSA MV 99
CXC-AMN20	(74)	SDGPVDVKAEFFNMTKGATGESTLVIPISITLHQQTIRTFGDTEVEVFV FAND (123)
ACTINORHODIN DEHYDRASE	100	ITTGCLALTC-LWP--RVDWGEIEELRPPNVTFRDRLTLHVGE RQVELT CVGP 146
CXC-AMN20	(124)	GHSFGDVMMLWLPKQRITLIGGDVVVNSFMPIIMTPRGNITQLTSV LKEVEQL (173)
ACTINORHODIN DEHYDRASE	147	AHTTDHVVVWLPPEERVLFAGDVMVMSGVTP-FALFGSVAGT LALDRLLAE L 195
CXC-AMN20	(174)	PLVLTGHGENTSVKSVSRDIOFLTYASN AVHEALVKGTTPAKIQASLQ (223)
ACTINORHODIN DEHYDRASE	196	PEVAVVVGCHGPVAGPEVIDANRDYLRWVQRLAADAVDRRLT PLQAARRAD 245
CXC-AMN20	(224)	ATLRTKFGKAYQDFDTSISYLL EMMIDKQRLQFSPTIT----- (264)
ACTINORHODIN DEHYDRASE	246	LGAFAGLD AERLVANLHRAHEELLCGHV RDAMEIFAELVAYNGGQLPTC 295
CXC-AMN20	--	--
ACTINORHODIN DEHYDRASE	296	LA*

297

FIG.10

17/20




FIG. 11

18/20

# POOL 1

M - + + 1 2 3 4 5 6 7 8 9 10

2072  
1500  
600  
100




FIG.12A

POOL 2

M - + + 12 13 14 15 16 17 18 19 20





FIG.12B

20/20

# POOL 3

M - + + 21 22 23 27 30 31 32 33 34 35



2072  
1500  
600  
100

FIG.12C

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/06003

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : C12Q 1/04, 1/68; C12P 21/00; C07H 21/04; C12N 15/00

US CL : 435/6, 7.91, 34, 69.1, 71.1; 536/23.1; 935/23, 60

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 7.91, 34, 69.1, 71.1; 536/23.1; 935/23, 60

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Medline

search terms: library, pool

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P ---- Y, P	US 5,441,885 A (GOLDBERG ET AL.) 15 August 1995 (15.08.95), columns 2, and 10-15.	2, 4, 5, 6, 11, 13, 14, 15, 36 ----- 8
X ---- Y	STEGLITZ-MORS DORF et al. Cloning, heterologous expression, and sequencing of the <i>Proteus vulgaris</i> <i>glnAntrBC</i> operon and implications of nitrogen control on heterologous urease expression. FEMS Microbiology Letters. 1993, Vol. 106, pages 157-164, especially page 159.	2, 4, 6, 9, 10, 11, 13, 14, 15, 36, 39 ----- 8

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

21 JUNE 1996

Date of mailing of the international search report

30 JUL 1996

 Name and mailing address of the ISA/US  
 Commissioner of Patents and Trademarks  
 Box PCT  
 Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JOHN S. BRUSCA

Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/06003

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X ----- Y	RANI et al. Cloning and Expression of the mercury resistance genes of marine <i>Pseudomonas</i> sp. strain MR1 plasmid pMR1 in <i>Escherichia coli</i> . Research in Microbiology. 1994, Vol. 145, pages 121-127, especially pages 123-124.	2, 4, 6, 7, 11, 12, 13, 14, 15, 36 ----- 8
A ----- Y	T. MANIATIS et al., "Molecular Cloning", A Laboratory Manual" published 1982 by Cold Spring Harbor Laboratory, pages 229-246 and pages 295-296, see entire document.	1-19, 22-41 ----- 8

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/06003

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:  
1-19 and 22-41
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☒ No protest accompanied the payment of additional search fees.



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/06003

## BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claims 1, 4-19, and 22-41, drawn to an unselected DNA library comprising DNA of multiple organisms.

Group II, claims 2, and 4-18, drawn to an unselected DNA library containing concatameric DNA of one or more organisms.

Group III, claims 3-18, drawn to a selected DNA library comprising DNA of multiple organisms.

Group IV, claims 20, and 22-35, drawn to a method of making the library of group II.

Group V, claims 21-35, drawn to a method of making the library of group III.

Group VI, claims 36-41, drawn to a method of using the library of group II.

Group VII, claims 36-41, drawn to a method of using the library of group III.

The inventions listed as Groups I-VII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: There is no technical relationship shared among the inventions that qualifies as a special technical feature under Rule 13.2 because there is no technical feature that defines a contribution of any invention over the prior art.